

# Paradigms of Dynamic Control of Thyroid Hormone Signaling

Antonio C. Bianco,<sup>1</sup> Alexandra Dumitrescu,<sup>1</sup> Balázs Gereben,<sup>2</sup> Miriam O. Ribeiro,<sup>3</sup> Tatiana L. Fonseca,<sup>1</sup> Gustavo W. Fernandes,<sup>1</sup> and Barbara M. L. C. Bocco<sup>1</sup>

<sup>1</sup>Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Medical Center, Chicago, Illinois 60637; <sup>2</sup>Department of Endocrine Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary; and <sup>3</sup>Developmental Disorders Program, Center of Biologic Sciences and Health, Mackenzie Presbyterian University, São Paulo, São Paulo 01302-907, Brazil

**ORCID numbers:** 0000-0001-7737-6813 (A. C. Bianco).

**ABSTRACT** Thyroid hormone (TH) molecules enter cells via membrane transporters and, depending on the cell type, can be activated (*i.e.*, T<sub>4</sub> to T<sub>3</sub> conversion) or inactivated (*i.e.*, T<sub>3</sub> to 3,3'-diiodo-L-thyronine or T<sub>4</sub> to reverse T<sub>3</sub> conversion). These reactions are catalyzed by the deiodinases. The biologically active hormone, T<sub>3</sub>, eventually binds to intracellular TH receptors (TRs), TR $\alpha$  and TR $\beta$ , and initiate TH signaling, that is, regulation of target genes and other metabolic pathways. At least three families of transmembrane transporters, MCT, OATP, and LAT, facilitate the entry of TH into cells, which follow the gradient of free hormone between the extracellular fluid and the cytoplasm. Inactivation or marked downregulation of TH transporters can dampen TH signaling. At the same time, dynamic modifications in the expression or activity of TRs and transcriptional coregulators can affect positively or negatively the intensity of TH signaling. However, the deiodinases are the element that provides greatest amplitude in dynamic control of TH signaling. Cells that express the activating deiodinase *DIO2* can rapidly enhance TH signaling due to intracellular buildup of T<sub>3</sub>. In contrast, TH signaling is dampened in cells that express the inactivating deiodinase *DIO3*. This explains how THs can regulate pathways in development, metabolism, and growth, despite rather stable levels in the circulation. As a consequence, TH signaling is unique for each cell (tissue or organ), depending on circulating TH levels and on the exclusive blend of transporters, deiodinases, and TRs present in each cell. In this review we explore the key mechanisms underlying customization of TH signaling during development, in health and in disease states. (*Endocrine Reviews* 40: 1000 – 1047, 2019)

**M**ultiple processes and systems in vertebrates are sensitive to the thyroid hormones (THs) T<sub>4</sub> and T<sub>3</sub> (1, 2). However, circulating TH levels are remarkably stable, which is difficult to reconcile with the idea that important biologic processes are initiated or terminated by T<sub>3</sub>, the most biologically active TH. Historically, this was explained by the concept of the “permissive effect” of TH; TH was thought to be necessary but not sufficient to initiate critical biologic events (3). Progress in our understanding of TH action illuminated this apparent inconsistency, with the discovery that a number of cellular and molecular processes such as gene transcription are indeed highly sensitive to T<sub>3</sub> action *per se* (1, 2). The work of several groups resolved the logistical hurdle of steady T<sub>3</sub> plasma levels by demonstrating the existence of “local” mechanisms that function within target cells to rapidly modulate TH signaling up or down in the short- or long-term, despite relatively stable circulating levels of T<sub>3</sub>

(4–8). The signaling TRIAD, that is, transmembrane transport, intracellular deiodination, and TH receptor (TR)-mediated gene transcription, constitutes the basis for cellular customization of TH signaling [see Ref. (9) for a comprehensive review of methods and experimental approaches to study the signaling TRIAD].

## Transmembrane transport

The cellular lipid bilayer that forms the plasma membrane is not significantly permeable to T<sub>4</sub> or T<sub>3</sub>; both molecules enter and exit cells through specific transporters that are embedded in the plasma membrane (10–12). Knowledge about these transporters originated from work with L- and T-type amino acid transporters (13), and eventually led to identification of monocarboxylate transporter (MCT) 8, a highly effective T<sub>4</sub> and T<sub>3</sub> transporter (14). The homologous molecule, MCT10, is also capable of T<sub>3</sub> transport but

ISSN Print: 0163-769X  
ISSN Online: 1945-7189  
Printed in USA

Copyright © 2019  
Endocrine Society

Received: 30 November 2018

Accepted: 15 March 2019

First Published Online:

29 April 2019

**ESSENTIAL POINTS**

- Thyroid hormone (TH) signaling is customized to different cell types
- Customization in TH signaling is mediated by TH transporters, deiodinases, and TH receptors
- Deiodinases provide the greatest amplitude in dynamic control of TH signaling
- TH signaling is customized during development to ensure that cells are exposed to T<sub>3</sub> at the appropriate timing, which is different among tissues
- Critical illness is associated with changes in TH signaling, which are viewed as an adaptive phenomena

less effective than MCT8 for T<sub>4</sub> (15). In addition to the MCTs, at least two other families of TH transporters exist: the organic anion-transporting polypeptide (OATP) family, highly expressed in the brain with substrate specificity for T<sub>4</sub>, and the L-type amino acid transporters (LATs) 1 and 2, which transport both T<sub>4</sub> and T<sub>3</sub> but with relative low affinity (16).

**Intracellular deiodination**

Once inside the cells, TH molecules can be activated or inactivated by the deiodinase group of enzymes (1, 4, 5, 17) (Fig. 1). These are dimeric integral membrane selenoproteins composed of a single N-terminal transmembrane segment connected to a larger globular domain with a selenocysteine-containing active center embedded in a thioredoxin-like fold (18–21) (Fig. 2). Deiodinases modify the biologic activity of TH molecules, either by activating T<sub>4</sub> via outer ring deiodination [type II iodothyronine deiodinase (D<sub>2</sub>)] or inactivating T<sub>4</sub> and T<sub>3</sub> via inner ring deiodination [type III iodothyronine deiodinase (D<sub>3</sub>)], thus modulating T<sub>3</sub> levels inside target cells. *DIO<sub>2</sub>* is primarily expressed in the brain, pituitary gland, and brown adipose tissue (BAT), whereas *DIO<sub>3</sub>* expression predominates in most fetal tissues, subsiding after birth (22, 23). In adults, brain, placenta, skin, and pancreatic  $\beta$ -cells (24, 25) are the tissues with highest D<sub>3</sub> activity. However, D<sub>3</sub> can be expressed ectopically in almost any tissue during critical illness (26, 27). A third deiodinase gene, *DIO<sub>1</sub>*, is expressed in liver and kidney; type I iodothyronine deiodinase (D<sub>1</sub>) is capable of both outer and inner ring deiodination. However, D<sub>1</sub> exhibits three orders of magnitude lower affinity for T<sub>4</sub>. Whereas D<sub>1</sub> plays a role in thyroid economy (28), its low affinity for T<sub>4</sub> and presence in the plasma membrane precludes it from significantly affecting local TH signaling; its products, T<sub>3</sub> and reverse T<sub>3</sub> (rT<sub>3</sub>), rapidly exit the cells and enter the systemic circulation (29, 30).

**TR-mediated signaling**

Two types of T<sub>3</sub> receptors, TR $\alpha$  and TR $\beta$ , mediate most TH effects via interaction with transcriptional modulators to control multiple gene sets (2). Tissues vary in their expression levels of TR $\alpha$  and TR $\beta$ . For example, brain, heart, intestine, skeletal muscle (SKM), and skeleton are known for their predominance of TR $\alpha$ , whereas TR $\beta$  expression occurs primarily in liver and pituitary gland. In genes that are positively regulated by T<sub>3</sub>, unoccupied TRs are mostly bound to thyroid responsive elements (TREs) near the promoter region where they form complexes with transcriptional repressors, reducing the velocity at which target genes are transcribed. T<sub>3</sub> binding to TRs might direct additional TRs to specific DNA sites. Furthermore, binding to T<sub>3</sub> shifts the affinity of TRs from corepressors to coactivators, not only de-repressing but also transactivating transcription of target genes (2). In addition to transcriptional effects, TRs might also function via a noncanonical pathway that does not require binding to TREs (31). Although complete loss of canonical TH action is observed in knock-in mice with a TR mutation that abrogates binding to DNA, several important TH-dependent physiological effects are preserved, including heart rate, body temperature, blood glucose, and triglyceride concentration, indicating that they could be affected by noncanonical TR signaling (31).

The functions of all three components of the signaling TRIAD are intertwined and constitute the basis for localized control and tissue specificity displayed by TH action, with most tissues having their own unique blend of transporters, deiodinases, and TRs. The focus of this article is to review these mechanisms in the context of existing paradigms of dynamic control of TH signaling and their relevance to human disease.

**Circulating T<sub>3</sub> Underlies TH Signaling in Most Tissues**

Whether a cell or tissue responds to T<sub>3</sub> depends on the expression of TH transporters and the presence of TRs, which may vary from very few (minimally

responsive cells) to as many as 8000 TR molecules per cell, as seen in liver, pituitary, and BAT (32, 33). TRs display relatively high affinity and low capacity for T<sub>3</sub> and, as T<sub>3</sub> levels increase, T<sub>3</sub>–TR binding increases following an asymptote curve that reflects higher TR occupancy and consequently greater intensity of


TH-dependent biologic effects. This relationship has been demonstrated in isolated cell nuclei, in intact cells, and in whole animals (34–36); it is also evident in transgenic mouse models that assess TH signaling through a reporter gene (37, 38).

Based on the known TR affinity for T<sub>3</sub> ( $K_a$  of  $\sim 10^{12}$  L/M) and euthyroid plasma levels of free T<sub>3</sub> (FT<sub>3</sub>;  $\sim 10^{-12}$  M), it is estimated that about half of the TR pool in liver and kidney cells is occupied with T<sub>3</sub> derived from the circulation, a figure that has been confirmed experimentally (32, 39). In other words, the circulating level of FT<sub>3</sub> in euthyroid individuals provides the cell nucleus with sufficient T<sub>3</sub> to occupy about half of the TRs, respectively activating or suppressing genes that are positively or negatively regulated by T<sub>3</sub>, eventually leading to downstream biologic effects. The other half of the TRs in these organs remain empty but do exert biologic effects by repressing genes that are positively regulated by T<sub>3</sub>. Thus, the presence of TRs and the balance between occupied and unoccupied TRs are what define the type and intensity of T<sub>3</sub>-dependent biologic effects in any given cell or tissue.

Circulating T<sub>3</sub> levels are important determinants of TH signaling. Indeed, in most tissues the level of TR occupancy, expression of T<sub>3</sub>-responsive genes, and downstream biologic effects are greatly influenced by circulating T<sub>3</sub> levels. In other words, as long as TH transmembrane transporters are available, T<sub>3</sub> from plasma will enter cells at levels that occupy half of the

TR pool. Conversely, a drop in plasma T<sub>3</sub> will reduce TR occupancy in most tissues as well. For example, studies in rats estimate that a mere 10% drop in plasma T<sub>3</sub> levels reduces liver and kidney TR occupancy by  $\sim 15\%$  (40). These changes are of course magnified in patients with hypothyroidism or hyperthyroidism in whom plasma T<sub>3</sub> levels may fluctuate markedly. As a counterpoint, there are instances in which TR occupancy does not reflect the levels of plasma T<sub>3</sub>. For example, in cells that express *DIO2*, intracellular T<sub>3</sub> levels are higher than expected from circulating T<sub>3</sub> (33). In contrast, in cells that are deficient in functional TH transporters, as for example in the Allan-Herndon-Dudley syndrome, extracellular T<sub>3</sub> only minimally enters cells, and hence there is low TR occupancy (41, 42). Additionally, in cells that express *DIO3*, T<sub>3</sub> can enter but could be inactivated before reaching TRs (43, 44).

It is estimated that in healthy adult individuals  $\sim 100$   $\mu\text{g}$  of T<sub>4</sub> and 30  $\mu\text{g}$  of T<sub>3</sub> are produced daily (Fig. 3). About 5  $\mu\text{g}/\text{d}$  T<sub>3</sub> is secreted directly from the thyroid gland into the circulation, whereas the remainder of 25  $\mu\text{g}/\text{d}$  is produced outside the thyroid parenchyma via T<sub>4</sub> deiodination (5). Thyroidal T<sub>3</sub> derives from thyrocyte digestion of iodinated thyroglobulin; despite the existence of  $\sim 70$  tyrosine residues distributed within thyroglobulin, formation of T<sub>4</sub> and T<sub>3</sub> happens at relatively few sites. Whereas the molar ratio of T<sub>4</sub> to T<sub>3</sub> in human thyroglobulin is 15:1, some estimates are that thyroidal secretion contains a molar



**Figure 1.** Deiodinases modify local TH signaling. T<sub>4</sub> and T<sub>3</sub> enter virtually all cells through membrane transporters. Once inside the cells, T<sub>3</sub> diffuses to the nucleus and interacts with TRs to modulate gene expression. T<sub>3</sub>–TR complexes control specific sets of T<sub>3</sub>-responsive genes, thus promoting T<sub>3</sub>-dependent biological effects. While inside the cells, TH molecules can be modified through the deiodinase group of enzymes. Deiodinases modify the biological activity of TH molecules either activating T<sub>4</sub> (D2) or inactivating T<sub>4</sub> and T<sub>3</sub> (D3). As a result, the flow of T<sub>3</sub> molecules diffusing from the cell membrane to the nucleus can be enhanced with additional T<sub>3</sub> supplied by the D2 pathway, which locally converts T<sub>4</sub> to T<sub>3</sub>. In contrast, the D3 pathway decreases the flow of T<sub>3</sub> to the nucleus because it terminally inactivates T<sub>3</sub> to T<sub>2</sub>. D2 is an ER-resident protein, a cell compartment that is adjacent to the nucleus. This explains why D2 activity results in higher TR occupancy with locally generated T<sub>3</sub>. In contrast, D3 sorts to the plasma membrane, where it undergoes endocytosis and recycling via early endosomes. Notably, under hypoxic and/or ischemic conditions, D3 is redirected to the nuclear envelope, where it inactivates T<sub>3</sub> and slows down cellular metabolism. See reviews for more details (1, 4, 17). [Adapted with permission from "Hypothyroidism, thyroid hormones and deiodinases." [www.BiancoLab.org](http://www.BiancoLab.org).]

ratio of 11:1, which indicates that thyroidal T<sub>3</sub> secretion could be enriched via intrathyroidal deiodination of T<sub>4</sub> to T<sub>3</sub> (45–47).

In healthy adult individuals, ~40% of the T<sub>4</sub> produced daily is converted to T<sub>3</sub> via D1 or D2 pathways (Fig. 3). Essentially, circulating T<sub>4</sub> molecules enter deiodinase-containing cells, broadly distributed throughout the body, and are deiodinated to T<sub>3</sub>. In turn, these newly formed T<sub>3</sub> molecules exit cells and enter the circulation, mixing with the T<sub>3</sub> molecules that were secreted directly from the thyroid gland. In euthyroid individuals, D2 is thought to catalyze the bulk of daily T<sub>3</sub> production, ~20 µg/d, with a smaller contribution provided by D1 (5 µg/d) (5). Given the widespread *DIO2* expression throughout the body, it is likely that multiple organs/tissues collectively contribute to daily T<sub>3</sub> production. Relatively high D2 specific activity can be found in the brain, pituitary gland, and cold-stimulated BAT (5, 48). D2 is present in many other tissues at lower specific activity, including skin, SKM, skeleton, vascular smooth muscle, and testis (49–53). The brain, however, also expresses relatively high levels of *DIO3*, minimizing its potential as a source of plasma T<sub>3</sub>. BAT, alternatively, does not express *DIO3*, and thus it is potentially an important source of circulating T<sub>3</sub>. This has previously been shown in rodents (54), but the finding of D2-containing BAT in humans (55) indicates that, also in humans, BAT could be a relevant source of circulating T<sub>3</sub>. Less is known about the contribution from tissues that express *DIO2* at low levels; given the mass of some of these organs/tissues, it is probably relevant as well.

D1 expression is limited and can be found predominantly in liver, kidney, and thyroid gland. D1 also metabolizes conjugated T<sub>3</sub>, clearing these molecules from the circulation (28). For example, T<sub>3</sub> is a poor D1 substrate but, once it is sulfated in its outer ring, sulfated T<sub>3</sub> (T<sub>3</sub>S) gains water solubility and is rapidly metabolized via D1, conceivably to conserve iodide before the molecule is eliminated in the urine or bile (28, 56). T<sub>3</sub>S has no biologic activity, but sulfatases present in tissues, particularly the placenta, and the intestinal microflora can convert T<sub>3</sub>S back to T<sub>3</sub>. It is currently unclear the extent to which these pathways play a role in the human T<sub>3</sub> economy.


#### Adjustable T<sub>3</sub> production and clearance preserve stability of circulating T<sub>3</sub> levels

Two pathways cooperate to maintain stable circulating T<sub>3</sub> levels: (i) thyroidal T<sub>3</sub> secretion and (ii) the group of deiodinases. Combined, they stabilize plasma T<sub>3</sub> levels, preserving TH signaling and clinical euthyroidism in most tissues.

#### Thyroidal T<sub>3</sub> secretion

The hypothalamic–pituitary axis adjusts thyroidal T<sub>3</sub> output through controlled thyroglobulin iodination

**Figure 2.** Molecular structure of deiodinases. Deiodinases are homodimeric type I integral membrane selenoproteins composed of a single N-terminal transmembrane segment connected to a larger globular domain with a selenocysteine-containing active center embedded in a thioredoxin-like fold (18). The structure of the three deiodinases is similar as modeled through hydrophobic cluster analysis in combination with position-specific iterated BLAST. Their extramembrane portion belongs to the thioredoxin-fold superfamily (18). The crystal structure of an inactive catalytic domain of one of the deiodinases (mouse D3) was solved and confirmed most aspects revealed with the three-dimensional modeling (19). It also revealed a close structural similarity to 2-Cys peroxiredoxin(s) (Prx), which suggests a route for transferring protons to the substrate during deiodination and a mechanism for subsequent recycling of the transiently oxidized enzyme (19). [Adapted with permission from “Hypothyroidism, thyroid hormones and deiodinases.” [www.BiancoLab.org](http://www.BiancoLab.org).]



(i.e., the molar ratio of T<sub>4</sub> to T<sub>3</sub> in the thyroglobulin) and conversion of T<sub>4</sub> to T<sub>3</sub> within the thyrocyte. In light of studies on the *Mct8* knockout (*Mct8*-KO) mouse, it is conceivable that *Mct8* expression within the thyroid also modifies the T<sub>4</sub>/T<sub>3</sub> ratio that is secreted from the thyroid gland. In such animals there is reduced efflux of T<sub>4</sub> from thyrocytes, thereby providing more substrate for intrathyroidal deiodination to T<sub>3</sub> (57). The molar ratio of T<sub>4</sub> to T<sub>3</sub> in the thyroglobulin molecule is sensitive to TSH receptor stimulation. Thyroidal stimulation by TSH increases T<sub>3</sub> formation within thyroglobulin (58–60), thus lowering the thyroidal T<sub>4</sub>/T<sub>3</sub> molar ratio and increasing the relative secretion of T<sub>3</sub>. Iodine deficiency and Graves disease are two extreme examples of this phenomenon, in which the molar ratio of T<sub>4</sub> to T<sub>3</sub> in the thyroglobulin can drop to 5:1 (45, 46). It is not clear to what extent subtle changes in circulating TSH,

seen for example during circadian rhythmicity, contribute to daily variations in circulating T<sub>3</sub> as opposed to cues generated by the transition from fed to fast states (61), which affect extrathyroidal T<sub>3</sub> production via deiodination (62, 63). A cross-sectional study in healthy individuals with 24-hour blood sampling and cosinor analysis indicated that T<sub>3</sub> follows a circadian rhythm with periodicity that lags behind TSH, suggesting a more significant role for thyroidal secretion of T<sub>3</sub> (64).


In a remarkable show of adaptability, the thyroidal secretion is capable of preserving serum T<sub>3</sub> levels in mice with single or combined global inactivation of genes encoding D1 (*Dio1*) and/or D2 (*Dio2*) (65–68). In these animals, there is increased secretion of TSH that accelerates thyroidal T<sub>3</sub> output, making up for the lack of extrathyroidal T<sub>3</sub> production. A byproduct of the enhanced thyroidal activity is elevation of circulating T<sub>4</sub> that is tolerated without suppression of TSH. Serum T<sub>3</sub> is preserved even when *Dio2* is inactivated in a tissue-specific manner such as in TSH-producing cells (69), glial cells (70), SKM (71), adipose tissue, or liver (72). Notably, a similar hypothalamic–pituitary–thyroid (HPT)

response is involved in the maintenance of serum T<sub>3</sub> levels during iodine deficiency or mild hypothyroidism (73, 74). In both conditions, there is an increase in serum TSH levels due to decreased serum T<sub>4</sub> whereas serum T<sub>3</sub> remains within normal range or even above normal (75).

These analyses indicate that thyroidal T<sub>3</sub> secretion is the gateway through which the HPT axis affects systemic TH signaling. Thyroidal T<sub>3</sub> output is particularly sensitive to TSH signaling, thus explaining how the HPT axis plays such an important role (58). The HPT axis seems to be particularly driven to defend serum T<sub>3</sub> levels (67).

**The deiodinase group of enzymes**

These enzymes adjust T<sub>3</sub> production and clearance outside the thyroid parenchyma in response to fluctuations in circulating TH levels. *DIO2* and *DIO3* expression and activity exhibit inverse reciprocal relationship during hypothyroidism or hyperthyroidism (4, 76, 77). Whereas *DIO2* is negatively regulated by TH, the opposite is observed for *DIO3*. As a result, in hypothyroidism there is an increase in the fractional conversion of T<sub>4</sub> to T<sub>3</sub>, which is a reflection of the



**Figure 3.** Sources and clearance mechanisms of circulating T<sub>3</sub> in humans. The daily T<sub>3</sub> production in a 70-kg adult individual is ~30 μg/d. The thyroid gland contributes with ~5 μg/d and the rest is produced outside of the thyroid parenchyma via two deiodinase-mediated pathways, D1 and D2; the latter is the most important source of circulating T<sub>3</sub> in humans. Even though the thyroid contributes with a small fraction of the circulating T<sub>3</sub>, thyroidal T<sub>3</sub> secretion is upregulated in response to TSH stimulation. This occurs through an increase in the T<sub>3</sub>/T<sub>4</sub> ratio in the thyroglobulin and through increased thyroidal conversion of T<sub>4</sub> to T<sub>3</sub>. Through this mechanism and the homeostatic changes in deiodinase activity, circulating levels of T<sub>3</sub> are maintained fairly stable throughout the day. T<sub>3</sub> is cleared from the circulation by deiodination via the D3 pathway that converts T<sub>3</sub> to T<sub>2</sub>, as well as hepatic glucuronidation and sulfation, the latter followed by deiodination via the D1 pathway. In cells expressing D1, the T<sub>3</sub> residence time inside the cells is relatively short, that is, ~30 minutes, whereas in D2-expressing cells the residence time is several hours. This is probably the result of distinct subcellular localization of D1 vs D2, plasma membrane vs ER, respectively. Additionally, T<sub>3</sub> produced in D2-expressing cells finds its way to the cell nucleus and binds to TRs, triggering biological effects. See reviews for more details (5). [Adapted with permission from “Hypothyroidism, thyroid hormones and deiodinases.” [www.BiancoLab.org](http://www.BiancoLab.org).]



higher D2 activity; there is also decreased clearance of T<sub>3</sub>, which reflects lower D3 activity. Both adjustments contribute to maintenance of serum T<sub>3</sub> levels within the normal range (78–80).

Although *DIO2* expression is only weakly downregulated by T<sub>3</sub> (81), D2 activity is greatly decreased by T<sub>4</sub> via posttranslational mechanisms. D2 protein and catalytic activity are lost upon interaction with T<sub>4</sub> (82, 83) as a result of conjugation to ubiquitin (84, 85). This explains why D2 exhibits a variable half-life that depends on whether its natural substrate T<sub>4</sub> is available. In the presence of T<sub>4</sub>, D2 is inactivated with an ~20-minute half-life, whereas in the absence of T<sub>4</sub> its half-life is prolonged to hours. This provides a mechanism through which the production of T<sub>3</sub> can be regulated according to the availability of T<sub>4</sub>.

The covalent attachment of multiple ubiquitin molecules to D2 both inactivates the enzyme and targets it to degradation in the proteasomes (85–87) (Fig. 4). Ubiquitination is thought to inactivate D2 by disrupting conformation of the D2:D2 dimer, critical for enzyme activity (21, 84). A unique 18-amino acid loop in the D2 molecule confers its intrinsic metabolic instability, facilitating binding to proteins involved in the ubiquitination process (88, 89). The ubiquitin-activating enzymes (UBCs) 6 and 7 are critical for the process of D2 ubiquitination (90, 91), as are two ubiquitin ligases, the hedgehog-inducible WD repeat and SOCS box-containing 1 (WSB1), and membrane-associated ring-CH-type finger 6 (TEB4), a ligase involved in the degradation of endoplasmic reticulum (ER) proteins (89, 92, 93). Ubiquitinated D2 (Ubd2) is not immediately taken up by the proteasomes. Instead, Ubd2 can be reactivated by deubiquitination, a process catalyzed by two ubiquitin-specific peptidase (USP) class D2-interacting deubiquitinases, USP20 and USP33 (94).

D2 ubiquitination occurs via K48-linked ubiquitin chains (95). Once Ubd2 is formed, it can be taken up by 26S proteasomes after it is retrotranslocated to the cytoplasm via interaction with the p97-ATPase complex (Fig. 4). D2 retrotranslocation also includes deubiquitination by the p97-associated deubiquitinase Ataxin-3. Once in the cytosol, D2 is delivered to the proteasomes as evidenced by coprecipitation with 19S proteasome subunit S5a and increased colocalization with the 20S proteasome (95). Notably, the other two deiodinases, D1 and D3, are not known to be ubiquitinated or undergo posttranslational modifications.

### Food availability adjusts T<sub>3</sub> production and controls TH signaling


In humans and other mammals, food availability is a key factor for stimulation of the thyroid system, ensuring coupling between caloric intake and TH signaling (96, 97). Default thyroid activity, in the absence of food, is low, along with low circulating TH levels

and a slow rate of energy expenditure. Once caloric intake is initiated, thyroidal activity is accelerated and circulating TH levels increase; for example, this is seen in patients recovering from anorexia nervosa (98). In such patients, weight gain and elevation in serum T<sub>3</sub> are closely associated with acceleration in energy expenditure (98). These mechanisms are largely driven by the hypothalamus, based on molecules that signal nutritional status, for example, leptin and insulin (99–101).

A striking feature of the thyroid system during caloric restriction or fasting in humans includes low serum T<sub>3</sub>; serum T<sub>4</sub> may be low as well, and this coexists with normal/low serum TSH (102, 103). TSH-releasing hormone (TRH)/TSH may not be elevated because of the increase in medial basal hypothalamus (MBH) *Dio2* expression and TH signaling as seen in mice during fasting (104). As a result, serum TH levels diminish unopposed. In humans, the T<sub>3</sub> production rate declined by ~50% after a 6-day fasting but the metabolic clearance rate of T<sub>3</sub> remained unchanged (105). In contrast, rT<sub>3</sub> clearance is reduced by ~40% in these individuals, without changes in rT<sub>3</sub> production (106). The use of animal models to understand the mechanistic basis of these changes has its limitations. Fasting in rodents is associated with decreased thyroidal (107) and extrathyroidal T<sub>3</sub> production via reduced activity of the D2 pathway (62). The activity of the D1 pathway is reduced as well (63, 108), but it has been difficult to ascertain whether this is cause or consequence given that *Dio1* is inducible by T<sub>3</sub> as shown in rodents (107, 109). Notably, fasting for 16 to 36 hours reduced circulating levels of T<sub>4</sub> and T<sub>3</sub> in double D1/D2KO mice (110). In these animals, as well as in other mouse models of food deprivation (111), D3 activity was increased up to fourfold in skeletal muscle, liver, and kidney. Additionally, fasted mice also exhibit an increase in the expression of enzymes involved in glucuronidation and sulfation of iodothyronines in the liver, with the latter potentially followed by deiodination via the D1 pathway (112). These studies suggest that in rodents, as opposed to humans, an accelerated clearance of T<sub>4</sub> and T<sub>3</sub> plays a major role in fasting-induced changes in thyroid economy. Notwithstanding these differences, reduced levels of circulating T<sub>3</sub> in all models of fasting diminish TH signaling in most tissues, explaining the reduction in metabolic rate.

Among different nutrients, carbohydrates are the most effective to modulate circulating T<sub>3</sub> levels (96, 97). In fact, it is thought that our Paleolithic ancestors had low circulating T<sub>3</sub> levels, as they subsisted on a very low-carbohydrate/high-protein diet. The agricultural revolution with the increase in dietary carbohydrate, ~10,000 years ago, might have brought circulating T<sub>3</sub> levels to what they are today, increasing iodine requirements and hence expanding iodine deficiency (113). Mechanistically, a hint that D2-generated T<sub>3</sub> is nutritionally regulated came from the observation that insulin stimulates D2 activity in

**Figure 4.** D2 is inactivated by ubiquitination. ER stress rapidly reduces D2 activity via activation of eIF2 $\alpha$ , which inhibits translation of *Dio2* mRNA. D2 ubiquitination is the molecular mechanism underlying changes in D2 half-life, that is, the covalent attachment of multiple ubiquitin molecules to D2, which both inactivates the enzyme and targets it to degradation in the proteasomes. D2 is structured as a homodimer, D2:D2, and monomers are inactive. Ubiquitination is thought to inactivate D2 by disrupting the conformation of the D2:D2 dimer, critical for enzyme activity. A unique 18-amino acid loop confers intrinsic metabolic instability to D2, facilitating binding to proteins involved in the ubiquitination process. UBC6 and UBC7 are critical in the process of D2 ubiquitination, as well as two ubiquitin ligases, the hedgehog-inducible WSB1, and TEB4, a ligase involved in the degradation of proteins in the ER. The WD-40 propeller of WSB-1 recognizes an 18-amino acid loop in D2 that confers metabolic instability, whereas the SOCS box domain mediates its interaction with an ubiquitinating catalytic core complex, modeled as Elongin BC–Cul5–Rbx1. Ubiquitinated D2 (UbD2) can be reactivated by deubiquitination, a process catalyzed by two USP class D2–interacting deubiquitinases, USP20 and USP33. D2 ubiquitination occurs via K48-linked ubiquitin chains and exposure to its natural substrate, T4, accelerates UbD2 formation. UbD2 is retrotranslocated to the cytoplasm via interaction with the p97–ATPase complex. D2 retrotranslocation also includes deubiquitination by the p97-associated deubiquitinase Ataxin-3. Once in the cytosol, D2 is delivery to the proteasomes as evidenced by coprecipitation with 19S proteasome subunit S5a and increased colocalization with the 20S proteasome. See reviews for more details (86, 87). [Adapted with permission from “Hypothyroidism, thyroid hormones and deiodinases.” [www.BiancoLab.org](http://www.BiancoLab.org).]



rat brown adipocytes (114) and that insulin sensitizers stimulate *Dio2* expression in cultures of skeletal myocytes (115). Additionally, D2 activity in BAT is upregulated by growth factors such as IGF-1 and insulin (114, 116), which promotes glucose uptake and growth through nutrient sensing pathways such as the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) (117, 118) pathways (Fig. 5). Indeed, semistarvation in rats is associated with the higher gene encoding D3 (*Dio3*) and lower *Dio2* in skeletal muscle along with slower formation of T<sub>3</sub> from T<sub>4</sub>; these changes are associated with accumulation of slow-twitch fibers at the expense of fast-twitch fibers, which is a hallmark of reduced TH signaling in the skeletal muscle. Thus, it is conceivable that diminished skeletal muscle T<sub>3</sub> production and accelerated T<sub>3</sub> catabolism not only explain the slower muscle energy expenditure rate following caloric restriction but also contribute to the lower circulating levels of T<sub>3</sub> (119). Studies in cells and mice indicate that *Dio2* is normally inhibited by forkhead box, subgroup O (*Foxo*) 1 (*Foxo1*), a transcriptional regulator that binds the *Dio2* promoter. In turn, insulin signals through the


PI3K–mammalian target of rapamycin complex (mTORC) 2–serine/threonine kinase 1 (AKT) pathway to relieve *Foxo1* repression. These studies provide a mechanistic explanation for why in humans fasting is associated with a reduction in SKM D2 activity that is partially prevented by insulin administration (120).

*Dio2* expression in the cerebral cortex is not modified by fasting or refeeding, indicating that *Dio2* regulation by nutrient availability is not universal, likely occurring in tissues where the metabolic pathways are responsive to T<sub>3</sub> and insulin such as BAT, SKM, and neonatal liver (1, 72). Thus, the balance between PI3K–mTORC2–AKT and *Foxo1* signaling in metabolically relevant tissues should provide nutritional input and fine-tuning to the regulation of circulating levels of T<sub>3</sub> and T<sub>3</sub>-dependent processes.

#### Accelerated D1 activity increases T3 production in hyperthyroid patients

On the other end of the spectrum, circulating T<sub>3</sub> might be disproportionately high in patients with hyperthyroidism, particularly with Graves disease, which

**Figure 5.** Nutrient availability and activation of TH signaling. Leptin is a key molecule signaling food intake and the availability of energy substrates to the hypothalamus, where it activates the HPT axis by stimulating secretion of TRH and TSH, and hence thyroidal activity. There is a drop in serum T<sub>3</sub> levels with fasting, which reflects decreased thyroidal secretion and decreased extrathyroidal conversion of T<sub>4</sub> to T<sub>3</sub>. The mechanism regulating *DIO2* expression in skeletal muscle in this setting was modeled by shifting cells to media containing only 0.1% fetal bovine serum, which reduces *DIO2* expression via FOXO1-mediated transcriptional repression (62). There is a FOXO1 binding site within the *DIO2* promoter, close to the transcription start site. Binding of FOXO1 to this site suppresses *DIO2* gene expression. In contrast, shifting cells back to a media containing 10% fetal bovine serum (after 24 h of fasting) increases *DIO2* expression and D2 activity through a mechanism initiated by insulin and mediated by a series of kinases (PI3K–mTORC2–AKT) that end up phosphorylating FOXO1, hence relieving *DIO2* repression. These findings are relevant for hypothyroid patients maintained on L-T<sub>4</sub> that depend on D2 for >80% of all their T<sub>3</sub> needs; thus, they are at greater risk to develop low serum T<sub>3</sub> during caloric restriction (62). [Adapted with permission from “Hypothyroidism, thyroid hormones and deiodinases.” [www.BiancoLab.org](http://www.BiancoLab.org).]



contributes with the overall enhancement of TH signaling. This has been attributed to an accelerated thyroidal T<sub>3</sub> secretion and T<sub>4</sub> to T<sub>3</sub> conversion via the D1 pathway. T<sub>3</sub> secretion is accelerated thanks to increased T<sub>3</sub> synthesis (58) as well as increased intrathyroidal conversion of T<sub>4</sub> to T<sub>3</sub> (121). In a study of patients with Graves disease, higher serum T<sub>3</sub> levels correlated with higher thyroidal D1 and D2 activities (122). Similarly, patients with hyperthyroidism as part of the McCune–Albright syndrome also exhibit a lower circulating T<sub>4</sub>/T<sub>3</sub> ratio thanks to accelerated D1 and D2 activities in the thyroid parenchyma (123). In hyperthyroid patients *DIO1* expression is also up-regulated outside the thyroid gland (124), which is reminiscent of the fact that in rodents *Dio1* is highly sensitive and positively regulated by T<sub>3</sub> (109). Given this prominent role played by D1 in producing T<sub>3</sub> in hyperthyroid patients, propylthiouracil (PTU), which specifically inhibits D1 activity, has been advocated as a more effective antithyroid drug in severe thyrotoxicosis or thyroid storm (125).

### Transmembrane transport, deiodinases, and TRs fine-tune TH signaling

The signaling TRIAD, that is, (i) transmembrane transport, (ii) intracellular deiodination, and (iii) TR-mediated gene transcription, defines TH signaling; with each component, conditions exist that may, permanently or transiently, enhance or dampen TH signaling.

### Local mechanisms for customization of TH signaling

A number of physiological and pathophysiological conditions exist in which homeostatic or disease signals can transiently affect the TRIAD that controls TH action in specific organs or tissues, resulting in dynamic changes of local TH signaling. THs move across the plasma membrane (in and out of cells) via transporters following a concentration gradient of free hormone between the extracellular fluid and the cytoplasm. Thus, movement of TH molecules across the cell membrane requires the transporters, but a relative



excess of transporter molecules should not increase further intracellular levels of THs or TH signaling (126). In other words, increasing the expression of TH transporters beyond a critical minimal number will likely only speed up the time to equilibrium between the two compartments, not define the intracellular levels of THs. In fact, most of the situations in which TH transporters affect TH signaling are the result of transporter inactivation or marked down-regulation. In contrast, dynamic modifications of TRs and transcriptional coregulators have been shown to affect the intensity of TH signaling both ways, but by far the most impressive dynamic control of TH action is seen as a result of the deiodinase group. It is unlikely, however, that deiodinases define TH signaling universally, at all times. It is expected that future studies will reveal new components, pathways, and nuances underlying dynamic control of TH signaling, such as, for example, posttranslational modifications of TH transporters and TRs. Furthermore, it is imperative that we better understand how cytosolic T<sub>3</sub> finds its way to the cell nucleus. It is generally agreed that the T<sub>3</sub> equilibration between cytosol and cell nucleus is defined by simple diffusion. However, estimates of the concentration of FT<sub>3</sub> in these compartments revealed nuclear/cytosolic T<sub>3</sub> ratios of ~58 in the liver, ~56 in the kidney, ~81 in the heart, and ~251 in the brain, suggesting that a specific transport mechanism exists from cytosol to the cell nucleus (127). It remains to be seen whether D<sub>2</sub> with its perinuclear localization plays a role in the higher ratios observed in the brain.

Tissue-specific dynamic changes in TH signaling occur in a number of systems in response to multiple physiological cues, without antecedent changes in circulating levels of THs. For example, cold exposure through the sympathetic nervous system stimulates *Dio2* expression and T<sub>3</sub> production in BAT that adds to the intracellular T<sub>3</sub> entering from the circulation. As a result, there is an increase in cellular T<sub>3</sub> content that augments TR occupancy from its baseline level of ~75% (29, 33) to >95%, along with induction of T<sub>3</sub>-responsive genes (128). Such a role for D<sub>2</sub> in defining local TH signaling is not unique to BAT (4). For example, in the developing setting a timed surge in D<sub>2</sub>-generated T<sub>3</sub> is critical for a number of organs, including cochlea (129) and liver (72). In the adult mouse, D<sub>2</sub>-generated T<sub>3</sub> has also been shown to play a role in brain, lung, SKM, and skeleton (70, 130–132) (Fig. 6).

Unfortunately, measuring TR occupancy to assess changes in TH signaling is cumbersome and rarely done. Alternatively, investigators have measured tissue T<sub>3</sub> or relied on changes in mRNA levels of T<sub>3</sub>-responsive genes or well-known T<sub>3</sub>-dependent biologic effects to study TH signaling (9). For example, it is assumed that induction of *DIO3* in skin cells by members of the Hedgehog family of proteins reduces TH signaling. This is because the mRNA levels for cyclin D<sub>1</sub>, a gene that is negatively regulated by T<sub>3</sub>,


increase upon induction of *DIO3* and is followed by proliferation of keratinocytes (133). Similarly, two mouse models of *DIO2* overexpression in the myocardium further illustrate how deiodinase expression modifies TH signaling (134, 135). In both cases, modulation of T<sub>3</sub>-responsive genes and biologic effects were documented. Notwithstanding, there is still the possibility that dynamic changes in deiodinases (or other elements of the signaling TRIAD) coincide with but do not directly affect the expression of T<sub>3</sub>-responsive genes. Multiple approaches have been used to exclude random associations, including gene inactivation or silencing as well as phenotypic rescue with reintroduction of the targeted gene (9).

The availability of mouse models that express T<sub>3</sub> reporter systems has been helpful in the evaluation of the signaling TRIAD (38, 136). For example, a mouse with global *Dio3* inactivation (global-D<sub>3</sub>KO) was crossed with the transgenic mouse model FINDT<sub>3</sub> that expresses the reporter gene  $\beta$ -galactosidase as a readout of local TH signaling. Studies of the FINDT<sub>3</sub>/D<sub>3</sub>KO litter indicate that TH signaling in the central nervous system (CNS) of these animals fluctuates throughout the animal's life. Following a period of enhanced TH signaling in early development, most regions of the D<sub>3</sub>KO brain experience reduced TH signaling. Notably, TH signaling is elevated again later in adulthood and in old age, despite reduced circulating TH levels (136). As a counterpoint, the role played by *Dio2* activation in TH signaling can be visualized through bioluminescence in the TH action indicator mouse model (38), a transgenic mouse ubiquitously expressing a luciferase reporter gene regulated by a strong TRE that operates in the context of endogenously expressed levels of TH transporters, TRs, and transcriptional coregulators. Exposing these mice to cold (4°C) caused tissue-specific bioluminescence in the interscapular region (interscapular BAT), along with an ~3.0- to 9.0-fold increase in luciferase activity and mRNA in interscapular BAT, which was eliminated after surgical denervation of the organ (38).

### TH transporters

The type and expression level of TH transporters constitute an intrinsic property of each cell/tissue, which in general responds minimally to physiological or disease signals. For example, it is unclear whether the expression of TH transporters is affected by TH. Changes are small and there is conflicting evidence, with interspecies variability (137). Furthermore, TH transporters are typically multispansing plasma membrane proteins with long half-lives, unlikely to exhibit fast regulation. Notwithstanding, there are reports of increased transporter expression in liver and SKM of critically ill patients and in a rabbit model of prolonged critical illness (138), as well as in thyroid tissue of patients with Graves disease (139). In contrast, *Mct8* and *Oatp1c1* expression in the mouse

**Figure 6.** Developmental control of TH signaling via timed expression of deiodinases. Profiles of *DIO2* (red line) and *DIO3* (blue line) expression in (a) placenta, (b) retina, (c) cochlea, (d) SKM, (e) BAT, and (f) bone at the indicated periods of life. In most cases *DIO2* and *DIO3* exhibit a reciprocal inverse relationship. In general, *D3* activity is high at early embryonic stages. Its expression drop is followed by an elevation in *DIO2*. See reviews for more details (7, 8, 48, 68, 132).



blood–brain barrier (BBB) is transiently diminished in response to an acute inflammatory challenge by lipopolysaccharide (140). *Mct8* is also downregulated in benign and malignant thyroid tumors (139) as well as in rat thyroid tissue after iodine overload (141). The impact of these changes in transporter expression on local TH signaling, if any, has yet to be determined.

Mutations may impair the function of TH transporters, which in turn may dampen cellular uptake of  $T_3$  and TH signaling in cells that depend (mostly) on a specific transporter (142). Fortunately, this is a rare condition due to redundancy of transporter molecules, but it can be seen in carriers of *MCT8* gene mutations that result in the X-linked Allan–Herndon–Dudley syndrome (41, 42) and in carriers of *OATP1C1* gene mutation that results in dementia with spasticity and cold intolerance (143). Intellectual disability and problems with movement in patients with *MCT8* mutations stem from developmental deficit of  $T_3$  in brain areas where neurons rely on *MCT8* to take up  $T_3$ . A mouse with *Mct8* inactivation exhibits somewhat reduced TH content in the cerebrum and cerebellum despite elevated circulating levels of  $T_3$ ; neurologic deficits are present, but much less intense than in humans (144–146). In this species, the combined inactivation of *Oatp1c1* is also required to lower brain  $T_3$  levels and cause locomotor abnormalities typical for Allan–Herndon–Dudley syndrome (147). Molecules with thyromimetic activity that enter cells via different mechanisms or transporters may be useful in these syndromes, as they could restore TH signaling. For example, administration of the TH

analog diiodothyropropionic acid, which is less dependent on *MCT8* to enter cells, seems to rescue brain hypothyroidism (148); Triac also bypasses the plasma membrane of fibroblasts obtained from carriers of *MCT8* mutations (149). Furthermore, diiodothyropropionic acid has been used in children with Allan–Herndon–Dudley syndrome with promising results (150).

### Deiodinases

The discovery that deiodinases convert  $T_4$  to  $T_3$  in humans heightened interest in these enzymes (151). From a physiological perspective, deiodination was found to activate  $T_4$  to  $T_3$  in the MBH and pituitary gland, transducing plasma  $T_4$  levels, via the  $T_3$  molecule, to the system that regulates TRH and TSH secretion (152, 153); this explained the effect of  $T_4$  on TSH secretion. Subsequently, local deiodination was identified as the source of most  $T_3$  in the brain. Additionally, because the acceleration in *D2* activity preserves  $T_3$  content in the cerebral cortex during iodine deficiency, this pathway was identified as key to cerebral cortex adaptation to low  $T_4$  in the circulation (29). Later, studies in cold-exposed rats led to the discovery that induction of *Dio2* expression can enhance TH signaling in a tissue-specific fashion, without antecedent changes in plasma  $T_4$  levels (33, 128, 154, 155). This mechanism explained the molecular link between deiodination and thermogenesis, specifically that the uncoupling protein 1 (UCP1) gene is transcriptionally upregulated by *D2*-generated  $T_3$  (156). Conversely, the observations that *D3* activity correlates inversely with tissue  $T_3$  content (157) and

that *DIO3* expression can be reactivated in almost any tissue (158, 159) led to the discovery of conditions in which *DIO3* expression dampens local TH signaling and even causes systemic hypothyroidism (160). Subsequent studies in a number of vertebrate species led to the discovery that coordinated reciprocal expression of *Dio2* and *Dio3* during development customizes TH signaling in most organs/tissues according to a predefined developmental program (22, 161, 162) (Fig. 6).

Deiodinases are anchored in cellular membranes with the catalytic active site located in the cytosol (18, 19, 30).  $T_3$  production via D1 and D2 occurs inside cells, but  $T_3$  molecules eventually exit such cells via TH transporters mixing with the pool of circulating  $T_3$ . In contrast, D3-expressing cells function as sinks for  $T_4$  and  $T_3$ , dampening local TH signaling and consuming circulating TH. Important differences exist between D1 and D2; D1 has low affinity for  $T_4$  ( $K_m$  of  $\sim 10^{-6}$  M), has a half-life measured in hours, is induced by TH, and is inhibited by PTU; D2 has high affinity for  $T_4$  ( $K_m$  of  $\sim 10^{-9}$  M), has a half-life measured in minutes, is inhibited by TH, and is inducible by cAMP. Additionally, the differing subcellular localizations of D1 and D2 impact the fate of  $T_3$  molecules produced by these enzymes (30, 163). D1 is located in the plasma membrane, possibly explaining why D1-generated  $T_3$  equilibrates rapidly with plasma; the mean residence time of D1-generated  $T_3$  inside cells is  $\sim 30$  minutes (39). In contrast, D2 is an ER-resident protein, possibly explaining why D2-generated  $T_3$  does not equilibrate rapidly with plasma; the mean residence time of D2-generated  $T_3$  is  $\sim 8$  hours (33, 39).

D3 has high affinity for  $T_3$  ( $K_m$  of  $\sim 10^{-9}$  M), and it is stimulated by developmental and disease signals. D3 is anchored in the plasma membrane and is constantly internalized to early endosomes and recycled back to the plasma membrane, which accounts for its relatively long half-life ( $\sim 12$  hours) (163). Both  $T_4$  and  $T_3$  entering cells from the circulation can be deiodinated via D3 to inactive molecules  $rT_3$  and 3,3'-diiodo-L-thyronine ( $T_2$ ), respectively. Thus, D3 activity depletes cells of TH and reduces TH signaling (126). Under hypoxic/ischemic conditions D3 is redirected to the cell nucleus where it accumulates in the nuclear envelope (164); this occurs via the cochaperone heat shock protein 40 (HSP40). Preventing nuclear D3 import by HSP40 knockdown increases the metabolic effects of  $T_3$ . In contrast, HSP40 overexpression increases nuclear import of D3 and minimized TH effects in cell metabolism (164).

Structural and functional properties of both D2 and D3 place these enzymes at the crossroads of TH action. The high catalytic activity of D2 associated with the longer residence time of D2-generated  $T_3$  link D2 to intracellular buildup of  $T_3$  molecules and enhanced TH signaling. On the contrary, the high catalytic

activity of D3 along with its potential to accumulate in the nuclear envelope link D3 to lower intracellular  $T_3$  content and reduced TH signaling.

An alternative way through which *DIO2* and *DIO3* expression can influence local TH signaling is by reacting to changes in circulating levels of  $T_4$  and  $T_3$ , hence minimizing the impact of these changes on TH signaling (165). For example, iodine deficiency in rats markedly lowers plasma  $T_4$  without affecting plasma  $T_3$ . Circulating  $T_3$  is preserved due to increased thyroidal  $T_3$  secretion, to accelerated conversion of  $T_4$  to  $T_3$  in *Dio2*-expressing tissues, and to reduced  $T_3$  clearance in *Dio3*-expressing tissues. Although the decrease in plasma  $T_4$  does not affect TH signaling in tissues that depend on circulating  $T_3$ , it places tissues that depend on local D2-mediated  $T_4$  to  $T_3$  conversion, such as brain, at risk for reduced TH signaling. Therefore, adaptive changes in *Dio2* and *Dio3* expression occur under these circumstances that preserve  $T_3$  content and TH signaling in these tissues. In the brain, iodine deficiency lowers *Dio3* mRNA expression and D3 activity several fold, whereas D2 activity is increased by  $\sim 20$ -fold. Thus, reciprocal changes in D2 and D3 activities are an integral component of the brain's physiological response to iodine deficiency (166). Indeed, cerebral  $T_3$  levels are preserved in iodine-deficient mouse pups throughout most of the postnatal period of brain development (167), highlighting the homeostatic efficiency of the deiodinases.

**Deiodinase genes.** Inactivating mutations in the genes encoding the deiodinases have not been reported. These are probably "concealed" by the extraordinary ability of the HPT axis to preserve circulating  $T_3$  levels as seen in mice with complete absence of deiodinases (168). However, we know of alternatively spliced *Dio2* mRNA molecules that encode an inactive D2 enzyme, including both deleted and insertion-extended *Dio2* mRNA (76). In the human *DIO2*, for example, a 108-bp region from the middle portion of the  $\sim 8$ -kb-long intron was found inserted downstream of codon 74, which results in an extra in-frame UGA codon and an  $\sim 35$ -kDa inactive D2 enzyme (169, 170). Additionally, there is also a *Dio2* mRNA variant that lacks 77 bp in the coding region at the conserved exon/intron junction, which results in an inactive D2 protein (169). The physiological and/or clinical implications of these mRNA variants remain poorly understood.

Notwithstanding, an array of single-nucleotide polymorphisms (SNPs) of the deiodinase genes exists that could disrupt TH signaling and explain associated clinical syndromes (171). Molecular scanning of *DIO2* identified a Thr92Ala variant present in 12% to 36% of the population (172) that is associated with metabolic parameters suggestive of reduced TH signaling (173). These original findings led to population-based studies suggesting associations

between Thr92Ala-*DIO2* and hypertension (174), insulin resistance (173, 175), type 2 diabetes (176), bipolar disorder (177), mental retardation (178), low IQ (179), recovery from lung injury (180), osteoarthritis (181), and increased bone turnover (182), all of which could reflect localized disruption in TH signaling. Perhaps unsurprisingly, the associations between *DIO2* SNPs and clinical syndromes have not been universally reproduced (87, 172, 183). Racial and other background factors that are difficult to control for may play important roles in such associations. Negative studies include the evaluation of 12,625 individuals, including 364 patients on TH replacement therapy. No associations between the Thr92Ala-*DIO2* SNP and thyroid parameters, quality of life, or cognitive functioning were observed (183).

The missense amino acid exchange encoded by Thr92Ala-*DIO2* is in the D2 coding region, specifically the very first amino acid in an 18-residue instability loop that explains the relatively short D2 half-life (18). Deletion of this loop stabilizes D2 (89) whereas its transfer to stable proteins shortens half-life (88). Mapping of this mutation to such a critical D2 residue supports the possibility that it could affect D2 activity and/or its stability, decreasing D2-mediated T3 production. However, several groups have failed to detect differences in enzyme kinetics [ $K_m(T_4)$  and  $V_{max}$ ] of the Thr92Ala-D2 protein when assayed in sonicates of cells transiently expressing Thr92Ala-*DIO2* (184, 185) or of tissue samples obtained from a mouse carrying the Thr92Ala-*Dio2* polymorphism (186). A contrasting finding was obtained in thyroid sonicates of individuals with the Thr92Ala-*DIO2* polymorphism, which revealed decreased  $V_{max}$  (184).

Understanding the impact of the Thr92Ala-*DIO2* polymorphism of D2 activity required utilizing intact cells. T<sub>4</sub>-dependent biologic effects were less evident in proliferating murine myoblasts and thyrotropes expressing Thr92Ala-D2, suggesting reduced D2-mediated T<sub>3</sub> production (187). Indeed, when assayed in intact cells, Thr92Ala-D2 exhibited ~20% reduced catalytic activity despite similar D2 protein levels (186). Three studies in patients indirectly support this: (i) higher doses of levothyroxine (L-T<sub>4</sub>) were needed to achieve target TSH levels in 191 thyroidectomized individuals carrying the Thr92Ala-*DIO2* polymorphism (188); (ii) the Thr92Ala-*DIO2* polymorphism is associated with delayed T<sub>3</sub> secretion in response to TRH stimulation (189); and (iii) in a study of 140 thyroidectomized subjects on L-T<sub>4</sub>, the *DIO2* genotype revealed an association between low FT<sub>3</sub> values and Thr92Ala, with the mean postsurgery FT<sub>3</sub> levels significantly lower in patients carrying the Thr92Ala allele(s) (187). Notwithstanding, results of all studies showed that individual carriers of the Thr92Ala-*DIO2* polymorphism with a normal thyroid gland are systemically euthyroid (185). Phenotypes related to polymorphisms in *DIO1* and *DIO3* have

also been reported, particularly in association with modifications in circulating TH levels (190–192), but their clinical significance has been less well documented [see Refs. (193, 194) for review].

**Deiodinase synthesis.** Genetic defects in two components of the complex machinery required for selenoprotein synthesis have been reported to cause inherited deficiencies in the deiodinases and abnormal thyroid function signaling (195, 196). One such defect is caused by mutations in the selenocysteine insertion sequence (SECIS)-binding protein 2 (*SECISBP2* or *SBP2*), MIM 607693 (195). The C-terminal region of the protein is responsible for SBP2 functions: SECIS-binding capacity, ribosome interaction, and selenocysteine insertion through two main domains in the C-terminal region [the RNA-binding domain and the selenocysteine (Sec) incorporation domain] (197). Most patients with partial SBP2 deficiency seek medical attention during childhood because of short stature and delayed bone age. These features prompt thyroid function testing, leading to the identification of thyroid abnormalities. Currently only 10 families have been reported worldwide (198, 199). Recessive mutations in SBP2 result in abnormalities in TH metabolism with characteristic thyroid test abnormalities, with high serum T<sub>4</sub>, low T<sub>3</sub>, high rT<sub>3</sub>, and normal or slightly elevated serum TSH (195), which have served as biomarkers to identify additional patients with SBP2 deficiency. Additional clinical features have been observed in some patients, such as axial muscular dystrophy, azoospermia, skin photosensitivity, abnormal immune cell function, and marked insulin sensitivity, indicating a multisystem disorder involving the defective biosynthesis of multiple selenoproteins (200). Of note, most reported patients are children, and the only known adult with this defect exhibits many more symptoms, raising the concern that additional phenotypic features can develop with age (200).

*In vitro* studies in cultured skin fibroblasts have demonstrated decreased D2 activity and glutathione peroxidase 1, as well as decreased selenium, selenoprotein P, and glutathione peroxidase 3 enzymatic activity in serum, which supported a generalized defect in selenoprotein biosynthesis. *In vivo* studies in patients have shown that higher amounts of L-T<sub>4</sub> and higher circulating serum T<sub>4</sub> levels are needed to suppress TSH in affected subjects compared with controls, although similar doses of liothyronine (L-T<sub>3</sub>) and circulating levels of T<sub>3</sub> were able to equally suppress TSH, indicating an impairment in deiodinase-mediated T<sub>4</sub> to T<sub>3</sub> conversion.

Considering that complete congenital *Sbp2* deficiency is not compatible with survival (201), other targeting strategies have been used (201–203). The hepatocyte and neuron-specific knockout (KO) models have not replicated the circulating thyroid function tests (201, 203). A recent mouse model of tamoxifen inducible conditional KO (iCKO) of *Sbp2*

---

“...when assayed in intact cells, Thr92Ala-D2 exhibited ~20% reduced catalytic activity despite similar D2 protein levels.”

---

has replicated most of the characteristic serum thyroid test abnormalities, with high T<sub>4</sub>, high rT<sub>3</sub>, and elevated TSH, with normal T<sub>3</sub> (202). It is notable that there seems to be an inverse relationship between T<sub>3</sub> and TSH between mice and humans with SBP2 deficiency. In patients, T<sub>3</sub> is distinctly low, although TSH is usually normal and only occasionally slightly elevated, whereas in mice, TSH is distinctly high and T<sub>3</sub> levels are comparable to those of wild-type controls (195, 202). Additionally, mouse models of *Dio1* KO, *Dio2* KO, double-KO, and even triple-KO *Dio1/Dio2/Dio3* maintain normal circulating T<sub>3</sub> levels (110, 204). Detailed studies in the *Sbp2* iCKO mice demonstrated decreased enzymatic activity of D1 in liver, of D2 in cerebrum, and decreased expression of *Dio3* in cerebrum. Additional insights from study of the *Sbp2* iCKO mice have brought up new aspects; in particular, the brain T<sub>3</sub> content was low, despite normal and high circulating T<sub>3</sub> and T<sub>4</sub>, respectively. This relative hypothyroidism at the cerebral level is expected to have consequences at the levels of TH-regulated genes.

Another inborn error in a component of the selenoprotein synthesis machinery was recently identified in a patient presenting with abdominal pain, fatigue, muscle weakness, reduced plasma selenium, and abnormal thyroid function tests similar to those of SBP2-deficient patients (196). This patient harbored a homozygous missense mutation in the *TRU-TCA1-1* gene, which encodes for tRNA[Ser]Sec. Whereas lack of tRNA[Ser]Sec in mice is embryonically lethal (205), studies on patients' cells showed preservation of reduced levels of tRNA[Ser]Sec (196). Identification of additional patients and further *in vitro* characterization will provide more insight into this new genetic defect that seems to also alter TH metabolism.

### TH receptors

At some point during early embryogenesis cells start expressing TR $\alpha$  and/or TR $\beta$ . The levels at which these genes are expressed might change during development but, in broad terms, stay relatively stable throughout life. Notably, hundreds of patients carrying mutations in the TR encoding genes with significant phenotypes have been reported. Mutations that inactivate TR $\beta$  cause a syndrome of TH resistance in which patients exhibit hyperthyroidism due to pituitary insensitivity to THs. There is enhanced TH signaling in tissues that predominantly express TR $\alpha$ , for example, brain and bone, and diminished TH signaling in tissues where TR $\beta$  predominates, for example, pituitary gland and liver (148, 206). Fewer families with TR $\alpha$  mutations have been reported (207, 208). These individuals have low to low-normal serum free T<sub>4</sub> (FT<sub>4</sub>), high-normal to high T<sub>3</sub>, and low rT<sub>3</sub>, with normal TSH levels, but they exhibit localized reduction in TH in tissues where TR $\alpha$  predominates (brain, skeleton, and gastrointestinal tract), resulting in growth retardation,

mild impairment of mental development, and constipation (209).

The expression of TR $\alpha$  or TR $\beta$  may fluctuate as part of normal homeostatic mechanisms or in disease states, but it is not clear that an overarching hypothesis of how TH signaling is dynamically affected by these changes can be developed at this time. The question of whether TR expression is affected by TH signaling and/or other signaling molecules remains an interesting one. TH has been shown to regulate the TR level in a number of tissues and cell lines, but the results are not always consistent. Analysis of I-125-radiolabeled T<sub>3</sub> binding to isolated nuclei revealed no differences (increases or decreases) in the number of TRs in response to hypothyroidism or hyperthyroidism (210, 211). In a comprehensive study, hypothyroid rats were treated with either saline or T<sub>3</sub> followed by analyses of mRNA encoding different TR isoforms (212). There was marked tissue-specific and differential regulation of the multiple TR transcripts by T<sub>3</sub>. In the pituitary, the levels of *TR $\alpha$ -1* mRNA increased, whereas the levels of the pituitary-specific *TR $\beta$ -2* decreased with T<sub>3</sub> treatment. In heart, kidney, liver, and brain the levels of *TR $\beta$ -1* were unaffected by thyroid status, whereas both *TR $\alpha$*  mRNAs decreased with T<sub>3</sub> treatment in all tissues except for the brain, where there was no change. The study, however, did not assess whether/how these changes affected TH signaling. Additionally, and also very importantly, there was a discrepancy between mRNA levels and nuclear binding sites for T<sub>3</sub>, indicating that relying on TR mRNA levels only might not be feasible (212).

Disease signals reportedly affect TR expression and TH signaling. Patients with nonthyroidal illness syndrome (NTIS) exhibit a drop in circulating T<sub>3</sub> levels but no obvious signs of clinical hypothyroidism. Studies on peripheral mononuclear cells from patients admitted to an intensive care unit revealed that this could be due to changes in TR expression (213). In such patients there were increases in mRNA levels of both *TR $\alpha$*  and *TR $\beta$*  when compared with peripheral mononuclear cells from normal individuals. Similar findings were obtained in liver biopsy specimens of patients with liver disease (213). Although these findings suggest that increases in TR expression during NTIS may support clinical euthyroidism in the face of reduced levels of circulating TH, they are certainly not universal. For example, patients with nonseptic shock and NTIS exhibited a reduction in skeletal muscle expression of *TR $\beta$* , *TR $\alpha$ 1*, and retinoid X receptor (RXR) $\gamma$  (214), indicating that more studies are needed before a unifying hypothesis could be formulated.

In addition to regulation at the gene expression level, TR $\alpha$  and TR $\beta$  properties and functions can be modified by posttranslational modifications, including phosphorylation, acetylation, and conjugation to small ubiquitin-like modifier (SUMO), a process referred to



as sumoylation (215, 216). These modifications affect TH signaling by altering TR/DNA binding, interaction with cofactors, and TR-mediated gene transcription. For example, TR phosphorylation promotes TR/DNA binding and heterodimerization with RXR. In the case of TR $\beta$ , phosphorylation is induced by TH at the cell membrane level and phosphorylation occurs via ERKs. In turn, TR $\alpha$  is susceptible to phosphorylation by casein 2 and protein kinase A, which reduces DNA binding (215, 216). Such TR modifications are unlikely to be permanent, but they allow for rapid crosstalk with other fast signaling networks. For example, TR phosphorylation facilitates a crosstalk with the PI3K/AKT pathway. It has been reported that an unoccupied TR $\beta$  molecule can be associated with the regulatory subunit of PI3K, an intracellular signaling kinase. Binding to T<sub>3</sub> dissociates the TR $\beta$ -PI3K complex and increases PI3K signaling. Abrogation of TR $\beta$ -PI3K binding in mice does not affect TR $\beta$  signaling but results in deficient synaptic strength and plasticity, possibly due to a developmental defect in PI3K signaling (217). Additionally, in human umbilical vein endothelial cells both T<sub>3</sub> and T<sub>4</sub> rapidly stimulate AKT phosphorylation and activate Ras-related C<sub>3</sub> botulinum toxin substrate 1 (Rac1), which results in PI3K-dependent cell migration. Human umbilical vein endothelial cells are known to express *DIO2* and have D<sub>2</sub> activity that, when blocked, abolishes AKT phosphorylation, Rac1 activation, and cell migration induced by T<sub>4</sub> but not by T<sub>3</sub>. These observations suggest that the D<sub>2</sub> pathway is involved in TR $\alpha$ 1/PI3K-mediated nongenomic actions of T<sub>4</sub> (218). If confirmed, the crosstalk between these pathways constitutes a mechanism through which TH signaling can be modified via downstream kinase cascades.

**TR coregulators.** TR functions alongside transcriptional regulators to ultimately define TH signaling. In the absence of T<sub>3</sub>, empty TRs recruit nuclear corepressors, nuclear receptor corepressor (NcoR) 1 and NcoR2 (SMRT), which in turn recruit histone deacetylase 3 (HDAC<sub>3</sub>) to repress transcription via histone deacetylation (219, 220). Even in the absence of ligand, TRs bind to TRE and repress genes positively regulated by T<sub>3</sub>. T<sub>3</sub> modifies this arrangement by disassembling the corepressor complex and recruiting members of the steroid receptor coactivators family of coactivators, p300/CREB-binding protein and other activators of histone acetylation, to accelerate transcriptional activity (221). Studies in which NcoR1 and steroid receptor coactivator-1 were selectively inactivated revealed that the target set point expression of a T<sub>3</sub>-responsive gene is affected by the balance between corepressors and coactivators (222). Therefore, TH signaling can be dynamically modified by the local levels of NcoR1/SMRT and local coactivators (223). There are numerous other potential coregulators that may play a role in TH action, including histone deacetylase Sirt1 and the

mediator subunit Med1 (224, 225). In fact, the unique environment in each cell that surrounds each TRE probably allows for its own blend of TR/coregulators, which then initiate or modulate TH signaling.

NcoR1 actions are tightly regulated by metabolic signals in liver, SKM, and adipose tissue, hence allowing for metabolic regulation of TH signaling in these tissues. For example, insulin and mTORC1 increase nuclear levels of NcoR1, which leads to repression of lipid oxidation genes (226, 227). Likewise, endurance exercise, fasting, high-fat diet (HFD), aging, and accelerated fat oxidation are all conditions associated with changes in *NcoR1* mRNA levels (226); TH signaling is expected to fluctuate accordingly. Other examples include the peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ) coactivator 1 $\alpha$  (PGC1 $\alpha$ ), a TR coactivator that is reduced in both genetic (ob/ob) and acquired obesity (HFD), setting the stage for reduced T<sub>3</sub> effects in individuals who are obese. Indeed, in the liver of individuals with obesity and during fatty liver disease, TH signaling is reduced, which seems to contribute to metabolic imbalance (228–230). For example, TR $\beta$  expression was inversely correlated with disease severity in 85 liver biopsies from patients with different stages of nonalcoholic steatohepatitis (231). That TH signaling is reduced during metabolic unbalance is also supported by the failure of TH to induce typical T<sub>3</sub>-responsive genes and accelerate energy expenditure in mice placed on an HFD (232). Remarkably, gene expression analyses of surgical liver biopsies from 13 subjects with obesity and five control subjects revealed that the top-ranking gene set downregulated in subjects with obesity was comprised of T<sub>3</sub>-responsive genes related to RNA metabolism, protein catabolism, and energy metabolism. Thus, despite normal serum T<sub>3</sub> levels, there is reduction in T<sub>3</sub> signaling in models of obesity linked to a drop in PGC1 $\alpha$  levels (232).

### Integrated Action of TH Transporters, Deiodinases, and TRs in Health and in Disease

Systemic and localized control of TH signaling is of paramount importance in development, growth, and normal adult life. The dynamic regulation of the elements in the signaling TRIAD allow for constant adjustment to TH signaling according to endogenous and environmental cues. At the same time, remarkable changes in TH economy and signaling occur during disease states (233). For example, most hospitalized patients exhibit a substantial drop in circulating T<sub>3</sub>, the explanation of which is multifactorial. TSH levels in these patients are inappropriately low for the reduced T<sub>4</sub> and T<sub>3</sub> serum levels. This is largely the result of increased *Dio2* expression in MBH tanycytes, which are specialized glial cells lining the third ventricle with projections to the median eminence. This leads to a

---

*“TR $\alpha$  and TR $\beta$  properties and functions can be modified by posttranslational modifications, including phosphorylation, acetylation, and conjugation to small ubiquitin-like modifier...”*

---

localized increase in TH signaling and suppression of TRH/TSH secretion at the same time that circulating TH levels are falling (234–236). In fact, the increase in MBH *Dio2* expression is the cause, rather than a consequence, of the drop in circulating TH levels (237–239). Additionally, depending on the nature of the disease, there can be also ectopic *Dio3* expression and accelerated D<sub>3</sub> activity in one or more affected organs/tissues (27, 236, 240, 241), which dampens local TH signaling and also contributes to the reduction in circulating T<sub>3</sub> levels. Indeed, the expression of the other elements in the TH signaling TRIAD can also be affected during NTIS in a tissue-specific fashion, depending on the nature of NTIS. This is elegantly illustrated in the study of liver and skeletal muscle of mice experiencing three models of NTIS (240). In the liver, NTIS was associated with variable degrees of reduction in Mct8, Mct10, TR $\beta$ , D<sub>1</sub> and D<sub>3</sub> activities, and T<sub>3</sub> content, markedly reducing the expression of a T<sub>3</sub>-responsive gene. In contrast, the skeletal muscle of the same animals behaved quite differently, with much less impressive changes, if any, in TRIAD elements and preserved TH signaling (240).

It is notable that, in disease states, systemic signaling and local TH signaling support a proinflammatory response in innate immune cells, such as neutrophils, macrophages, and dendritic cells, via TR $\alpha$  (242–244). *Dio2* expression in macrophages (245) is induced during the initial phase of inflammation (234, 245, 246). There is evidence that TH signaling in macrophages can occur through genomic and nongenomic pathways via integrin  $\alpha_v\beta_3$ , PI3K, and ERK1/2 (247). Both pathways increase phagocytic capacity, cytokine response, inducible nitric oxide synthase, and bacterial death (248–250). Accordingly, macrophages obtained from mice with global inactivation of *Dio2* (global-D<sub>2</sub>KO) have impaired phagocytosis and decreased cytokine production, similar to macrophages obtained from TR $\alpha$  KO mice (245, 247). At the same time, D<sub>3</sub> protein can be found in the cytoplasm and in granules containing either myeloperoxidase or lactoferrin of murine and human neutrophils expressing *Dio3* (251, 252). Accelerated D<sub>3</sub> activity lowers intracellular T<sub>3</sub> levels concomitantly with production of free iodide. The latter has been proposed as important for the generation of hypoiodite, a toxic compound that kills bacteria (253, 254). In fact, mice with global *Dio3* inactivation (global-D<sub>3</sub>KO) exhibit decreased bacterial killing ability (252), and zebrafish embryos with *Dio3* knockdown have increased mortality and reduced neutrophil infiltration during pneumococcal meningitis (255).

#### TH signaling triggers TRH and TSH negative feedback

The relationship between thyroid activity and the HPT axis is explained by a set point and maintained by a feedback mechanism. The set point is defined during

development, including the perinatal period, and fine-tuned by the hypothalamus, where environmental and endogenous cues are integrated. The feedback mechanism is based on constant monitoring of TH levels in the systemic circulation, which then leads to adjustments in TRH and TSH secretions and hence thyroidal activity. Circulating T<sub>4</sub> and T<sub>3</sub> play independent roles in this process: circulating T<sub>3</sub> is detected by TRH-expressing neurons in the paraventricular nucleus (PVN) and in the TSH-producing cells of the anterior pituitary gland; circulating T<sub>4</sub> requires local conversion to T<sub>3</sub> via the D<sub>2</sub> pathway present in the MBH and in the thyrotropes of the anterior pituitary gland.

The independent role played by T<sub>4</sub> in the feedback mechanism is illustrated by the increase in serum TSH that trails the decrease in serum T<sub>4</sub> associated with iodine deficiency or mild hypothyroidism, whereas serum T<sub>3</sub> remains within the normal range (73, 74). Few examples exist in which the independent role of T<sub>3</sub> in the feedback mechanism can be documented. Most cases in which serum T<sub>3</sub> is low in the face of normal serum T<sub>4</sub> levels indicate altered thyroid economy due to NTIS, which does not reflect normal HPT physiology (233). A unique experimental setup that points to serum T<sub>3</sub> *per se* as having an important role in TSH secretion is acute administration of large doses of PTU to thyroidectomized individuals kept on L-T<sub>4</sub> replacement therapy (256). The ~20% drop in serum T<sub>3</sub> that follows as a result of D<sub>1</sub> inhibition is sufficient to double serum TSH levels, even as serum T<sub>4</sub> levels remain stable (256).

The structures involved in monitoring circulating T<sub>4</sub> and T<sub>3</sub> levels are located inside and outside the BBB. Within the BBB, THs are transported via both MCT8 and OATP1C1, which are expressed in the barrier's endothelial cells. For example, TRH neurons in the PVN project to the outer zone of the median eminence, a region located below the floor of the third ventricle, which is outside of the BBB (238). The median eminence is a critical anatomic and functional region where the two sources of T<sub>3</sub> are integrated: T<sub>3</sub> from the systemic circulation and T<sub>3</sub> produced locally via D<sub>2</sub>-mediated deiodination of T<sub>4</sub> in the tanycytes. MCT8 is abundant in the axon varicosities of TRH neurons, suggesting that T<sub>3</sub> is taken up by these cells via this transporter (257). Indeed, the brain of a global *Mct8*-KO mouse takes up less T<sub>3</sub> and has decreased T<sub>3</sub> content, with marked upregulation of *Trh* mRNA in the PVN neurons (145). The role played by *Oatp1c1* is less clear (258). Whereas TH uptake is also affected in the brain of global mice with global *Oatp1c1* inactivation, *Trh* expression is not (259). In addition to expressing *Dio2*, tanycytes express both MCT8 and OATP1C1 (257, 260). It is thought that T<sub>3</sub> produced by tanycytes exits the cells through these transporters and is taken up by axon terminals of the PVN neurons that extend to the median eminence; indeed, these

axon terminals lie in close proximity to tanyocyte endfeet processes (257, 261). Thyroid hormone transporters might play similar roles in the human brain, where MCT8 is also found in PVN neurons and glial cells (262, 263).

At the same time, the presence of D2 in thyrotropes allows plasma T<sub>4</sub> to directly inhibit production of TSH in the pituitary (264). The direct role played by T<sub>4</sub> (and T<sub>3</sub>) in TSH secretion is critical given that not even an injection of a TRH bolus is able to elicit TSH secretion in patients with mildly elevated TH levels (265). Unfortunately, not so much is known about TH transport in the pituitary TSH-secreting thyrotropes: T<sub>3</sub> signaling in the pituitary gland is mildly impaired in mice with *Mct8* inactivation, but the transport mechanism remains elusive (258). The role played by D2 in the tanyocytes and thyrotropes for the HPT feedback mechanism was further elucidated through studies in the global-D2KO mouse (65). These animals exhibit normal serum T<sub>3</sub>, but serum TSH and T<sub>4</sub> are elevated, hinting at a relative hypothalamic and pituitary insensitivity to T<sub>4</sub>. Indeed, pituitary D2 specifically seems to play an important role in this phenotype given that a mouse with selective inactivation of *Dio2* in the pituitary gland also exhibits normal serum T<sub>3</sub> but elevated serum T<sub>4</sub> and TSH; PVN *TRH* mRNA levels are reduced as well as the TSH bioactivity (69). Unfortunately, objective demonstration of the relative role of D2 in tanyocytes is still missing given that selective inactivation of *Dio2* in these cells has yet to be achieved.

D<sub>3</sub> is also expressed in the HPT structures. It is conceivable that the presence of D<sub>3</sub> in the MBH and pituitary gland ensures that there is no local T<sub>3</sub> buildup and accurate reading of newly arrived/formed T<sub>3</sub> molecules. The role of D<sub>3</sub> is illustrated in studies of the global-D<sub>3</sub>KO mouse, which exhibits central hypothyroidism, with low circulating levels of T<sub>4</sub> and T<sub>3</sub>, and normal serum TSH. This is because *Dio3* inactivation results in neonatal thyrotoxicosis, later followed by central hypothyroidism that persists throughout life (266). A similar scenario is seen in mice exposed to high TH levels *in utero*. There is an increase in *Dio3* mRNA levels in the hypothalamus that explains the persistent central resistance to TH (267). In these mice, anterior pituitary *Dio3* mRNAs is increased, accelerating local T<sub>3</sub> clearance. A comparable phenotype is observed in adult humans who were exposed to high TH levels *in utero* (267).

Overall, the studies in animals with disruption of the deiodinase pathways indicate that each disruption triggers adjustments in the HPT function, namely changes in T<sub>4</sub>, TSH, and TRH, that are aimed at preserving serum T<sub>3</sub> levels (168). That serum T<sub>3</sub> levels are the main target around which serum T<sub>4</sub> and TSH are adjusted constitutes a shift

in the paradigm traditionally accepted for the function of the HPT axis. It is unexpected that the HPT axis tolerates an elevated serum T<sub>4</sub> to preserve serum T<sub>3</sub> (67–69).

The idea that circulating T<sub>4</sub> is detected by the hypothalamus and the pituitary gland via the D2 pathway has been challenged over the years because of the intrinsic homeostatic nature of D2; that is, D2 activity accelerates under low serum T<sub>4</sub> conditions, whereas high serum T<sub>4</sub> levels result in loss of D2 activity (29). Such D2 response at the hypothalamus and/or thyrotrope, if operational, would impair the detection of changes in serum T<sub>4</sub>, leaving TSH levels unchanged. However, studies using the T $\alpha$ T1 mouse tumor cell line that secretes TSH indicate that the T<sub>4</sub>-induced loss of D2 activity in these cells is offset by the combined effect of D2 reactivation via deubiquitination and a particularly rapid rate of D2 synthesis. As a result, higher T<sub>4</sub> levels are rapidly translated into greater D2-mediated T<sub>3</sub> production and suppression of TSH $\beta$  gene expression; this explains the operation of the T<sub>4</sub>-mediated TSH feedback mechanism (264). A similar situation is observed in the MBH. *In vitro* analysis of D2 ubiquitination driven by hypothalamic and other tissue extracts revealed less ubiquitinated D2 when hypothalamic extracts were used, including when compared with other areas of the brain (268). In other words, D2 activity does not fluctuate as much in the MBH in response to changes in T<sub>4</sub> levels. As a result, the hypothalamus remains exquisitely sensitive to elevations or drops of circulating T<sub>4</sub>, in contrast to what is observed in other tissues (268).

Given the pivotal role played by D2 and D<sub>3</sub> in the HPT axis, it is no surprise that drugs or pathways that influence the activity of these enzymes have the potential to interfere with the normal feedback mechanism. For example, the widely prescribed cardiac antiarrhythmic drug amiodarone (AMIO) and its main metabolite, desethylamiodarone (DEA), elevate serum TSH levels (269). This is because both AMIO and DEA behave as noncompetitive inhibitors of D2 (270), and a disruption in the D2 pathway interferes with the transduction of the T<sub>4</sub> signal, generating less T<sub>3</sub> and softening the TSH feedback mechanism. The underlying effect on TSH is at the pituitary gland given that in AMIO-treated mice, there is a reduction in paraventricular *TRH* mRNA levels (270). Quite the opposite is observed in mice with inactivation of the fatty acid amide hydrolase (FAAH) gene. These animals are prone to adiposity and, in humans, mutations in FAAH are associated with obesity. In these animals there is a PPAR $\gamma$ -mediated increase in MBH *Dio2* expression, which leads to a localized increase in TH signaling and suppressed TRH/TSH secretion (271). The reduced energy expenditure in global *Faah* KO mice is attributed to lower circulating THs secondary to a suppressed HPT axis (271).

---

“...can deiodinases alone preserve circulating T<sub>3</sub> homeostasis in the absence of a functional thyroid gland?”

---

### Is TH signaling restored in patients with hypothyroidism on therapy with L-T<sub>4</sub>?

A significant clinical concern is whether the loss of adjustable thyroidal T<sub>3</sub> secretion, as seen in patients who are hypothyroid, compromises the ability to preserve circulating T<sub>3</sub>, and therefore systemic TH signaling (86, 87, 272). In other words, can deiodinases alone preserve circulating T<sub>3</sub> homeostasis in the absence of a functional thyroid gland? If not, could this compromise systemic TH signaling and be a contributing factor to residual “hypothyroid-like” symptoms among some of the L-T<sub>4</sub>-treated patients with hypothyroidism?

Historically it was assumed that circulating T<sub>3</sub> is fully normalized in L-T<sub>4</sub>-treated patients (273–275). However, the issue has been revisited through very large studies, and serum T<sub>3</sub> levels were found to be lower than normal in many clinically euthyroid patients maintained on L-T<sub>4</sub>. A cross-sectional study involving ~1800 patients with athyreosis with normal serum TSH levels on L-T<sub>4</sub> monotherapy revealed that the distribution of serum FT<sub>3</sub> levels shifted to the left (lower levels) and that of FT<sub>4</sub> levels shifted to the right (higher levels) compared with the distribution patterns of ~3900 controls (276). In a subsequent large national study using cross-sectional data from the US National Health and Nutrition Examination Survey, L-T<sub>4</sub>-treated participants had higher serum total and FT<sub>4</sub> and lower serum total and FT<sub>3</sub> than did controls when matched for sex, age, ethnic background, and serum TSH. Thus, the current consensus is that although L-T<sub>4</sub>-treated patients maintain normal serum TSH levels, they also exhibit slightly lower T<sub>3</sub> levels and slightly higher T<sub>4</sub> levels than do control individuals (277). Although studies with a relatively small number of patients suggest that monotherapy with L-T<sub>4</sub> is able to normalize serum T<sub>3</sub> without suppressing serum TSH (278), the larger studies failed to replicate these findings. Normal serum T<sub>3</sub> levels can be achieved with L-T<sub>4</sub> alone, but at the expense of having relatively lower/suppressed serum TSH (279, 280).

What are the underlying mechanisms that explain the relatively lower levels of T<sub>3</sub> in L-T<sub>4</sub>-treated patients? This has been addressed in rodent models, including in L-T<sub>4</sub>-treated thyroidectomized rats (67, 68). In these rats, the daily dose of L-T<sub>4</sub> that normalizes serum TSH results in serum T<sub>4</sub> levels above the reference range and lower than normal serum T<sub>3</sub> levels. Indeed, only combined therapy with L-T<sub>4</sub> and L-T<sub>3</sub> normalize serum T<sub>4</sub>, T<sub>3</sub>, and TSH concentrations simultaneously (281). Studies of the D<sub>2</sub> pathway in L-T<sub>4</sub>-treated mice indicate that tissue-specific differences in D<sub>2</sub> ubiquitination account for the high T<sub>4</sub>/T<sub>3</sub> serum ratio in L-T<sub>4</sub>-treated thyroidectomized rats (268). L-T<sub>4</sub> administration at doses that normalize plasma TSH reduces whole-body D<sub>2</sub>-dependent T<sub>4</sub> to T<sub>3</sub> conversion, and a larger fraction of the circulating T<sub>3</sub> is derived from the D<sub>1</sub>

pathway. Thus, as the dose of L-T<sub>4</sub> given to thyroidectomized rats is increased, there is relatively less T<sub>3</sub> being produced via the D<sub>2</sub> pathway in peripheral tissues. Notwithstanding, D<sub>2</sub> activity and T<sub>3</sub> production in the hypothalamus of the same animals are only minimally affected by L-T<sub>4</sub> treatment. This difference in the way D<sub>2</sub> responds to therapy with L-T<sub>4</sub> creates a situation in which TSH secretion is normalized whereas circulating T<sub>3</sub> is not (Fig. 7).

*In vitro* analysis of D<sub>2</sub> ubiquitination driven by different tissue extracts indicates that the hypothalamus is less capable of maintaining D<sub>2</sub> in the ubiquitinated form. In contrast to other D<sub>2</sub>-expressing tissues, the hypothalamus exhibits less D<sub>2</sub> down-regulation when exposed to T<sub>4</sub>. As a consequence, fluctuations in plasma T<sub>4</sub> are faithfully transduced as variations in local TH signaling because the rate of local T<sub>4</sub> to T<sub>3</sub> conversion is kept stable in the face of fluctuating plasma T<sub>4</sub> levels. This is also supported by findings obtained in the TH action indicator mouse in which hypothalamic TH signaling in the hypothalamus is affected by hypothyroidism (38). These studies reveal that tissue-specific differences in D<sub>2</sub> ubiquitination are an inherent property of the HPT feedback mechanism, explaining why replacement with L-T<sub>4</sub> alone results in relatively lower plasma T<sub>3</sub> levels (Fig. 7).

The reduction in circulating T<sub>3</sub> seen in L-T<sub>4</sub>-treated patients is modest. There is understandable skepticism as to whether this is sufficient to cause even mild hypothyroidism. This was tested in a preclinical animal model, that is, thyroidectomized rats receiving L-T<sub>4</sub> at doses that normalize serum TSH but not serum T<sub>3</sub> (268). Previous studies in similarly treated animals demonstrated that T<sub>3</sub> content in most tissues is not normalized (281). Furthermore, an in-depth analysis of multiple T<sub>3</sub>-dependent markers revealed widespread signs of hypothyroidism, including an ~20% reduction in mitochondrial content in liver and SKM, and a failure to normalize serum cholesterol, which remained ~30% elevated in L-T<sub>4</sub>-treated rats. The cerebral cortex, cerebellum, and hippocampus were also analyzed for the expression of 14 T<sub>3</sub>-responsive genes, but only 5 genes were normalized; all the other genes indicated reduction in TH signaling, despite normal serum TSH. Notably, all of these parameters were normalized in rats that received combined L-T<sub>4</sub> and L-T<sub>3</sub> treatment, which normalized serum T<sub>3</sub> levels (268).

Evidence that a similar scenario happens in L-T<sub>4</sub>-treated patients already exists. In the US National Health and Nutrition Examination Survey, L-T<sub>4</sub>-treated participants with normal serum TSH differed in 12 out of 52 objective and subjective measures, including higher body mass index, despite reportedly consuming fewer calories per day per kilogram of body weight (282). This is likely explained by the fact that these patients have lower energy




expenditure (283, 284) and lower total metabolic equivalents (282). Additionally, they were more likely to be taking beta-blockers, antidepressants, and statins. Indeed, a systematic review of publications of overt hypothyroidism in which participants were treated with L-T<sub>4</sub> and had normal serum TSH levels followed by meta-analysis showed that L-T<sub>4</sub>-treated participants had  $3.3 \pm 1.6$  mg/dL higher serum low-density lipoprotein (LDL) levels and  $9.6 \pm 3.6$  mg/dL higher serum total cholesterol levels compared with controls. In studies that did not concomitantly assess healthy controls, serum LDL levels were  $138 \pm 4.6$  mg/dL (reference range,  $<129$  mg/dL) and serum total cholesterol levels were  $210 \pm 3.4$  mg/dL (reference range,  $<200$  mg/dL) (285). Taken together, these studies support the idea that L-T<sub>4</sub>-treated individuals, with normal serum TSH, exhibit objective signs of mild reduction in systemic TH signaling (285).

It is intriguing that the Thr<sub>92</sub>Ala-*DIO2* polymorphism has been linked to altered responsiveness of patients with hypothyroidism to TH replacement therapy (286, 287). In a double-blind clinical trial, Thr<sub>92</sub>Ala-*DIO2* polymorphism carriers achieved better quality of life in response to combination therapy with L-T<sub>4</sub> and L-T<sub>3</sub> compared with L-T<sub>4</sub> alone (288). This supports the idea that Thr<sub>92</sub>Ala-*DIO2* polymorphism carriers have systemic or localized dampening of TH signaling that can be overcome using L-T<sub>3</sub>. This outcome was reproduced in a subsequent study in which the compound Thr<sub>92</sub>Ala-*DIO2* and *MCT10* polymorphisms enhanced patients' preference for L-T<sub>4</sub> plus L-T<sub>3</sub> replacement therapy (289), but not in all studies (183). Subsequent studies that focused on circulating T<sub>3</sub> levels in L-T<sub>4</sub>-treated thyroidectomized carriers of the Thr<sub>92</sub>Ala-*DIO2* polymorphism support the idea that such patients might be at a greater risk of systemic and/or localized hypothyroidism (187). However, why would such a risk be detected only after hypothyroidism is diagnosed? The answer might be in the studies of mice with combined *Dio1* and *Dio2* deficiencies. These animals maintain circulating T<sub>3</sub> levels despite their inability to convert T<sub>4</sub> to T<sub>3</sub> thanks to an adjustment in thyroidal T<sub>3</sub> secretion (67). Carriers of the Thr<sub>92</sub>Ala-*DIO2* polymorphism do well for as long as their thyroid gland is functional, probably because their HPT axis adjusts thyroidal T<sub>3</sub> secretion up to compensate for deficiencies in the D<sub>2</sub> pathway (67). Once they develop hypothyroidism and are treated with L-T<sub>4</sub>, they no longer have the ability to activate the thyroid and compensate, and hence become symptomatic.

### The central nervous system

TH is essential for CNS development and function (290, 291), with documented effects on proliferation, differentiation, migration, synaptogenesis, and

**Figure 7.** TSH levels are normalized to slightly higher circulating T<sub>4</sub>/lower T<sub>3</sub> in LT<sub>4</sub>-treated patients with hypothyroidism. TSH secretion is defined by the balance between the positive input provided by TRH secretion and the negative input provided by circulating T<sub>4</sub> and T<sub>3</sub> levels. In LT<sub>4</sub>-treated patients with hypothyroidism the negative input is based on a slightly higher circulating T<sub>4</sub>/T<sub>3</sub> ratio when compared with normal individuals. This is because of an imbalance between D<sub>2</sub> ubiquitination in the hypothalamus vs the rest of the body. While outside the hypothalamus T<sub>4</sub>-induced D<sub>2</sub> ubiquitination limits T<sub>3</sub> production; in the hypothalamus-pituitary axis this mechanism is less efficient, preserving D<sub>2</sub>-mediated T<sub>3</sub> production even as circulating T<sub>4</sub> rises with LT<sub>4</sub> administration. A growing body of work suggests that the relatively lower circulating T<sub>3</sub> levels in LT<sub>4</sub>-treated patients with hypothyroidism are clinically relevant. LT<sub>4</sub>-treated patients weigh ~10 pounds (4.5 kg) more, exhibit higher serum cholesterol levels, are more likely to be on statin and antidepressive medications, and display a slower rate of energy expenditure. See reviews for more details (86, 87). [Adapted with permission from "Hypothyroidism, thyroid hormones and deiodinases." [www.BiancoLab.org](http://www.BiancoLab.org).]



myelination (292). In fact, TH signaling not only affects neuronal development throughout embryogenesis but also in the adult brain, regulating neural stem cell function in the hippocampus and the sub-ventricular zone, the main sites of neurogenesis in the adult mammalian brain (292, 293). Despite that D<sub>2</sub> generates most T<sub>3</sub> in the brain (294, 295), *Dio2* inactivation, globally or locally, results in a limited neurologic phenotype, suggesting the existence of compensatory mechanisms that minimize functional abnormalities caused by the absence of D<sub>2</sub>-generated T<sub>3</sub> (296). Indeed, the brain has a sophisticated range of mechanisms to control TH signaling that could potentially offset a *Dio2* deficiency, including different sets of transporters, D<sub>3</sub> and TRs (297–300) (Fig. 8). In the case of TRs, TR $\alpha$  is the isoform that predominates in the brain, with some areas also expressing TR $\beta$  (301).


Tissue architecture also affects how deiodinases and transporters modify TH signaling in the brain. *Dio2* is typically expressed in glial cells whereas



neurons express *Dio3* (294, 302–305). Details about this system were obtained after it was modeled *in vitro* using a coculture system of D2-expressing human glioma cells and D3-expressing human neuroblastoma cells. In this system, glial cell D2 activity produced T3 that acted in a paracrine fashion to induce T3-responsive genes in the cocultured neurons. D3 activity in the neurons responded to known stimuli and modulated T3 effects (239). Of course, these signaling pathways require transit of T4 and T3 across cell membranes. Glial cells are likely to take up T4 through OATP1C1 and release T3 that acts in neighboring neurons (239, 299). Additionally, limited amounts of circulating T3 also reach neurons through MCT8, contributing with ~20% of the intracellular T3 in the cerebral cortex. The resulting relatively high content of T3 causes higher than usual occupation of TRs in the brain, close to saturation levels. In some rare cases TH transport is limiting, such as in patients with Allan–Herndon–Dudley syndrome, in whom neurons that

rely on MCT8 for T3 transport have diminished TH signaling despite normal TH levels in the circulation (41, 42).

The presence of D3 in neurons at first seems puzzling and counterintuitive. Why would neurons inhibit entry of T3 if THs are so critical for brain development and function? Indeed, this does not seem to be the case. Studies performed in rats using labeled T3 and T4 molecules indicate that TRs are almost fully occupied with T3 (295). In other words, glial cells produce so much T3 that almost all TRs in the brain are bound to T3. This suggests that D3 activity in neurons does not limit T3 entry or access to the neuronal nucleus. Although having control over both local production and catabolism of T3 is intuitively advantageous, an additional hypothesis that remains to be tested is that D3 in neurons serves to minimize cellular exit of T3, preventing neurons from becoming a secondary source of T3 in the CNS.



**Figure 8.** Transport and metabolism modulate TH signaling in the brain. T4 crosses the BBB through Oatp1c1, reaching astrocytes where it is converted to T3 via D2. T3 exits astrocytes and is likely to enter neurons via MCT8. Circulating T3 can also reach neurons crossing the BBB through MCT8. The presence of D3 in neurons inactivates T3 to T2. It is not clear whether D3 preferentially targets incoming, outgoing, or both flows of T3 molecules. Shown are conditions known to affect TH signaling along with their main characteristics: (1) global-D2KO mouse; (2) Astro-D2KO mouse; (3) global-D3KO mouse; and (4) mutations of MCT8; also shown are conditions known to stimulate (5) *Dio2* or (6) *Dio3* pathways. See reviews for more details (10, 294, 299, 300). [Adapted with permission from “Depression due to deiodinase defect, despite normal thyroid hormone levels. PMID: 27501182.” [www.BiancoLab.org](http://www.BiancoLab.org)]

### Development of sensory structures and function

During development, deiodinase expression is timed for each tissue to minimize or activate local TH signaling according to a predefined developmental program. The development of sensory structures in the brain constitutes elegant models in which deiodinase expression exerts a time and spatial control of TH signaling (306–308). TH acting via TR $\beta$  controls maturation of auditory function (309) by regulating the expression of fast-activating potassium conductance in the cochlea (310). During the fetal and neonatal period, there is relatively high D<sub>3</sub> activity in the immature cochlea that dampens TH signaling (311). Later, in the postnatal phase, cochlea *Dio3* expression and D<sub>3</sub> activity decrease at the same time that D<sub>2</sub> activity rises and peaks around postnatal day 7, only to decline by postnatal day 10. Peak local TH signaling occurs at a critical stage of cochlear development, the absence of which causes an auditory phenotype similar to TR $\beta$  inactivation (312). In addition to deiodinases, TH transporters also play a critical role in this process. *Dio2* and TR $\beta$  are not coexpressed in the same cochlear cells. *Dio2* is expressed in periosteal connective tissue whereas TR $\beta$  expression is expressed in the sensory epithelium. Thus, D<sub>2</sub> generates T<sub>3</sub> in the connective tissue that acts in a paracrine-like fashion on the greater epithelial ridge and sensory epithelium residing inside the bony labyrinth to activate TR $\beta$  (129). This special compartmental anatomy of the cochlea hints to the existence of transport mechanisms that convey T<sub>3</sub> to target tissues. Different TH transporters are involved: LAT1 is located in the cochlear blood vessels and sensory hair cells, whereas MCT8 is found in the greater epithelial ridge and other structures, partly overlapping with the TR $\beta$  expression; MCT10 and OATP1C1 can also be found in the cochlea (308). Indeed, mice with inactivating mutations in *Mct8* and *Mct10* develop hearing loss (313). These animals have retarded development of the sensory epithelium, compounded with a progressive degeneration of cochlear hair cells. This phenotype is largely rescued with the administration of T<sub>3</sub>, confirming the role played by TH transporters and TH signaling in the cochlea development and function (313).

In the development of the visual system, local TH signaling plays a role in defining the fate of distinct populations of cone photoreceptors in the retina. Rodents have dichromatic vision with two types of photoreceptors that are sensitive to middle (M, green) or short (S, blue) wavelengths, depending on the photopigment they express. Cone photoreceptors throughout the retina have the potential to follow a default S-cone pathway but, upon activation of TR $\beta$ , they commit to an M-cone identity (314). Notably, TH signaling is symmetrically distributed in the retina at birth as S-pigment expression begins, due to minimal TH signaling caused by *Dio3* expression. Over time,

TH signaling is strengthened in the dorsal retina at the time of M-pigment onset (postnatal day 10), illustrating how the ratio and patterning of cone types may be determined by TH availability during retinal development (315, 316). The study of human retinal organoids confirmed that similar deiodinase-mediated control of TH signaling takes place in humans. In these organoids, S cones are specified first, followed by red (L)/M cones; TH signaling controls this temporal switch through timed expression of *DIO3* and *DIO2* within the retina. This ensures that early low TH signaling specifies S cones and high TH signaling later produces L/M cones (317). Notably, the fate of retinal cones continues to be affected by the deiodinases and TH signaling even during adulthood (318, 319). Suppression of TH signaling by overexpression of *Dio3* preserves cones in a mouse model of retinal degeneration (319). Indeed, *Dio2* inactivation improved cone survival and function in these mouse models. Additionally, cellular oxidative stress responses were increased in animal models of retina degeneration, which were improved by *Dio2* deficiency and worsened by treatment with T<sub>3</sub>. These studies suggest that dampening TH signaling in degenerating retinas might constitute a therapeutic approach aimed at cone preservation (318).

### Motor activity

TH signaling controls formation of the transient external germinal layer in the cerebellum. Both *DIO2* and *DIO3* are expressed in the cerebellum, but *DIO3* expression predominates at embryonic and neonatal stages, indicating that during this period local TH signaling is limited. If this is disrupted, as in the global-D<sub>3</sub>KO mouse, there are locomotor behavioral abnormalities manifested as impaired ability in descending a vertical pole (320). Following the perinatal period of reduced TH signaling, *Dio2* expression increases, and the enhanced local TH signaling plays a role in the adult cerebellum. Adult global-D<sub>2</sub>KO mice exhibit diminished agility and an altered global gait pattern (they walk slower, with shorter strides and with a hindlimb wider base of support than do wild-type mice). There is also impaired coordination and prehensile reflex and decreased muscle strength (321). This phenotype in the global-D<sub>2</sub>KO mouse is associated with structural cerebellar alteration, with reduced foliation, accelerated disappearance of the cerebellar external germinal layer, and premature expansion of the molecular layer at juvenile ages.

### Cognition and mood

*DIO2* and *DIO3* are expressed in multiple brain areas involved in behavioral and mood processes, with important roles played by local TH signaling. Indeed, global-D<sub>2</sub>KO mice, which have reduced brain T<sub>3</sub> content and TH signaling (304), have increased anxiety and fear memory (322). Furthermore, a mouse in

which *Dio2* has been selectively inactivated in astrocytes (Astro-D2KO) has anxiety/depression-like behavior (70). Notably, the opposite phenotype, that is, hyperactivity and significantly decreased anxiety-like behavior, was observed in the global-D3KO mouse, a model of enhanced TH signaling in the brain (323).

The effects of a more subtle impairment of T<sub>4</sub> to T<sub>3</sub> conversion in the brain were studied in a mouse carrier of the Thr92Ala-*Dio2* polymorphism, in which there was an ~20% reduction in D<sub>2</sub>-mediated T<sub>3</sub> production (186). Despite normal serum T<sub>3</sub> levels, microarray analyses of the Ala92-*Dio2* brain revealed reduced TH signaling in the striatum, amygdala, prefrontal cortex, hippocampus, and cerebellum (186). These mice underwent testing for mood and behavior and were found to have higher exploratory and more risk assessment behavior than did control mice. The pattern of higher mobility in Ala92-*Dio2* mice was maintained during the highly anxiogenic tail suspension studies (186). Notably, once settled in the environment, Ala92-*Dio2* mice traveled ~30% shorter distances and slept ~4.2-fold longer than did control mice. Cognition in these animals was tested through standard memory tests, with the Ala92-*Dio2* mice failing the 3-hour recall test. Increasing TH signaling with L-T<sub>3</sub> administration partially rescued the Ala92-*Dio2* mouse phenotype, confirming that localized reduction in TH signaling plays a role in the phenotype (186).

In contrast, the localized increase in brain TH signaling seen in the global-D3KO mouse was associated with a significant increase in aggression-related behaviors and mild deficits in olfactory function (324). Additionally, 85% of global-D3KO dams manifested no pup-retrieval behavior and increased aggression toward newborns. The abnormal social behaviors of global-D3KO mice are associated with sexually dimorphic alterations in oxytocin and arginine vasopressin, two neuropeptides that affect social interactions. Global-D3KO mice exhibited lower serum oxytocin and arginine vasopressin levels, as well as abnormal expression of both peptides and their receptors in the neonatal and adult hypothalamus (324). Developmental overexposure to T<sub>3</sub> as a result of *Dio3* inactivation changed hypothalamic gene expression of more than a thousand genes in postnatal day 15 mice. The alterations in gene expression extended to other brain regions and, in adulthood, were associated with decreased anxiety-like behavior, increased marble burying, and reduced physical activity (325). Overall, these studies indicate that *Dio2* and *Dio3* are important in establishing mood, with *Dio3* also involved in aggression and maternal behaviors.

#### **Traumatic and hypoxic-ischemic brain injury**

TH signaling in the brain can be disrupted by a severe insult such as traumatic brain injury (TBI) (326). In rats, TBI is associated with reduction in *MCT8* and *Dio2* mRNA levels in the brain, as well as an elevation

of *Dio3* mRNA levels, which is compatible with a reduction in TH signaling. The cortex, compared with the hippocampus and cerebellum, sustained the greatest injury and displayed the most significant change in gene expression as a result of injury (326). Insults such as ischemia or hypoxia, in which there is induction of *DIO3* as a result of hypoxia-inducible factor (HIF)1 $\alpha$  activation in neurons, also leads to reduced TH signaling (239). Hypoxia (HIF1 $\alpha$ ) induction of *DIO3* has also been observed in the hypertrophic ventricular myocardium (43, 44, 327) and in the postinfarction myocardium (327, 328). *DIO3* induction in the brain during hypoxic or ischemic disease is associated with incorporation of D<sub>3</sub> into the nuclear membrane, which in cell models reduces the paracrine effects of T<sub>3</sub> (164). After unilateral ischemia in the rat brain, D<sub>3</sub> protein is increased predominantly in the neuronal nuclei in the pyramidal and granular ipsilateral layers, as well as in the hilus of the dentate gyrus of the hippocampal formation (239). Similar observations were made in hippocampal neurons in culture as well as in a human neuroblastoma cell line (164). Incorporation of D<sub>3</sub> into the nuclear membrane dampens TH signaling and may reduce brain damage caused by hypoxic or ischemic disease. Notably, concentration of D<sub>3</sub> in the nuclear membrane of neurons was also seen in hippocampal sections of mice after brain hypoxia was induced by status epilepticus, an abnormally prolonged seizure that lasted 3 hours (329).

Other studies in mice, however, indicate that ischemia increases D<sub>2</sub> activity in cerebral cortex and striatum, whereas D<sub>3</sub> activity remains stable (330). In another study, D<sub>2</sub> activity was induced in a cell model by hypoxia without changes in *Dio2* mRNA levels (331). In this case, hypoxia stabilized and prolonged the half-life of D<sub>2</sub> by decreasing its susceptibility to the ubiquitin-proteasome pathway, whereas D<sub>3</sub> was not affected. TBI also increases *Dio2* mRNA expression, although it is not clear how much of this effect is due to changes in plasma and local levels of TH (332, 333). In the mouse model of status epilepticus, there was also a rapid increase in *Dio2* expression and reduction in *Dio3* expression in hippocampus, amygdala, and prefrontal cortex (329). An analysis of the hippocampal transcriptome of mice undergoing status epilepticus revealed changes in a number of genes, including those involved with response to oxidative stress, cellular homeostasis, cell signaling, and mitochondrial structure. In contrast, when Astro-D2KO mice underwent status epilepticus, the highly induced genes in the hippocampus were related to inflammation, apoptosis, and cell death (329).

Collectively, these studies suggest that a severe brain insult affects *Dio2* and *Dio3* expression, most of the time in a reciprocal fashion, modifying TH signaling in localized brain areas, which could affect the balance between adaptive and maladaptive mechanisms. The reduction in TH signaling seen during

hypoxic-ischemic events reduces energy expenditure and oxygen consumption, and it could be interpreted as an adaptive mechanism (334). Indeed, administration of the D<sub>2</sub> inhibitor rT<sub>3</sub> in rats undergoing middle cerebral artery occlusion reduced neuronal injury markers, infarct size, and neurologic deficit. Similarly, rT<sub>3</sub> increased cellular survival in primary cerebral neurons under oxygen glucose deprivation/reoxygenation stress (335). However, it is clear that not all types of brain injuries/insults result in the same changes in deiodinase and TH signaling. Notably, in the setting of TBI, treatment with T<sub>4</sub> significantly increased the expression of mRNA from B-cell lymphoma 2 (*Bcl2*), vascular endothelial growth factor (*VEGF*)A, SRY box 2 (*Sox2*), and neurotrophin, genes important for neuronal survival and recovery (326). Also, under hypoxic conditions, treatment with T<sub>3</sub> accelerated by 8 hours the expression of hypoxia-mediated genes (*VEGF*, *enolase*, *HIF2 $\alpha$* , *c-Jun*). Thus, although it is clear that injury to the brain reduces TH signaling, more studies are needed to establish whether these changes are adaptive or maladaptive, and a unifying hypothesis can be formulated (336).

#### Demyelination syndromes

Demyelinating disease is any disease of the nervous system in which the neuronal myelin sheath is damaged. This damage impairs the transmission of signals that, in turn, impairs sensation, movement, cognition, or other functions. Oligodendrocytes produce myelin, and investigators have looked for molecules that promote proliferation, differentiation, and maturation of oligodendrocyte precursor cells (OPCs). TH signaling has a well-established role in promoting oligodendrocyte differentiation and maturation, and it has been used in some settings to accelerate remyelination (337–339).

At the same time, TH signaling also plays a role upstream of the OPC maturation, namely in the differentiation of neuronal stem cells located in the subventricular zone into OPCs. Investigators noted that in the adult subventricular zone, the fate of differentiating neuronal stem cells that can give rise to neurons or OPCs depends on *Dio3* expression (340). Those cells that express *Dio3* experience a transient period of reduced TH signaling that promotes differentiation of stem cells into OPCs. As a result, there is functional remyelination and restored neural conduction, with important clinical implications (340). Thus, D<sub>3</sub>-mediated dampening of TH signaling accelerates generation of OPCs whereas exposure of OPCs to T<sub>3</sub> accelerates maturation into oligodendrocytes.

Intraventricular hemorrhage (IVH) that compromises blood flow to different brain areas remains a major cause of white matter injury in preterm infants. TH signaling seems to play a role in how the brain

responds to such injury. In both autopsy materials from human preterm infants and a rabbit model of IVH there was a reduction in D<sub>2</sub> levels, whereas D<sub>3</sub> levels were increased compared with controls without IVH; TR $\alpha$  expression was also increased in infants with IVH (341). Notably, treatment with TH accelerated recovery, which included proliferation and maturation of OPCs, augmented myelination, and restored neurologic function in pups with IVH. Furthermore, in TH-treated human preterm infants the density of myelinating oligodendrocytes was almost doubled as compared with controls. Thus, the combined elevation in D<sub>3</sub> and reduction in D<sub>2</sub> activity levels decreases TH signaling, which could be worsened by the increase in unliganded TR $\alpha$ . Given that TH promotes neurologic recovery in IVH, TH treatment should be further explored to improve the neurodevelopmental outcome of preterm infants with IVH (341).

#### Brain degenerative disease

Carriers of the Thr92Ala-*DIO2* polymorphism exhibit alterations in the transcriptome of the temporal lobe, which are typically associated with neurodegenerative diseases, such as amyloid- $\beta$  peptide processing (342). This observation led to a study designed to test the hypothesis that carriers of the Thr92Ala-*DIO2* polymorphism have increased risk for incident Alzheimer's disease (AD). Although this locus has not been identified in previous genome-wide association studies (343–345), the candidate gene approach could still lead to identification of a moderate association that provides insight into AD pathogenesis (346, 347). Knowing that the epidemiology and tissue pathology of AD vary by ethnicity (348), large cohorts comprised of thousands of blacks were compared with European Americans. The assessment indicated that black carriers of Thr92Ala-*DIO2* have 1.3-fold higher odds of developing AD. In a second cohort, Thr92Ala-*DIO2* blacks exhibited 1.35-fold higher odds of developing cognitive impairment. In contrast, in European Americans there was no association between Thr92Ala-*DIO2* and AD or dementia (349).

These findings prompted more detailed studies of cells expressing Ala92-D<sub>2</sub>, which led to the discovery that D<sub>2</sub> is normally a cargo protein in ER-Golgi intermediary compartment (ERGIC) vesicles, recycling between ER and Golgi. The Thr92 to Ala substitution (Ala92-D<sub>2</sub>) causes ER stress and activates the unfolded protein response. This pushes Ala92-D<sub>2</sub> to the Golgi apparatus via the adaptor protein ERGIC53, and accumulation in the *trans*-Golgi. Remarkably, all of these changes are restored by eliminating ER stress with the chemical chaperone 4-phenyl butyric acid (4-PBA) (186, 342). A detailed study of mice carrying the Thr92Ala-*DIO2* polymorphism revealed that different areas of their brain also exhibit ER stress and activation of the unfolded protein response, which could contribute to the phenotype of impaired cognition and

---

“...severe brain insult affects *Dio2* and *Dio3* expression, most of the time in a reciprocal fashion, modifying TH signaling in localized brain areas...”

---



motivation for physical activity (186). Furthermore, treatment with 4-PBA for 10 days reversed most of this phenotype, indicating a potential mechanism through which cognition is affected in these animals (186).

### Metabolic control

TH synergizes with the sympathetic nervous system to markedly accelerate the rate of energy expenditure, which in patients with severe hypothyroidism can fall as much as ~50% and in thyrotoxic patients can be increased by ~50%, an approximately threefold excursion over the hypothyroid baseline (350, 351). Most effects of T<sub>3</sub> are direct and take place in metabolically relevant tissues, such as BAT, liver, SKM, heart, and pancreatic islets, where dynamic regulation occurs through the action of the deiodinases. Important metabolic effects of T<sub>3</sub> have also been reported in different areas of the brain. For example, central administration of T<sub>3</sub> promotes *de novo* lipogenesis in liver and lipid oxidation in BAT through the autonomic nervous system (352, 353). Evidence exists that the TH derivative 3,5-diiodo-L-thyronine also exerts thermogenic effects by directly influencing mitochondrial activity (354, 355). However, the pathways leading to the endogenous synthesis of this molecule are presently unknown, downplaying its physiological role and potential as a signaling molecule.

Mice with targeted disruption of deiodinases exhibit a variety of metabolic phenotypes. The expression of *Dio2* and *Dio3* in the MBH strategically places both enzymes at the crossroads of neural regulation of metabolism. For example, studies in mice show that food deprivation increases hypothalamic *Dio2* mRNA levels and D2 activity. *Dio2* mRNA levels are also increased in the MBH of mice fasted for 48 hours (356). Hence, this localized increase in TH signaling could explain the reduction in *Trh* mRNA observed in fasted rats (104, 357). Deiodinase-mediated control of TH signaling in the hypothalamus might also play a role in regulating the torpor state, in which there is a dramatic reduction in metabolism and in body temperature, diminishing the energy requirements of the animal (358). In hamsters, hypothalamic *Dio2* expression is decreased during spontaneous daily torpor as well as fasting-induced torpor, indicating reduced hypothalamic TH signaling in these animals (358). Additionally, reciprocal expression of *Dio2* and *Dio3* in the MBH was shown to be critical for photoperiodically induced gonadal growth in birds (359). Long photoperiods induce hypothalamic *Dio2* expression and simultaneously reduce *Dio3* expression, indicating that long days enhance TH signaling in the MBH (359, 360). Notably, the global-D<sub>3</sub>KO mouse exhibits increased TH signaling in the hypothalamus, with abnormal expression and T<sub>3</sub> sensitivity of genes in the melanocortin system, suggesting leptin resistance. They also have decreased adiposity, reduced

BAT size, and accelerated fat loss in response to treatment with L-T<sub>3</sub>. Notably, global-D<sub>3</sub>KO mice display increased locomotor activity and an increased rate of energy expenditure along with expanded nighttime activity periods, suggesting a disrupted circadian rhythm (361).

### Dynamic changes in TH signaling affect adaptive thermogenesis and metabolism


The ability to thermoregulate is an evolutionary advantage of mammals. In the warm climate, most animals can dissipate heat efficiently. However, when exposed to cold, mammals not only minimize heat losses but at the same time increase heat production by accelerating their metabolic rate, a process known as adaptive thermogenesis (362). This is accomplished in large part due to release of norepinephrine (NE) in a number of tissues, including BAT, which upregulates cAMP-responsive genes, such as *Dio2*, *PGC1 $\alpha$* , and *UCP1* (363, 364) [Fig. 9 (365)]. All three  $\beta$ -adrenergic receptor subtypes respond to NE and increase cAMP production, but each play slightly different roles in thermogenesis and metabolic control (366–368).

*Dio2* is a cAMP-responsive gene, hence cold exposure enhances local TH signaling in BAT, essential for adaptive thermogenesis (351). When exposed to cold, thyroidectomized rats become hypothermic and fail to induce *UCP1* expression; this response is limited to ~20% of what is observed in controls. L-T<sub>4</sub> is particularly effective in restoring thermogenesis given its activation to T<sub>3</sub> in BAT via D2 (154). Circulating T<sub>3</sub> is important, but NE-induced several-fold activation of D2 activity and local T<sub>3</sub> production is critical for thermogenic function. Local TH signaling amplifies cAMP production and directly induces *UCP1* expression (155, 369, 370) and the activity of malic enzyme, glucose-6-phosphate dehydrogenase, and acetyl-coenzyme A carboxylase, key enzymes involved in BAT lipogenesis (371–373). The latter is likely to involve T<sub>3</sub> induction of the carbohydrate response element-binding protein, a T<sub>3</sub>-target gene in BAT that mediates glucose regulation of key lipogenic genes (374). The overwhelming data available on the role of *Dio2* in BAT catapulted this gene into the thermogenic program that includes *PGC1 $\alpha$*  and *UCP1* (375).

BAT expresses both TR $\alpha$  and TR $\beta$  (365). Indeed, when a selective TR $\beta$  agonist is given to hypothyroid mice there is stimulation of the BAT thermogenic program, for example, induction of *Dio2*, *UCP1*, and *PGC1 $\alpha$* , but these animals fail to generate normal amounts of cAMP and to produce heat in response to NE (376). These observations suggest that TH signaling augments BAT thermogenesis via a coordinated effort between TR $\alpha$  and TR $\beta$ . Induction of the thermogenic program depends on TR $\beta$ , whereas potentiation of cAMP generation and heat production in response to NE infusion cannot be elicited by



**Figure 9.** Local TH signaling accelerates BAT thermogenesis. BAT is a specialized organ that produces heat in response to cold exposure or excessive caloric intake (362). BAT expresses both TR $\alpha$  and TR $\beta$  (365). Heat is generated due to mitochondrial uncoupling triggered by the sympathetic nervous system [*i.e.*, NE-induced adenylyl cyclase (AC) activation and cAMP production] that also stimulates *Dio2*, increases T3, and leads to the induction of T3-responsive thermogenic genes, including *Ucp1*. Moreover, D2-generated T3 also stimulates BAT lipogenesis, which generates fatty acids used to sustain accelerated mitochondrial activity. Hypothyroid animals have impaired the ability to thermoregulate in the cold due to decreased BAT function. Global-D2KO animals exhibit a reduction in the expression of genes that define the tissue thermogenic identity (*i.e.*, *Ucp1*, *Pgc1 $\alpha$* , and *Dio2*) and exhibit impaired oxidative capacity. See reviews for more details (350, 362–364). [Adapted with permission from “Hypothyroidism, thyroid hormones and deiodinases.” [www.BiancoLab.org](http://www.BiancoLab.org).]



treatment with TR $\beta$  agonist alone, depending on activation of TR $\alpha$  as well (376). It is notable that expression of the thermogenic program in white adipose cells, also known as browning of adipose tissue, can also be activated via stimulation of TR $\beta$  (377).

***Dio2* inactivation and BAT thermogenesis.** Inhibition of BAT D2 with iopanoic acid *in vivo* (378) and in freshly isolated brown adipocytes decreases adrenergic induction of *UCP1* expression (370) and local lipogenesis (371). Studies in the global-D2KO mouse revealed an impaired thermogenic response to cold and to NE infusion (379). These animals survive by compensating for reduced TH signaling with increased sympathetic activity (380) and shivering, a behavior not typically observed in cold-exposed rodents (379). Room temperature of 21°C is sufficiently low to activate cold-induced thermogenesis in small mammals. Therefore, the overall compensatory increase in sympathetic activity renders global-D2KO mice resistant to diet-induced obesity, even when kept at room temperature. Remarkably, this phenotype is reversed when NE turnover is minimized by acclimatization at thermoneutrality (30°C), which “turns off” sympathetic activity to the BAT. As a result of the unopposed reduction in TH signaling, global-D2KO mice become markedly sensitized to diet-induced obesity, not only gaining excessive weight but also developing severe hepatic steatosis (381).

***Dio2* plays a role in defining BAT identity during development.** BAT development is a coordinated process during which local TH signaling reflects synchronized changes in deiodinase expression and activity. In the mouse, BAT develops between embryonic day (E)16.5 and E18.5, during which time *Dio2* expression is increased and *Dio3* expression is decreased, thus increasing local TH signaling (382) (Fig. 6). Targeted disruption of *Dio2* results in defective brown adipocytes, including impaired expression of genes in the adipogenic program (fatty acid-binding protein 4, cell death-inducing DNA fragmentation factor,  $\alpha$  subunit-like effector A, and acyl-coenzyme A synthetase long-chain family member 5) and thermogenic identity of these cells (*Ucp1*, *Pgc1 $\alpha$* , and *Dio2*). Global-D2KO preadipocytes exhibit delayed maturation, with fewer cells terminally differentiating into brown adipocytes (382).

**Other metabolic signals affect *Dio2* expression and local TH signaling.** A number of endogenous and exogenous molecules modulate BAT function via the *Dio2* pathway, including bile acids (383), flavonols (384), chemical chaperones (385), and the adipokine adipocyte-specific fatty acid-binding protein (AFABP) (386). Bile acids activate BAT D2 and UCP1-mediated thermogenesis via the G-protein-coupled bile acid receptor 1 (TGR5) pathway; TGR5 is a G-protein-coupled receptor that

accelerates cAMP production and BAT thermogenesis, protecting against diet-induced obesity and insulin resistance. Treatment of human skeletal myocytes with bile acid increases D<sub>2</sub> activity and O<sub>2</sub> consumption through a cAMP-dependent process (383). In fact, the TGR<sub>5</sub> selective agonist INT-777 is efficacious *in vivo*, increasing energy expenditure and reducing adiposity in a mouse model of diet-induced obesity (387). Oral supplementation of the bile acid chenodeoxycholic acid in 12 healthy female subjects for 2 days increased BAT activity and whole-body energy expenditure (388). Additionally, the study of 10 healthy subjects and 8 patients with liver cirrhosis revealed a positive correlation between circulating bile acids and whole-body energy expenditure (389). *In vitro* treatment of primary human brown adipocytes with chenodeoxycholic acid or specific TGR<sub>5</sub> agonists increased mitochondrial uncoupling and *DIO2* expression, an effect that was absent in human primary white adipocytes (388). Along the same lines but through a different pathway, kaempferol and other flavonols stimulate *DIO2* expression via a cAMP-mediated mechanism in primary cultures of human skeletal myocytes, leading to D<sub>2</sub>-mediated T<sub>3</sub> production, expression of thermogenically relevant genes, and acceleration of O<sub>2</sub> consumption (384).

ER stress constitutes a link between metabolic homeostasis and D<sub>2</sub>-mediated TH signaling (186, 390). ER stress is present when its functions are affected by factors such as buildup of misfolded proteins, disruption of redox state, or calcium homeostasis (391). In general, cells respond to ER stress in a number of ways, including blockade of mRNA translation and protein synthesis, which then minimizes ER stress (392). From a metabolic perspective, ER stress is recognized as an important pathway that can be triggered by an HFD and obesity; in adipose tissue, ER stress downregulates insulin sensitivity (393). In this regard, it is notable that ER stress leads to rapid loss of D<sub>2</sub> activity, to as low as 30% of control levels, without affecting *Dio2* mRNA levels; this drop in D<sub>2</sub> activity is accompanied by a slowdown in intracellular D<sub>2</sub>-mediated T<sub>3</sub> production, hence TH signaling (390). This drop in D<sub>2</sub> levels involves eukaryotic initiation factor 2, which blocks *Dio2* mRNA translation, hence D<sub>2</sub> synthesis. These data seem to be clinically relevant. For example, primary human airway cells normally exhibit D<sub>2</sub> activity. However, in cells obtained from patients with cystic fibrosis, the ensuing ER stress results in complete loss of D<sub>2</sub> activity (390). Notably, the chemical chaperones tauroursodeoxycholic acid (TUDCA) and 4-PBA, both molecules that minimize ER stress, increase *Dio2* expression, D<sub>2</sub> activity, and local T<sub>3</sub> production (385). In brown adipocytes, treatment with TUDCA or 4-PBA enhances TH signaling, expression of T<sub>3</sub>-dependent genes, and acceleration of O<sub>2</sub> consumption. In control mice, but not in global-D<sub>2</sub>KO mice,

treatment with TUDCA accelerates BAT D<sub>2</sub> activity, lowers the respiratory quotient, and normalizes the glucose intolerance associated with feeding an HFD (385).

#### **Human BAT is sensitive to TH signaling.**

*Dio2* is present in interscapular BAT depots in pre-mature and full-term neonatal humans in amounts comparable to rodents in terms of onset of development and peak distribution (394). In adult humans with positive fluorodeoxyglucose uptake in positron emission tomography scans, biopsies have proven the presence of D<sub>2</sub> at levels higher than in corresponding white adipose depots (395). BAT in humans seems to be responsive to TH signaling as studied in a patient with thyroid cancer who underwent positron emission tomography and CT scanning while systemically hypothyroid and during suppressive treatment with L-T<sub>4</sub>. The transient systemic hypothyroid state suppressed fluorodeoxyglucose uptake in BAT that had been previously active during the systemic hyperthyroid state created by suppressive L-T<sub>4</sub> therapy (55).

**Metabolic roles of *Dio2* in tissues other than BAT.** Studies in mice with fat-specific, Astro-specific, or skeletal muscle-specific D<sub>2</sub>KO have shed light on the role of *Dio2* in metabolically relevant tissues. The Astro-D<sub>2</sub>KO mice exhibit lower diurnal respiratory quotient and greater contribution of fatty acid oxidation to energy expenditure, but no differences in food intake. In contrast, the mice with fat-specific *Dio2* inactivation (Fat-D<sub>2</sub>KO) exhibit greater contribution of carbohydrate oxidation to energy expenditure, as illustrated by a sustained (24-hour) increase in respiratory quotient, food intake, glucose tolerance, and insulin sensitivity. Furthermore, Fat-D<sub>2</sub>KO animals that were kept on an HFD gained more body weight and fat, indicating impaired BAT thermogenesis and/or inability to oxidize the fat excess. Acclimatization of Fat-D<sub>2</sub>KO mice at thermoneutrality dissipated both features of this phenotype. Notably, muscle D<sub>2</sub> does not seem to play a significant metabolic role given that mice with skeletal muscle-specific *Dio2* inactivation (Skm-D<sub>2</sub>KO) exhibited no metabolic phenotype (71). The interpretation of these findings must also take into consideration the fact that there is BAT mixed with muscle fibers (396), suggesting that some of the local D<sub>2</sub>-mediated TH signaling and consequent metabolic effects are mediated at the BAT level and not SKM fiber.

***Dio2* polymorphism and metabolism.** Reduced catalytic activity of Thr<sub>92</sub>Ala-D<sub>2</sub> could potentially dampen TH signaling in metabolically relevant tissues that express *DIO2* (186, 187), similar to what was observed in the brain of mice carrying the Thr<sub>92</sub>Ala-*Dio2* polymorphism (186). Indeed, the first description of the Thr<sub>92</sub>Ala-*DIO2* polymorphism was described in patients at higher risk of exhibiting insulin resistance (397) and type 2 diabetes mellitus (184). Furthermore, individuals with compounded

Thr92Ala-*DIO2* and Trp64Arg  $\beta_3$ -adrenergic receptor polymorphism, a receptor variant that generates less cAMP (398), exhibit higher body mass index (173); this suggests an interaction between these variants. Of note, the current literature about the Thr92Ala-*DIO2* polymorphism is controversial, with poor reproducibility among different studies (176, 399–403). It is likely that additional unidentified linkage factors such as ethnic background play a significant role in the physiological and clinical relevance of the Thr92Ala-*DIO2* polymorphism (171, 176, 404).

### **Susceptibility to hepatic steatosis is defined by a perinatal surge in hepatic Dio2**

TR $\beta$  predominates in the adult liver, where TH signaling is mostly a reflection of circulating levels of T<sub>3</sub>. Liver has high D<sub>1</sub> activity, but D<sub>1</sub>-generated T<sub>3</sub> equilibrates rapidly with plasma, not contributing significantly to local TH signaling (39). TH signaling is a potent stimulus for lipogenesis, which is in agreement with the coupling between food intake and thyroid activity. Many of the key lipogenic enzymes and transcriptional factors are induced by T<sub>3</sub> in the liver and adipose tissue. Whereas D<sub>2</sub>-generated T<sub>3</sub> is key to ensuring high lipogenic rates in cold-stimulated BAT (371), circulating T<sub>3</sub> is thought to be the key factor defining TH signaling in liver and white adipose tissue, as in the adult mouse *Dio2* is not expressed in these tissues (405).

Notwithstanding, the global-D<sub>2</sub>KO mouse exhibits intense steatosis when placed on an HFD (381, 406, 407). Additionally, *Dio2* is ectopically expressed in the liver of mice with targeted deletion of both liver X receptor (LXR)  $\alpha$  and  $\beta$  (407), suggesting that LXR and RXR signaling inhibit *Dio2* expression. Indeed, 22(*R*)-OH-cholesterol negatively regulates human *DIO2* in a dose-dependent manner through a specific region, –901 to –584 bp, within its promoter (406). Remarkably, the adipokine AFABP induces expression of *Dio2* in BAT via inhibition of the nuclear receptor LXR $\alpha$ , thereby increasing local TH signaling. AFABP accelerates thermogenesis by activating D<sub>2</sub>-mediated T<sub>3</sub> production in brown adipocytes. The thermogenic responses to T<sub>4</sub> are abrogated in *Afabp*-KO mice but enhanced by AFABP (386).

These observations prompted follow-up studies that revealed, at around the first day of life, a transient surge in hepatocyte *Dio2* expression activates T<sub>4</sub> to T<sub>3</sub> and local TH signaling. This T<sub>3</sub> surge doubles local T<sub>3</sub> concentration and modifies the expression of ~165 genes involved in broad aspects of hepatocyte function, including lipid metabolism (72, 408) (Fig. 10). The role of *Dio2* expression was further investigated through the creation of a mouse with liver-specific *Dio2* inactivation (Alb-D<sub>2</sub>KO). These animals exhibit delay in neonatal liver expression of key lipid-related genes and a persistent reduction in *PPAR* $\gamma$  expression. Notably, the absence of a neonatal *Dio2* peak significantly modifies

the baseline and long-term hepatic transcriptional response to an HFD. In control animals, feeding an HFD changes the expression of ~400 genes involved in synthesis of fatty acids and triglycerides, whereas in Alb-D<sub>2</sub>KO animals, the response to an HFD is restricted to a different set of only ~200 genes associated with reverse cholesterol transport and lipase activity (72). A whole-genome methylation profile coupled to multiple analytical platforms indicates that 10% to 20% of these differences can be related to the presence of differentially methylated local regions mapped to sites of active/suppressed chromatin, thus qualifying as epigenetic modifications occurring as a result of neonatal *Dio2* inactivation. The resulting phenotype of the adult Alb-D<sub>2</sub>KO mouse is dramatic, with greatly reduced susceptibility to diet-induced steatosis, hypertriglyceridemia, and obesity (72).

One of the genes that underlies the Alb-D<sub>2</sub>KO phenotype is zinc finger protein-125 (*Zfp125*) (72, 408). *Zfp125* is a Foxo1-inducible transcriptional repressor that causes lipid accumulation in the alpha mouse liver 12 cell line (AML12) and liver steatosis in mice by reducing liver secretion of triglycerides and hepatocyte efflux of cholesterol (408). *Zfp125* acts by repressing 18 genes involved in lipoprotein structure and lipid binding, as well as transport. The apolipoprotein E (*APOE*) promoter contains a functional *Zfp125*-binding element that is also present in 17 other lipid-related genes repressed by *Zfp125*. Whereas liver-specific knockdown of *Zfp125* causes an “Alb-D<sub>2</sub>KO-like” metabolic phenotype, liver-specific normalization of *Zfp125* expression in Alb-D<sub>2</sub>KO mice rescues the phenotype, restoring normal susceptibility to diet-induced obesity, liver steatosis, and hypercholesterolemia (408). Overall, these studies indicate that the neonatal liver is particularly sensitive to TH signaling. The transient peak of D<sub>2</sub>-generated T<sub>3</sub> on the first day of life that doubles the local T<sub>3</sub> concentration mediates a series of epigenetic events (72), including expression of the transcriptional repressor *Zfp125*, that defines the future ability of the liver to secrete very LDL (VLDL) (408). These mechanisms are aligned with the overall positive effect of TH on liver lipogenesis and carry significant implications for future development of obesity and liver steatosis.

### **Dio3 expression in pancreatic $\beta$ -cells dampens TH signaling**

TH is transported into pancreatic islets via MCT8 (409) and OATP1C1, with T<sub>3</sub> playing a metabolic role in these cells (410). Islet cells express both *TR $\alpha$ 1* and *TR $\beta$ 1*, with a relative higher level of *TR $\alpha$ 1* found in murine pancreas  $\alpha$ -cells (411); however, glucagon secretion does not seem to be regulated by TH signaling. Exposure of zebrafish during the larval to juvenile transition to exogenous TH precociously activates the  $\beta$ -cell differentiation genes paired box 6b (*Pax6b*) and motor neuron and pancreas homeobox 1

---

“Myocardium *DIO2* was found to be protective against adverse myocardial remodeling caused by pressure overload.”

---

(*Mnx1*) while downregulating aristaless related homeobox a (*Arxa*), a master regulator of  $\alpha$ -cell development and function (412). *In vivo* studies in neonatal rats indicate that TH accelerates metabolic development of  $\beta$ -cells by inducing expression of a transcription factor, v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog a (*Mafa*), via TR $\beta$ . Additionally, THs also accelerate  $\beta$ -cell senescence through a TR $\alpha$ -dependent mechanism (413). Interspecies variability in the effects of TH signaling on  $\beta$ -cell maturation might exist vis-à-vis the observation that hypothyroidism *in utero* stimulates pancreatic  $\beta$ -cell proliferation and hyperinsulinemia in the ovine fetus during late gestation (414).


Studies involving isolated mature murine pancreatic islets indicate that TH inhibits insulin secretion (24, 25). Furthermore, T<sub>3</sub> suppresses glucagon-like peptide 1 (*GLP1*)-stimulated insulin secretion in MIN6 cells (415), which are derived from a mouse insulinoma cell line. However, the presence of *Dio3*

mRNA and D<sub>3</sub> protein in embryonic and adult human and murine pancreatic  $\beta$ -cells minimizes the inhibitory effects of T<sub>3</sub> (24, 25). In MIN6 cells, *Dio3* expression is stimulated by *GLP1*, an effect mediated via the cAMP-protein kinase A pathway. Exendin-4, a *GLP1* receptor agonist, also stimulates *Dio3* expression in MIN6 cells. Accordingly, mice with *Dio3* inactivation in pancreatic islets are glucose intolerant due to *in vitro* and *in vivo* impaired glucose-stimulated insulin secretion, without changes in peripheral sensitivity to insulin (24, 25). In these animals, neonatal (postnatal day 0) and adult pancreas exhibited reduced total islet area due to reduced  $\beta$ -cell mass, insulin content, and impaired expression of key  $\beta$ -cells genes. It is conceivable that *Dio3* expression in perinatal pancreatic  $\beta$ -cells prevents untimely exposure to TH, the absence of which leads to impaired  $\beta$ -cell function, insulin secretion, and disruption of glucose homeostasis (25). Studies in adult heterozygous mice with *Dio3* inactivation indicate that *Dio3* is preferentially expressed from the maternal allele in pancreatic islets and that inactivation of this allele is sufficient to disrupt glucose homeostasis by reducing pancreatic islet area, insulin gene expression, and glucose-stimulated insulin secretion (24).

### Heart

TR $\alpha$ 1 is present in the myocardium and in the peripheral ventricular conduction system, whereas the TR $\beta$ 1 isoform can be found in cells that form the peripheral ventricular conduction system. In the atria and in the proximal conduction system (sinoatrial node, atrioventricular node), TR $\alpha$ 1 and TR $\beta$ 1 isoforms are coexpressed (416). TH acts in the myocardium, triggering chronotropic and inotropic effects. TH signaling not only affects electrical transmission and rhythmicity but also myocardial energy metabolism, changing the types of energy substrates and the rate at which they are used. An important component of TH effects in the heart is mediated indirectly via acceleration of the rate of oxygen consumption throughout the body. By increasing global demand for oxygen, TH causes vasodilation that requires an increase in cardiac output to sustain mean arterial blood pressure.

The finding of *DIO2* mRNA in the healthy human (but not rodent) myocardium along with the identification of *DIO3* mRNA in human cardiomyocytes that were differentiated from human induced pluripotent stem cells (417) and in the myocardium of patients with various cardiac diseases suggest the existence of local mechanisms that control TH signaling (405, 418). These observations sparked general interest, given that the commonly prescribed antiarrhythmic AMIO and its active metabolite, *N-DEA*, inhibit D<sub>2</sub> activity (270). In fact, it has been proposed that inhibition of myocardial D<sub>2</sub> and consequent reduction in local TH signaling contributes to the antiarrhythmic efficacy of AMIO (419). Given the



**Figure 10.** Perinatal *Dio2* liver expression defines future susceptibility to obesity and liver steatosis. A brief surge in *Dio2* expression in the liver around the first day of life affects the methylation status [differentially methylated region (DMR)] of hundreds of genes, including *Foxo1*. The neonatal surge in TH signaling prevents methylation of three sites within the *Foxo1* promoter, allowing the gene to be expressed and stimulate *Zfp125*, a liver transcription factor that suppresses the expression of 18 genes involved in the assembly and secretion of VLDL particles. As a result, normal mice develop steatosis when placed on an HFD. In contrast, mice in which liver *Dio2* was inactivated exhibit three DMRs in the *Foxo1* gene, reducing its expression to about half of that in control mice. Consequently, the expression of the *Foxo1* downstream target *Zfp125* is also greatly reduced in the absence of the perinatal surge in *Dio2*. The reduction in *Zfp125* expression accelerates VLDL secretion, minimizing lipid deposition and steatosis when animals are fed with an HFD (72, 408).



similarities between these molecules with T<sub>3</sub>, AMIO is also thought to reduce cardiac TH signaling by inhibiting TH transport across the plasma membrane (420), and/or direct binding to TR $\alpha$  and TR $\beta$  (421, 422), and even TR-dependent gene transcription (423).

The role played by D<sub>2</sub>-generated T<sub>3</sub> in the myocardium was investigated in transgenic mice that express *DIO2* in the myocardium under the  $\alpha$ -myosin heavy chain (*MHC*) promoter (134). This mouse has normal thyroid function but exhibits a discrete increase in myocardial T<sub>3</sub> content and a gene expression profile compatible with increased TH signaling, that is, increased mRNA levels of hyperpolarization-activated cyclic nucleotide-gated potassium and sodium channel 2 (*HCN2*; an ion channel that is key to the cardiac pacemaker) and decreased  $\beta$ *MHC* mRNA levels (134). In perfused *ex vivo* studies, the  $\alpha$ MHC-D<sub>2</sub> heart had an ~20% higher heart rate and decreased levels of phosphocreatine and adenosine diphosphate, indicating accelerated metabolic rates. This is supported by results of *in vivo* studies in which glucose uptake is increased by ~2.5-fold in the  $\alpha$ MHC-D<sub>2</sub> heart (424). The increase in TH signaling is associated with an enhanced capacity of the  $\alpha$ MHC-D<sub>2</sub> heart to generate cAMP in response to catecholamine stimulation (425). The effects of increased cardiac-specific TH signaling were studied in a second  $\alpha$ MHC-D<sub>2</sub> mouse model conditionally expressing *DIO2* in the myocardium (135). Myocardium *DIO2* was found to be protective against adverse myocardial remodeling caused by pressure overload (135) or doxorubicin-induced chemical injury (424). D<sub>2</sub>-generated T<sub>3</sub> provided a host of mechanical improvements to the heart such as increased fractional shortening, velocity of circumferential fiber shortening, peak aortic outflow velocity, and aortic velocity acceleration (135). It is thus conceivable that the increase in *Dio2* mRNA observed in some murine models of cardiac remodeling is an attempt to increase cardiac performance. For example, a knock-in mouse model of inherited dilated cardiomyopathy with a deletion mutation ( $\Delta$ K210) in the cardiac troponin T gene exhibits an increase in myocardial *Dio2* mRNA and D<sub>2</sub> activity, likely as a result of generalized activation in cAMP-dependent pathways (426). Similarly, postmyocardial infarction mice develop markedly enlarged hearts with left ventricle systolic dysfunction and upregulation of *Dio2* mRNA expression in the heart (426).

Taken together, these studies support the assumption that myocardial TH signaling might enhance cardiac performance in some settings. For example, in pediatric patients undergoing cardiac surgery with cardiopulmonary bypass, the use of L-T<sub>3</sub> infusion in the postoperative period decreased the requirement for inotropic support, increased spontaneous conversion to normal sinus rhythm, and improved clinical outcomes (427). In adult high-risk

patients undergoing coronary artery bypass grafting, randomized postoperative administration of L-T<sub>3</sub> was associated with a higher mean cardiac index and lower systemic vascular resistance, but it did not change outcomes or alter the need for standard postoperative therapy (428). Additionally, in patients with depressed left ventricle function undergoing coronary artery bypass grafting, perioperative administration of L-T<sub>3</sub> resulted in a lower incidence of atrial fibrillation, fewer required instances of cardioversion or anticoagulation during hospitalization, and decreased required antiarrhythmic therapy at discharge (429). Beneficial effects of short-term L-T<sub>3</sub> replacement therapy, such as improved ventricular performance, were also observed in stable patients with ischemic or nonischemic dilated cardiomyopathy (430).

#### **Myocardial injury dampens local TH signaling**

In most models of ischemic heart disease with myocardial injury, there is ectopic cardiac expression of *Dio3*, which inactivates TH and dampens local TH signaling (27, 431, 432). It remains controversial as to whether this is an adaptive response in view of the positive effects of T<sub>3</sub> on the myocardium (see above). Dampening of TH signaling reverses the myocardial gene expression profile to that observed during embryonic development and might enhance the regeneration potential as seen in a mouse expressing a dominant-negative TR $\alpha$  (433). Dampening of TR signaling occurs through reactivation of *Dio3* (432) and increased expression of TR $\alpha$  (434), thereby shifting the balance toward unoccupied TRs. In fact, *Dio3* is expressed in human cardiomyocytes differentiated from human induced pluripotent stem cells. Exposure of these cells to iopanoic acid, a competitive inhibitor of deiodinases, changes the expression of downstream targets of T<sub>3</sub>, that is,  $\alpha$ MHC and  $\beta$ MHC, ATPase sarcoplasmic/ER Ca<sup>2+</sup> (*SERCA*), and phospholamban (*PLB*) mRNA levels, confirming dampening of TH signaling (417).

*Dio3* expression has also been observed in animal models of adverse remodeling such as myocardial infarction (328) and chronic pulmonary hypertension with right ventricular hypertrophy and ventricular failure (treatment with monocrotaline) (43, 44). Subsequent studies identified induction of cardiac *Dio3* and dampening of TH signaling in cardiomyocytes obtained from a transgenic model of progressive dilated cardiomyopathy (435). Studies in the postmyocardial infarction heart suggested that miRNAs (miRs) might play a role as well. These are noncoding RNA molecules that bind to complementary sequences of target mRNAs and function as RNA silencers and posttranscriptional regulators of gene expression, interfering with translation or causing target degradation. In the postmyocardial infarction, miR-214 is the miRNA with the highest potential to target *Dio3* mRNA (436). In this setting, miR-214 and

D<sub>3</sub> protein are coexpressed in cardiomyocytes, but *Dio3* mRNA expression precedes *miR-214* expression. This suggests that a D<sub>3</sub>-mediated decrease in TH signaling induces cardiac *miR-214* expression, which in turn suppresses both mRNA and protein D<sub>3</sub> expression. These results support the existence of a negative feedback mechanism regulating *Dio3* expression in the heart during myocardial injury (436).

Taken together, these studies served as the basis for a clinical trial that enrolled patients undergoing elective open heart surgery to assess TH deiodination in the human heart (437). Myocardial TH metabolism was assessed by analyzing the difference in serum TH levels between the aortic root (incoming blood) and the coronary sinus (outgoing blood) of patients undergoing cardiac surgery. Immediately before cardiopulmonary bypass, blood flowing through the myocardium of patients with aortic stenosis (with left ventricular hypertrophy) exhibited ~5% reduction in T<sub>3</sub> and ~7% increase in rT<sub>3</sub> levels, a decrease in the T<sub>3</sub>/rT<sub>3</sub> ratio of ~10%. In contrast, no myocardial TH metabolism was observed in patients with coronary artery disease (no ventricular hypertrophy). The accelerated TH inactivation in the myocardium of patients with aortic stenosis is likely the result of *DIO3* expression. Notably, there was no evidence to suggest TH activation in the myocardium in this study (437).

Whereas the injured myocardium could benefit from dampening of TH signaling, activation of TH signaling in other tissues of the heart seems to improve outcomes for myocardial injury. For example, activation of TH signaling in endothelial cells by selective expression of TR $\alpha$ 1 in a transgenic mouse model increased coronary blood flow by 77%, coronary conductance by 60%, and coronary reserve by 47% (438). Notably, systemic blood pressure decreased by 20% in these transgenic mice after TR $\alpha$ 1 expression, with no effects on heart rate. Furthermore, these animals exhibited much improved performance in response to myocardial ischemia followed by reperfusion, and reduced infarct size by 45%. It is thus conceivable that selective activation of TR $\alpha$ 1 in endothelial cells protects the heart against injury after an ischemic insult and does not result in adverse cardiac or systemic effects (438).

### Lung

Normal human lung exhibits both D<sub>1</sub> and D<sub>2</sub> activity (439), hinting that deiodinases control how local TH signaling affects fetal lung development and function. In fact, it is well known that TH signaling and steroids affect the maturation of pneumocytes. Prenatal administration of glucocorticoids is commonly used to accelerate lung maturation and attenuate the severity of respiratory distress syndrome (RDS). Knock-in mutations of the nuclear corepressor *SMRT* in mice (*SMRT* mRID), which specifically disrupt the interaction between *SMRT* and TRs, produces RDS caused by prematurity of the alveolar type I epithelial

cells (440). Remarkably, administration of anti-TH drugs rescues *SMRT*-induced RDS, indicating that an untimely increase in TH signaling is detrimental for lung development. Subsequent studies indicate that TR affects alveolar type I epithelial cell differentiation through Krüppel-like factor 2, a transcription factor that activates specific gene programs in these cells (440).

### *Dio2* activation plays a role in pulmonary response to injury

In addition to normal lung development and physiology, local TH signaling also plays a role in how the lung responds to injury. In mouse models of acute lung injury (lipopolysaccharide- and ventilator-induced lung injury), there is induction of both *Dio2* mRNA and D<sub>2</sub> protein in lung, with expression directly increasing with the extent of lung injury. Mice with *Dio2* knockdown exhibit increased lung injury, suggesting a protective role for *Dio2* in acute lung injury (180). In subsequent studies of ventilator-induced lung injury (VILI), global-D<sub>2</sub>KO mice exhibit greater susceptibility to VILI when compared with control mice, with poorer alveoli integrity and greater induction of lung chemokine and cytokine gene expression (441). Systemically hypothyroid mice exhibited a similar response to VILI, suggesting that the global-D<sub>2</sub>KO lungs were functionally hypothyroid. Treatment of global-D<sub>2</sub>KO mice with T<sub>3</sub> rescued many of the lung chemokine and cytokine profiles in response to VILI, suggesting that administration of T<sub>3</sub> could be beneficial for the treatment of lung injury (441).

Indeed, this was tested in a mouse model of pulmonary fibrosis, a condition in which the normal lung tissue is replaced as a result of active remodeling; there is deposition of extracellular matrix and dramatic changes in the phenotype of both fibroblasts and alveolar type II epithelial cells (442, 443). Idiopathic pulmonary fibrosis (IPF) affects ~120,000 patients in the United States (444, 445). IPF is the result of multiple cycles of epithelial cell injury and activation that provoke the migration, proliferation, and activation of mesenchymal cells with the formation of fibroblastic/myofibroblastic foci, accumulation of extracellular matrix, and abnormal wound repair (442, 446). A search in a database of IPF lungs for abnormal expression of genes involved in lung bioenergetics revealed *DIO2* among the top 20 significantly increased genes (447). *DIO2* expression was eightfold higher in lungs of patients with IPF compared with controls. Subsequent studies indicated that disruption of TH signaling via *Dio2* inactivation or systemic hypothyroidism enhanced bleomycin-induced fibrosis whereas local or systemic supplementation with TH after bleomycin administration blunted fibrosis. Aerosolized TH delivery increased survival and resolved fibrosis in two models of pulmonary fibrosis in mice (447). Sobetirome, a TR $\beta$ -selective agonist,

also blunted bleomycin-induced lung fibrosis. After bleomycin-induced injury, TH promoted mitochondrial biogenesis, improved mitochondrial bioenergetics, and attenuated mitochondria-regulated apoptosis in alveolar epithelial cells both *in vivo* and *in vitro*. TH did not blunt fibrosis in PGC1 $\alpha$ - or PTEN-induced putative kinase 1 KO mice, suggesting dependence on these pathways (447). It is conceivable that the anti-fibrotic properties of TH are associated with protection of alveolar epithelial cells and restoration of mitochondrial function and that TH may thus represent a potential therapy for pulmonary fibrosis (447).

## Musculoskeletal system

### Skeletal muscle

SKM is a target of TH signaling, with T<sub>3</sub> affecting differentiation, development, regeneration, and metabolism (448–450). TH gains access to skeletal myocytes predominantly via MCT8/OATP1C1 and signal through TR $\alpha$  (451). *DIO2* is expressed in human and murine SKM (4, 115, 450–452), with higher levels in slow-twitch compared with fast-twitch muscle (453). However, an issue remains, which is low D<sub>2</sub> activity level observed in the tissue, at least two orders of magnitude lower than brain (453–455). Is this low baseline D<sub>2</sub> activity sufficient to affect local TH signaling?

Although the role of SKM *Dio2* in TH signaling remains controversial, in some settings the global-D<sub>2</sub>KO mouse does exhibit signs of reduced TH signaling in SKM (456). In this regard, deiodinases have been studied in the context of SKM development (457, 458). Cell culture studies indicate that D<sub>2</sub> activity is increased during maturation of mouse myoblasts (115). Indeed, there is a temporal association between induction of *Dio2* and expression of developmental genes in primary muscle precursor pp6 cells (456). If these cells are obtained from global-D<sub>2</sub>KO animals, they remain in the proliferating phase and do not differentiate into myotubes, a phenotype that is rescued by addition of T<sub>3</sub> (456). Notably, during this process, the *Dio3* expression pattern is reciprocal to that of *Dio2*, a mechanism that is controlled by the histone H<sub>3</sub> demethylating enzyme (LSD-1) that induces *Dio2* and represses *Dio3* (450) (Fig. 6).

Other studies on the role of *Dio2* in defining TH signaling in SKM used animals in which SKM *Dio2* inactivation was limited to SKM (452). Floxed-*Dio2* mice were crossed with mice expressing Cre-recombinase under the myosin light chain 1f to disrupt *Dio2* expression in the late developmental stages of skeletal myocytes (SkM-D<sub>2</sub>KO). This led to an ~50% loss in D<sub>2</sub> activity in neonatal and adult SKM and ~75% loss in isolated SkM-D<sub>2</sub>KO myocytes. However, soleus (SOL) T<sub>3</sub> content was not affected. The expression of several T<sub>3</sub>-responsive genes in SKM was also preserved in neonatal SkM-D<sub>2</sub>KO hindlimb muscles, at a time that coincides with a peak of D<sub>2</sub>

activity in control animals. In adult SOL the baseline level of D<sub>2</sub> activity was about sixfold lower, and in the SkM-D<sub>2</sub>KO SOL, the expression of only one of five T<sub>3</sub>-responsive genes was reduced (452). Despite these results, adult SkM-D<sub>2</sub>KO animals performed indistinguishably from controls on a treadmill test of endurance and on muscle strength (452). These studies indicate the existence of multiple sources of *Dio2* expression in mouse SKM, with limited roles in postnatal SKM fibers.

The *Dio2* role on SKM development was further tested in mice with disruption of *Dio2* driven by two early developmental SKM promoters: myogenic regulator factor-5 (*Myf5*) and muscle determination gene (*MyoD*) (459). *Myf5* myoblasts in culture differentiate normally into myotubes, despite loss of almost all D<sub>2</sub> activity. *Dio2* mRNA levels in developing SKM obtained from *Myf5*-D<sub>2</sub>KO embryos (E18.5) were ~54% of control littermates, but the expression of the T<sub>3</sub>-responsive genes myosin, heavy polypeptide (*Myh*) 1 and 7, and ATPase sarcoplasmic/ER Ca<sup>2+</sup> transporting (*Atp2a*) 1 and 2 was not affected. In *Myf5*-D<sub>2</sub>KO and *MyoD*-D<sub>2</sub>KO neonatal hindlimb muscle, the expression of *Myh1* and *Myh7* and *Atp2a2* remained unaffected, despite a 60% to 70% loss in D<sub>2</sub> activity and/or mRNA. Only in *MyoD*-D<sub>2</sub>KO neonatal muscle was there a 40% reduction in *Atp2a1* mRNA (459). Postnatal growth of both mouse models and SKM function as assessed by exercise capacity and measurement of muscle strength were normal. Furthermore, an analysis of the adult SOL revealed no changes in the expression of T<sub>3</sub>-responsive genes, except for an ~18% increase in *MyoD*-D<sub>2</sub>KO SOL *Myh7* mRNA.


The report of two mouse models of early developmental disruption of *Dio2* in myocyte precursors with no significant SKM phenotype adds to the controversy regarding the role of D<sub>2</sub> during SKM development and as a determinant of TH signaling in adult SKM. However, there are studies indicating that TH signaling can be enhanced in SKM via induction of *Dio2* expression by physical activity (130) (Fig. 11). An acute treadmill exercise session (20 minutes at 70% to 75% of maximal aerobic capacity) increased *Dio2* expression/activity (1.5- to 2.7-fold) as well as *PGC1 $\alpha$*  mRNA levels (1.5- to 5-fold) in rat SOL muscle and white gastrocnemius muscle and in mouse SOL muscle. However, induction of *PGC1 $\alpha$*  was only partial (~40% less) in the SkM-D<sub>2</sub>KO mice by acute treadmill exercise as well as in primary SkM-D<sub>2</sub>KO myocytes stimulated with cAMP. Chronic exercise training (6 weeks) increased SOL muscle *PGC1 $\alpha$*  mRNA levels (~25%) and the mitochondrial enzyme citrate synthase (~20%). In contrast, *PGC1 $\alpha$*  expression did not change and citrate synthase decreased by ~30% in SkM-D<sub>2</sub>KO mice. SOL muscle *PGC1 $\alpha$*  response to chronic exercise was also blunted in *Myf5*-D<sub>2</sub>KO

---

"*Dio2* expression mediates part of PGC1 $\alpha$  induction by treadmill exercise and its downstream effects on mitochondrial function."

---

**Figure 11.** Physical exercise enhances TH signaling in skeletal muscle via induction of *Dio2*. One of the downstream targets of T<sub>3</sub> is the thermogenic coactivator PGC1 $\alpha$  that is key to mitochondrial function. Physical exercise accelerates cAMP production within skeletal myocytes, which induce the expression of both *Dio2* and PGC1 $\alpha$ . *Dio2* expression accelerates local activation of T<sub>4</sub> to T<sub>3</sub>, which enhances TH signaling and further stimulates PGC1 $\alpha$  expression. This TH-mediated mechanism for induction of PGC1 $\alpha$  is a component of the mitochondrial adaptation induced by exercise, which is lost in animals with skeletal muscle-specific *Dio2* inactivation (130). [Adapted with permission from “Physical exercise activates thyroid hormone in skeletal muscle.” [www.BiancoLab.org](http://www.BiancoLab.org).]



mice (130). These studies indicate that *Dio2* expression mediates part of PGC1 $\alpha$  induction by treadmill exercise and its downstream effects on mitochondrial function.

### Skeleton

TH plays a key role on postnatal bone development and metabolism, as undiagnosed congenital TH deficiency can lead to delayed growth, and hyperthyroidism in adults can lead to osteoporosis (460). TH signaling in bone cells occurs predominantly via MCT8 and TR $\alpha$ ; other TH transporters such as LATs and MCT10 are also expressed. TH induces endochondral ossification and linear bone growth by acting directly in reserve and proliferating TR-expressing chondrocytes to induce differentiation. In turn, hypertrophic chondrocytes do not express TRs (460, 461). T<sub>3</sub> acts in osteoblastic cells via TR $\alpha$  to induce differentiation and increase bone formation. Bone resorption is also accelerated by T<sub>3</sub> via induction of osteoclastic activity; however, this is an indirect effect via osteoblasts that is likely to involve expression of osteoblastic–osteoclastic coupling factors (460, 461). Studies in *Mct8*-KO animals indicate that postnatal endochondral ossification and linear growth are delayed. Furthermore, bone mass and mineralization are decreased in adult *Mct8*-KO mice (462), a phenotype that is consistent with decreased TH signaling in growth plate chondrocytes and increased TH signaling in adult bone. It is conceivable that in addition to the essential physiological requirement for MCT8 in chondrocytes, other TH

transporters in other skeletal cells play a role in adult bone maintenance (462).

Fetuses harvested from pregnant hypothyroid mice exhibited marked reduction in tissue concentration of both T<sub>4</sub> and T<sub>3</sub>, but bone development, as assessed at the distal epiphyseal growth plate of the femur and vertebra, is largely preserved up to E16.5 (463). Only at E18.5 do hypothyroid fetuses exhibit a reduction in femoral type I and type X collagen and osteocalcin mRNA levels, in the length and area of the proliferative and hypertrophic zones, in the number of chondrocytes per proliferative column, and in the number of hypertrophic chondrocytes, in addition to a slight delay in endochondral and intramembranous ossification. This suggests that up to E16.5, TH signaling in bone is kept to a minimum. In fact, *Dio3* mRNA, which in mice is present in growth plate chondrocytes, osteoblasts, and osteoclasts (460), is readily detected as early as E14.5 and its expression decreases markedly (~10-fold) at E18.5, and even more at 14 days after birth (463). In contrast, *Dio2* mRNA expression increases significantly by E18.5 and markedly (~2.5-fold) by postnatal day 14. *Dio2* mRNA was detected in growth plate chondrocytes, osteoblasts and osteoclasts, but D2 activity was only detected in osteoblasts (460, 461). Reciprocal expression patterns of *Dio2* and *Dio3* during early bone development along with the absence of a “hypothyroid-like” bone phenotype at this time suggest that coordinated reciprocal deiodinase expression keeps TH signaling in bone to very low levels up until E18.5 (463). Indeed, activation of TH signaling accelerates differentiation of



chondrogenic cells and cultured mouse tibias, but T<sub>4</sub> is as potent as T<sub>3</sub>, which indicates that T<sub>4</sub> is converted locally to T<sub>3</sub> (464). *Dio2* mRNA is present in neonatal mouse tibias (464), and D<sub>2</sub> activity can be detected in bone extracts at multiple sites of the mouse skeleton, bone marrow, and in osteoblastic cell line (53). Treatment with vitamin D [1,25(OH)<sub>2</sub>VD] induces D<sub>2</sub> activity by twofold to threefold, but estradiol, parathyroid hormone, forskolin, leptin, TNF $\alpha$ , TGF $\beta$ , and dexamethasone do not affect D<sub>2</sub> (53).

*Dio2* continues to play an important physiological role in TH signaling in adult animals. Studies in global-D<sub>2</sub>KO mice revealed bones that have reduced toughness and are brittle, displaying increased susceptibility to fracture (131). This phenotype is characterized by a 50% reduction in bone formation and a generalized increase in skeletal mineralization resulting from local deficiency of T<sub>3</sub> in osteoblasts. Articular cartilage is preserved in adult global-D<sub>2</sub>KO mice, but they exhibit increased subchondral bone mineral content (465). Therefore, osteoblast *Dio2* expression plays an essential role in the optimization of bone strength and mineralization (131).

## Reproductive organs

### Gonads

Ovaries express multiple elements of the signaling TRIAD but little is known about dynamic control of TH signaling in this organ (466). TR $\alpha$  predominates and Lats and Mct8 are the most abundant transporters in the mouse ovary (467, 468). Expression of *Dio1* and *Dio2* have also been detected at different neonatal ages, with *Dio2* mRNA levels predominating over *Dio1* (161). Indeed, evidence exists that ovarian steroidogenesis is affected by TH signaling. Ovarian granulosa cells obtained from infertile women exhibit a reduction in biological markers of fertility, which is associated with reduced expression of TRs (469). However, it is unclear whether this relationship involves modifications in TH signaling. A clearer but incomplete picture exists for the testis. The rat and human testes express TR $\alpha$  during development and adulthood (mostly in the Sertoli cells) and thus are a potential target of TH (470). Both MCT and OATP types of transporters are present in the testis (471, 472). *OATP1C1* has been identified in the Leydig cells (473) whereas *MCT8* is also expressed in the Sertoli cells. *DIO2* and *DIO3* are also expressed in the testis, suggesting that local control of TH signaling plays a role. In rodents, D<sub>2</sub> activity is located in germ cells at late stages of differentiation (51). The highest D<sub>2</sub> activity level coincides with the peak of TH in the circulation at ~3 weeks of age (161), a time that marks the end of the high proliferation rate of Sertoli cells and spermatogonia (474). This suggests that *DIO2* may assist the rising circulating TH levels in enhancing local TH signaling to trigger differentiation processes

in both cell types (470). However, adult global-D<sub>2</sub>KO mice have no specific testicular phenotype, suggesting the existence of redundant mechanisms (471). At the same time, *Dio3* expression is high in the mouse developing testis, peaking around the first 2 weeks of life. Although global-D<sub>3</sub>KO mice exhibit a dramatic testicular phenotype, it is not clear how much of the phenotype is due to deficient local D<sub>3</sub>-mediated regulation of TH signaling as opposed to systemic neonatal thyrotoxicosis that is typical in these animals, or to both (471).

### Uterus

In uterus, TR $\alpha$  is expressed in the uterine luminal epithelium, endometrial gland epithelium, and endometrial stromal cells and, moderately, with myometrial smooth muscle. In oviduct, they were observed moderately in the epithelium of the tube and the smooth muscle cells of the muscular layer (475). *Dio2* and *Dio3* are expressed in the mouse and human uterus, suggesting that local TH signaling and/or the flow of TH to the fetus is regulated by these enzymes (476–478). *Dio2* expression is in the murine endometrial stromal cells, particularly in the region adjacent to the epithelial cells of the uterine lumen (478). D<sub>3</sub> can also be found in the endometrial glands of nonpregnant human uteri, and endometrial activity approximated that of term placenta (477). Once the embryo implants into the receptive mouse uterus, *Dio3* expression and D<sub>3</sub> activity are induced in the stromal cells via progesterone and cAMP, leading to a drop in uterine T<sub>3</sub> levels and TH signaling (476). Notably, addition of T<sub>3</sub> or *Dio3* knockdown compromises decidualization (479).

### Placenta

Rat placenta expresses significant levels of TR $\alpha$  and TR $\beta$  transcripts and proteins (480). In human term placenta the use of laser capture microdissection revealed that trophoblasts express substantially less mRNA encoding TR $\alpha$  and TR $\beta$  than do stromal cells (481). Human term placenta expresses different TH transporters, including *MCT8*, *MCT10*, *LAT1*, *LAT2*, *OATP1A2*, and *OATP4A1*. These transporters are often present in the apical (maternal-facing) microvillous membrane of syncytiotrophoblasts (STBs). Studies using *Mct8*, *Mct10*, and *Lat2* KO mice indicate that none of these transporters, independently, is essential for fetal development, albeit the study of *Lat1* is inconclusive, as its inactivation is embryonic lethal (482).

Human placenta expresses *DIO2* and *DIO3* during the entire gestational period, which may affect TH signaling in the fetus (483) (Fig. 6). Before 16 weeks' gestation, the fetus relies on transplacental delivery of maternal TH. Maternofetal TH transfer is regulated by trophoblast cell membrane transporters, which mediate influx and efflux of THs, as

well as placental D<sub>3</sub> and D<sub>2</sub> that control intraplacental TH levels. *DIO<sub>2</sub>* is expressed mainly in mixed fetal membranes, but also in trophoblasts (484). D<sub>2</sub> activity declines during pregnancy, to hardly detectable levels at term. Notably, D<sub>2</sub> activity is ~200-fold lower than D<sub>3</sub> activity at all gestational ages, suggesting that placental D<sub>2</sub> plays no significant role in fetal TH levels, but it may play a role in local TH signaling, inducing differentiation of trophoblasts (485–490).

In humans, high *DIO<sub>3</sub>* expression is present in the placental STBs and cytotrophoblasts, endothelium of fetal vessels, and maternal decidua. D<sub>3</sub> is also present at other sites of maternal–fetal interface, including the umbilical arteries and vein and the fetal respiratory, digestive, and urinary tract epithelium (477). This is likely to account for the low fetal serum T<sub>3</sub> and high serum rT<sub>3</sub> levels. Placental D<sub>3</sub>-specific activity also decreases during gestation and is likely to function as a barrier for maternal TH to reach the fetus, possibly contributing to low T<sub>3</sub> and high rT<sub>3</sub> serum concentrations observed in the fetus (491). The disappearance of D<sub>3</sub> at birth is likely to explain many of the changes in neonatal TH economy occurring early in the postnatal life (492). It is uncertain exactly which cells in the placenta constitute a barrier for maternal–fetal TH transfer in the different stages of gestation, but it is clear that STBs play a role in this process. Given all the D<sub>3</sub> activity, it is unexpected that some T<sub>4</sub> molecules undergo transcellular transport across STBs without being inactivated. This suggests an alternative mechanism for T<sub>4</sub> transport, namely complexed with transthyretin (TTR) that is produced by STBs (482).

#### Tumors and kinase inhibitors

TH signaling affects the progression of certain tumors to the point that it can halt growth of basal cell carcinomas (BCCs) (133). *DIO<sub>3</sub>* is the element in the signaling TRIAD that plays the most relevant role, but other deiodinases, TRs, and TH transporters have been studied in this context as well.

#### Deiodinases

*DIO<sub>3</sub>* is predominantly expressed during embryonic development, coordinated with *DIO<sub>2</sub>* expression to fine-tune TH signaling in different tissues (5, 451). As an oncofetal protein, D<sub>3</sub> is only minimally expressed in most adult tissues (except for brain and placenta), with much higher expression levels seen in many malignant tumors (493, 494). In this regard, TGF $\beta$  and the Hedgehog family of proteins are known to stimulate *DIO<sub>3</sub>* expression and dampen TH signaling (133, 495, 496). TGF $\beta$  transcriptionally induces *DIO<sub>3</sub>* expression in human cells, including SKM myoblasts, fibroblasts, fetal epithelium, endometrium, and tumors such as hemangioma and glioma (77). Hedgehog

proteins also transcriptionally induce *DIO<sub>3</sub>*, but they also dampen TH signaling through coordinated inhibition of D<sub>2</sub> activity (133, 495, 496) and by inducing expression of *SMRT* through Gli, the effector of the Hedgehog pathway (497). The effects of the Hedgehog family of proteins are illustrated in the chicken developing growth plate, where Indian Hedgehog signaling inhibits D<sub>2</sub>-mediated T<sub>3</sub> production by inducing the ubiquitin ligase WSB1 (84, 89) and at the same time stimulates *Dio<sub>3</sub>* expression, further dampening TH signaling.

In the skin setting, the Shh pathway is constitutively active in BCCs, creating an example of how TH signaling is fine-tuned by the coordinated expression of deiodinases. Shh, signaling through Gli2, induces *DIO<sub>3</sub>* in proliferating keratinocytes, in mouse and human BCCs. Gli-induced *DIO<sub>3</sub>* dampens TH signaling, thus increasing cyclin D<sub>1</sub> and keratinocyte proliferation (498, 499). *DIO<sub>3</sub>* knockdown reduces growth of BCC xenografts in nude mice by about fivefold. This crosstalk between Shh/Gli2 and TH explains how Shh induces keratinocyte proliferation (133). Notably, BCC cells express not only *DIO<sub>3</sub>* but also substantial levels of *DIO<sub>2</sub>*. In these cells, *DIO<sub>2</sub>* inactivation accelerates cell cycle progression, thereby enhancing the proportion of S-phase cells and cyclin D<sub>1</sub> expression. Furthermore, the basal apoptotic rate is oppositely regulated in D<sub>2</sub>- and D<sub>3</sub>-depleted cells. The dual regulation of D<sub>2</sub> and D<sub>3</sub> expression plays a critical role in cell cycle progression and cell death by influencing cyclin D<sub>1</sub>-mediated entry into the G<sub>1</sub>-S phase, and may constitute a potential therapeutic approach to BCC (498, 499).

High levels of *DIO<sub>3</sub>* expression have been reported in a number of tumors, including gliomas, gliosarcomas, glioblastomas, TSH/adrenocorticotrophic hormone-producing tumors, papillary thyroid carcinoma, as well as tumor-derived cell lines of breast cancer (MCF7 cells), colon adenocarcinoma (Caco2, SW280, and HCT116 cells), endometrial cancer (ECC-1 cells), and neuroblastoma (SH-SY5Y cells), as a result of activation of ERK and p38 pathways (160, 493, 500–509). *DIO<sub>3</sub>* lies downstream of the Wnt/ $\beta$ -catenin pathway and contributes to colon carcinoma cell growth (493) and tumorigenic capacity in stem cells via T<sub>3</sub>-induced bone morphogenetic protein 4 gene, which exhibits high antitumor activity in colorectal cancer (510). *DIO<sub>3</sub>* expression in vascular tumors such as hepatic hemangiomas is most striking. Hemangiomas are common tumors of infancy that express variable levels of *DIO<sub>3</sub>*. Depending on the size of the tumor, D<sub>3</sub> levels can be so high that the tumor inactivates circulating TH faster than the thyroid gland can secrete, resulting in what it is known as consumptive hypothyroidism (505).

In recent studies, a similar condition has been observed in patients with metastatic renal cell carcinoma or gastrointestinal stromal tumors receiving

treatment with the tyrosine kinase inhibitor sunitinib (511, 512). Hepatic D<sub>3</sub> activity increases markedly in rats undergoing similar treatment with this kinase inhibitor, indicating that *DIO<sub>3</sub>* induction plays a role in sunitinib-induced hypothyroidism (511). Similar to hemangiomas, gastrointestinal stromal tumors themselves can produce consumptive hypothyroidism caused by marked overexpression of *DIO<sub>3</sub>* within the tumor (513, 514). Some kinase inhibitors might have a broader effect on TH signaling by affecting other components of the TRIAD. For example, in a study of 57 consecutive patients with hepatocellular carcinoma who were treated with sorafenib, 4 patients developed thyroiditis and 16 had elevation of TSH or FT<sub>4</sub> above the normal range; simultaneously, the serum T<sub>3</sub>/rT<sub>3</sub> ratio decreased (515). In cellular studies, sorafenib decreased T<sub>3</sub> uptake via MCT8 and to a lesser extent via MCT10 (515).

Conversely, some tumors overexpress *DIO<sub>1</sub>* and *DIO<sub>2</sub>*, with systemic consequences for thyroid economy. There are reports of patients with large or widely metastatic follicular thyroid carcinoma who had a persistently increased ratio of serum T<sub>3</sub>/T<sub>4</sub> and exhibited increased D<sub>2</sub> activity in their tumors (516, 517). In turn, *DIO<sub>1</sub>* expression can be reduced in several types of human malignancies such as papillary thyroid carcinoma, clear cell renal cell carcinoma, lung cancer, gastric cancer, hepatic adenoma, and some pituitary tumors, whereas in breast cancer, follicular thyroid carcinoma, and anaplastic thyroid cancer there is an increase in D<sub>1</sub> levels (439, 498, 518–524). Loss of *DIO<sub>1</sub>* expression is associated with proliferation and migration of renal cancer cells, downregulating oncoproteins and affecting key metabolic pathways (499, 525). In this context, miRNAs seem to play an alternative role as regulators of *DIO<sub>1</sub>* expression (521). The use of bioinformatics analyses revealed that the *DIO<sub>1</sub>* 3' untranslated region is targeted by two miRNAs, miR-224 and miR-383, with the former mediating loss of D<sub>1</sub> in renal cancer and reducing the intratumoral levels of T<sub>3</sub>. This suggests that in renal cancer cells, miR-224 dampens D<sub>1</sub>-mediated TH signaling (521). Stable reexpression of *DIO<sub>1</sub>* in these cells downregulated 26 proteins consisting mainly of oncoproteins (e.g., STAT3, ANPEP, TGFBI, TGM2) that promote proliferation, migration, and invasion. Furthermore, *DIO<sub>1</sub>* reexpression enhanced expression of LAT1 components and elevated intracellular concentration of T<sub>4</sub>. Expression of *DIO<sub>1</sub>*-affected genes strongly correlated with *DIO<sub>1</sub>* mRNA levels in biopsies of renal cancer patients as well as with their poor survival (499). Overall, this is a unique situation given that D<sub>1</sub> is not known for affecting local TH signaling in other systems.

### TRs and transcriptional coregulators

Studies in a renal cell cancer (RCC)-derived cell line indicate a possible disruption of TH signaling due to

decreased TR-interacting protein 11 (TRIP11) levels, a TR coactivator that is regulated by T<sub>3</sub> (526). Additionally, the expression of TR $\alpha$  and TR $\beta$  are also reduced in RCC tumor samples and correlated with poor prognosis in pairs of RCC tumor-control samples (526). Whether this disruption in TH signaling plays a role in tumor progression or it is just an associated event remains to be determined. However, in other tumor types a causal relationship has been established. Studies in cultured cells *in vitro* and in xenograft models *in vivo* indicate that TR $\beta$ 1 could function as a tumor suppressor (527, 528). At the same time, NCoR depletion enhances cancer cell invasion and increases tumor growth and metastatic potential in nude mice (529). Expression of TR $\beta$  increases NCoR levels, an essential step to inhibit tumor growth and metastasis. Indeed, NCoR is downregulated in human hepatocarcinomas and in the more aggressive breast cancer tumors, and its expression correlates positively with that of TR $\beta$  (529). The TR $\alpha$  pathway has also been associated with tumorigenesis: increased expression of *TR $\alpha$ 1* has been reported in cohorts of patients with colorectal tumors. In these cases, *TR $\alpha$ 1* gene expression correlates directly with Wnt activity (530). In fact, ectopic expression of *TR $\alpha$ 1* in the intestine epithelium of mice accelerates tumorigenesis and the development of more aggressive tumor phenotypes (531). In colon cancer cells, *TR $\alpha$ 1* levels regulate Wnt activity to affect cell proliferation and migration: increased expression of *TR $\alpha$ 1* was accompanied by decreased levels of several cellular inhibitors of Wnt signaling (530). Such inverse correlation found in mouse models was also demonstrated in cohorts of patients with colorectal tumors. This accounts for how the elevated *TR $\alpha$ 1* led to the activation of Wnt signaling (530), thereby establishing the potential oncogenic role of TR $\alpha$ 1 in the intestine epithelium (532). The contrasting functions of TR isoforms in tumorigenesis are puzzling. A better understanding of how both TR $\alpha$  and TR $\beta$  crosstalk with other cellular networks of tumor promoters and suppressors is necessary to characterize their role in tumorigenesis (532).

### Tissue regeneration

The observations that TH signaling as modulated by the deiodinases plays a role in tumor cell proliferation sparked interest regarding a possible similar role in tissue regeneration. In the SKM, tissue damage caused by turpentine injection results in *Dio3* expression, suggesting that reduced TH signaling is important for the initial steps of muscle regeneration (451). In fact, satellite cell-specific inactivation of *Dio3* severely impairs SKM regeneration due to massive satellite cell apoptosis (533). The proapoptotic program requires an intact *FoxO3/MyoD* axis, with both genes positively regulated by TH signaling. Induction of *Dio3* is followed by a several-fold induction of *Dio2* in the later stages of muscle

---

"D<sub>3</sub> levels can be so high that the tumor inactivates circulating TH faster than the thyroid gland can secrete, resulting in what is known as consumptive hypothyroidism."

---

regeneration, enhancing TH signaling that possibly plays a role in muscle differentiation (130, 456, 495).

Partial hepatectomy in rodents is another well-known model of tissue regeneration. *Dio3* mRNA and D<sub>3</sub> activity are several-fold increased hours after partial hepatectomy (534). This increase in D<sub>3</sub> reduces serum and liver T<sub>3</sub> and T<sub>4</sub> levels by twofold to threefold, which coincides with a peak in hepatocyte proliferation. This temporal profile also suggests that in this model dampening TH signaling via induction of *Dio3* expression favors cellular proliferation. Similar observations of reduced local TH signaling were made in rats with cholestatic liver injury and fibrosis caused by bile duct ligation (535). In this model there is strong induction of hepatic *Dio3* expression in stromal cells, whereas *Dio1* expression, which is typical in hepatocytes, decreases to low levels. *Dio3* expression occurs in the injury-activated hepatic stellate cells, which play important roles in hepatic wound healing and regeneration. Notably, hepatic stellate cell activation and *Dio3* expression are controlled by Hedgehog signaling (535). The Hedgehog family of proteins also plays a role in advanced liver fibrosis that might be present in patients with nonalcoholic fatty liver disease (535). In these patients, the reduced FT<sub>3</sub>/rT<sub>3</sub> ratio confirms the switch from *DIO1* to *DIO3* expression, reducing local TH signaling as evidenced by lower mRNA levels of T<sub>3</sub>-responsive genes.

These studies indicate that the Hedgehog-dependent changes in liver stromal cells drive repair-related changes

in hepatic deiodinase expression that dampens local TH signaling and is likely to affect cellular differentiation (535). However, this could not be verified when a novel mutant mouse with hepatocyte-specific *Dio3* deficiency was studied (536). These animals exhibited normal local responses to toxin-induced hepatonecrosis, including normal levels of tissue necrosis and regeneration. Notably, these mice exhibited accelerated systemic recovery from NTIS-induced hypothyroxinemia and low serum T<sub>3</sub> levels, confirming that peripheral reactivation of *Dio3* expression is an important factor in the pathogenesis of NTIS (536).

## Conclusions

The tranquility of the plasma T<sub>3</sub> levels contrasts with a stormy intracellular environment of a large number of tissues, in which T<sub>3</sub> levels and TH signaling rapidly increase or decrease whereas serum T<sub>3</sub> concentration remains unchanged. This is possible due to the signaling TRIAD, namely the TH transporters, deiodinases, and TRs, which modulate entry and metabolism of TH molecules as well as transduction of TH signaling. These mechanisms control how the biologic activity of the thyroid secretion impacts tissues at various life moments, during health and disease states. Understanding these mechanisms should allow for the development of customized approaches to manipulate TH signaling, with enormous therapeutic implications.

## References and Notes

- Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. *Physiol Rev.* 2014;**94**(2): 355–382.
- Brent GA. Mechanisms of thyroid hormone action. *J Clin Invest.* 2012;**122**(9):3035–3043.
- Martial JA, Seeburg PH, Guenzi D, Goodman HM, Baxter JD. Regulation of growth hormone gene expression: synergistic effects of thyroid and glucocorticoid hormones. *Proc Natl Acad Sci USA.* 1977;**74**(10):4293–4295.
- Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, Zeöld A, Bianco AC. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. *Endocr Rev.* 2008;**29**(7): 898–938.
- Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. *Endocr Rev.* 2002;**23**(1):38–89.
- Peeters RP, Visser TJ. Metabolism of thyroid hormone. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, eds. *Endotext* [Internet]. South Dartmouth, MA:MDText.com; 2000. Available at: [www.ncbi.nlm.nih.gov/books/NBK285545/](http://www.ncbi.nlm.nih.gov/books/NBK285545/).
- Galton VA. The ups and downs of the thyroxine pro-hormone hypothesis. *Mol Cell Endocrinol.* 2017;**458**:105–111.
- St Germain DL, Galton VA, Hernandez A. Defining the roles of the iodothyronine deiodinases: current concepts and challenges. *Endocrinology.* 2009;**150**(3):1097–1107.
- Bianco AC, Anderson G, Forrest D, Galton VA, Gereben B, Kim BW, Kopp PA, Liao XH, Obregon MJ, Peeters RP, Refetoff S, Sharlin DS, Simonides WS, Weiss RE, Williams GR; American Thyroid Association Task Force on Approaches and Strategies to Investigate Thyroid Hormone Economy and Action. American Thyroid Association guide to investigating thyroid hormone economy and action in rodent and cell models. *Thyroid.* 2014;**24**(1):88–168.
- Bernal J, Guadaño-Ferraz A, Morte B. Thyroid hormone transporters-functions and clinical implications. *Nat Rev Endocrinol.* 2015;**11**(12):690.
- Mendoza A, Hollenberg AN. New insights into thyroid hormone action. *Pharmacol Ther.* 2017;**173**: 135–145.
- Schweizer U, Johannes J, Bayer D, Braun D. Structure and function of thyroid hormone plasma membrane transporters. *Eur Thyroid J.* 2014;**3**(3):143–153.
- Abe T, Kakyo M, Sakagami H, Tokui T, Nishio T, Tanemoto M, Nomura H, Hebert SC, Matsuno S, Kondo H, Yawo H. Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2. *J Biol Chem.* 1998;**273**(35):22395–22401.
- Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. *J Biol Chem.* 2003;**278**(41):40128–40135.
- Friesema EC, Jansen J, Jachtenberg JW, Visser WE, Kester MH, Visser TJ. Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. *Mol Endocrinol.* 2008;**22**(6):1357–1369.
- Visser TJ. Cellular uptake of thyroid hormones. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, eds. *Endotext* [Internet]. South Dartmouth, MA:MDText.com; 2000. Available at: [www.ncbi.nlm.nih.gov/books/NBK285565/](http://www.ncbi.nlm.nih.gov/books/NBK285565/).
- Groeneweg S, Visser WE, Visser TJ. Disorder of thyroid hormone transport into the tissues. *Best Pract Res Clin Endocrinol Metab.* 2017;**31**(2): 241–253.
- Callebaut I, Curcio-Morelli C, Mornon JP, Gereben B, Buettner C, Huang S, Castro B, Fonseca TL, Harney JW, Larsen PR, Bianco AC. The iodothyronine selenodeiodinases are thioredoxin-fold family proteins containing a glycoside hydrolase clan GH-A-like structure. *J Biol Chem.* 2003;**278**(38):36887–36896.
- Schweizer U, Schlicker C, Braun D, Köhrle J, Steegborn C. Crystal structure of mammalian



- selenocysteine-dependent iodothyronine deiodinase suggests a peroxiredoxin-like catalytic mechanism. *Proc Natl Acad Sci USA*. 2014;**111**(29):10526–10531.
20. Curcio-Morelli C, Gereben B, Zavacki AM, Kim BW, Huang S, Harney JW, Larsen PR, Bianco AC. In vivo dimerization of types 1, 2, and 3 iodothyronine selenodeiodinases. *Endocrinology*. 2003;**144**(3):937–946.
  21. Sagar GD, Gereben B, Callebaut I, Mornon JP, Zeöld A, Curcio-Morelli C, Harney JW, Luongo C, Mulcahey MA, Larsen PR, Huang SA, Bianco AC. The thyroid hormone-inactivating deiodinase functions as a homodimer. *Mol Endocrinol*. 2008;**22**(6):1382–1393.
  22. Becker KB, Stephens KC, Davey JC, Schneider MJ, Galton VA. The type 2 and type 3 iodothyronine deiodinases play important roles in coordinating development in *Rana catesbeiana* tadpoles. *Endocrinology*. 1997;**138**(7):2989–2997.
  23. Darras VM, Hume R, Visser TJ. Regulation of thyroid hormone metabolism during fetal development. *Mol Cell Endocrinol*. 1999;**151**(1–2):37–47.
  24. Medina MC, Fonesca TL, Molina J, Fachado A, Castillo M, Dong L, Soares R, Hernández A, Caicedo A, Bianco AC. Maternal inheritance of an inactive type III deiodinase gene allele affects mouse pancreatic  $\beta$ -cells and disrupts glucose homeostasis. *Endocrinology*. 2014;**155**(8):3160–3171.
  25. Medina MC, Molina J, Gadea Y, Fachado A, Murillo M, Simovic G, Pileggi A, Hernández A, Edlund H, Bianco AC. The thyroid hormone-inactivating type III deiodinase is expressed in mouse and human  $\beta$ -cells and its targeted inactivation impairs insulin secretion. *Endocrinology*. 2011;**152**(10):3717–3727.
  26. Peeters RP, Wouters PJ, van Toor H, Kaptein E, Visser TJ, Van den Berghe G. Serum 3,3',5'-triiodothyronine (rT3) and 3,5,3'-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. *J Clin Endocrinol Metab*. 2005;**90**(8):4559–4565.
  27. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. *J Clin Endocrinol Metab*. 2003;**88**(7):3202–3211.
  28. Schneider MJ, Fiering SN, Thai B, Wu SY, St Germain E, Parlow AF, St Germain DL, Galton VA. Targeted disruption of the type 1 selenodeiodinase gene (*Dio1*) results in marked changes in thyroid hormone economy in mice. *Endocrinology*. 2006;**147**(1):580–589.
  29. Larsen PR, Silva JE, Kaplan MM. Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. *Endocr Rev*. 1981;**2**(1):87–102.
  30. Baqui MM, Gereben B, Harney JW, Larsen PR, Bianco AC. Distinct subcellular localization of transiently expressed types 1 and 2 iodothyronine deiodinases as determined by immunofluorescence confocal microscopy. *Endocrinology*. 2000;**141**(11):4309–4312.
  31. Hönes GS, Rakov H, Logan J, Liao XH, Werbenko E, Pollard AS, Præstholm SM, Siersbæk MS, Rijntjes E, Gassen J, Latteyer S, Engels K, Strucksberg KH, Kleinbongard P, Zwanziger D, Rozman J, Gailus-Durner V, Fuchs H, Hrabec de Angelis M, Klein-Hitpass L, Köhrle J, Armstrong DL, Grøntved L, Bassett JH, Williams GR, Refetoff S, Führer D, Moeller LC. Noncanonical thyroid hormone signaling mediates cardiometabolic effects in vivo. *Proc Natl Acad Sci USA*. 2017;**114**(52):E11323–E11332.
  32. Oppenheimer JH, Schwartz HL, Surks MI. Tissue differences in the concentration of triiodothyronine nuclear binding sites in the rat: liver, kidney, pituitary, heart, brain, spleen, and testis. *Endocrinology*. 1974;**95**(3):897–903.
  33. Bianco AC, Silva JE. Nuclear 3,5,3'-triiodothyronine (T3) in brown adipose tissue: receptor occupancy and sources of T3 as determined by in vivo techniques. *Endocrinology*. 1987;**120**(1):55–62.
  34. Oppenheimer JH, Schwartz HL. Molecular basis of thyroid hormone-dependent brain development. *Endocr Rev*. 1997;**18**(4):462–475.
  35. Oppenheimer JH, Schwartz HL, Mariash CN, Kinlaw WB, Wong NCW, Freaker HC. Advances in our understanding of thyroid hormone action at the cellular level. *Endocr Rev*. 1987;**8**(3):288–308.
  36. Oppenheimer JH. Thyroid hormone action at the cellular level. *Science*. 1979;**203**(4384):971–979.
  37. Quignodon L, Legrand C, Allioli N, Guadaño-Ferraz A, Bernal J, Samarut J, Flamant F. Thyroid hormone signaling is highly heterogeneous during pre- and postnatal brain development. *J Mol Endocrinol*. 2004;**33**(2):467–476.
  38. Mohácsik P, Erdélyi F, Baranyi M, Botz B, Szabó G, Tóth M, Haltrich I, Helyes Z, Sperlágh B, Tóth Z, Sínkó R, Lechan RM, Bianco AC, Fekete C, Gereben B. A transgenic mouse model for detection of tissue-specific thyroid hormone action. *Endocrinology*. 2018;**159**(2):1159–1171.
  39. Silva JE, Dick TE, Larsen PR. The contribution of local tissue thyroxine monodeiodination to the nuclear 3,5,3'-triiodothyronine in pituitary, liver, and kidney of euthyroid rats. *Endocrinology*. 1978;**103**(4):1196–1207.
  40. Silva JE, Larsen PR. Contributions of plasma triiodothyronine and local thyroxine monodeiodination to triiodothyronine to nuclear triiodothyronine receptor saturation in pituitary, liver, and kidney of hypothyroid rats. Further evidence relating saturation of pituitary nuclear triiodothyronine receptors and the acute inhibition of thyroid-stimulating hormone release. *J Clin Invest*. 1978;**61**(5):1247–1259.
  41. Friesema EC, Grueters A, Biebermann H, Krude H, von Moers A, Reeser M, Barrett TG, Mancilla EE, Svensson J, Kester MH, Kuiper GG, Balkasmi S, Uitterlinden AG, Koehler J, Rodien P, Halestrap AP, Visser TJ. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. *Lancet*. 2004;**364**(9443):1435–1437.
  42. Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. *Am J Hum Genet*. 2004;**74**(1):168–175.
  43. Simonides WS, Mulcahey MA, Redout EM, Muller A, Zuidwijk MJ, Visser TJ, Wassen FW, Crescenzi A, da-Silva WS, Harney J, Engel FB, Obregon MJ, Larsen PR, Bianco AC, Huang SA. Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. *J Clin Invest*. 2008;**118**(3):975–983.
  44. Wassen FW, Schiel AE, Kuiper GG, Kaptein E, Bakker O, Visser TJ, Simonides WS. Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. *Endocrinology*. 2002;**143**(7):2812–2815.
  45. Laurberg P. Mechanisms governing the relative proportions of thyroxine and 3,5,3'-triiodothyronine in thyroid secretion. *Metabolism*. 1984;**33**(4):379–392.
  46. Laurberg P. Thyroxine and 3,5,3'-triiodothyronine content of thyroglobulin in thyroid needle aspirates in hyperthyroidism and hypothyroidism. *J Clin Endocrinol Metab*. 1987;**64**(5):969–974.
  47. Pilo A, Iervasi G, Vitek F, Ferdeghini M, Cazzuola F, Bianchi R. Thyroidal and peripheral production of 3,5,3'-triiodothyronine in humans by multi-compartmental analysis. *Am J Physiol*. 1990;**258**(4 Pt 1):E715–E726.
  48. St Germain DL, Hernandez A, Schneider MJ, Galton VA. Insights into the role of deiodinases from studies of genetically modified animals. *Thyroid*. 2005;**15**(8):905–916.
  49. Hosoi Y, Murakami M, Mizuma H, Ogiwara T, Imamura M, Mori M. Expression and regulation of type II iodothyronine deiodinase in cultured human skeletal muscle cells. *J Clin Endocrinol Metab*. 1999;**84**(9):3293–3300.
  50. Mizuma H, Murakami M, Mori M. Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase. *Circ Res*. 2001;**88**(3):313–318.
  51. Wajner SM, dos Santos Wagner M, Melo RC, Parreira GG, Chiarini-Garcia H, Bianco AC, Fekete C, Sanchez E, Lechan RM, Maia AL. Type 2 iodothyronine deiodinase is highly expressed in germ cells of adult rat testis. *J Endocrinol*. 2007;**194**(1):47–54.
  52. Williams AJ, Robson H, Kester MH, van Leeuwen JP, Shalet SM, Visser TJ, Williams GR. Iodothyronine deiodinase enzyme activities in bone. *Bone*. 2008;**43**(1):126–134.
  53. Gouveia CH, Christoffoleti MA, Zaitune CR, Dora JM, Harney JW, Maia AL, Bianco AC. Type 2 iodothyronine selenodeiodinase is expressed throughout the mouse skeleton and in the MC3T3-E1 mouse osteoblastic cell line during differentiation. *Endocrinology*. 2005;**146**(1):195–200.
  54. Silva JE, Larsen PR. Potential of brown adipose tissue type II thyroxine 5'-deiodinase as a local and systemic source of triiodothyronine in rats. *J Clin Invest*. 1985;**76**:2296–2305.
  55. Skarulis MC, Celi FS, Mueller E, Zemskova M, Malek R, Hugendubler L, Cochran C, Solomon J, Chen C, Gorden P. Thyroid hormone induced brown adipose tissue and amelioration of diabetes in a patient with extreme insulin resistance. *J Clin Endocrinol Metab*. 2010;**95**(1):256–262.
  56. Visser TJ. Role of sulfation in thyroid hormone metabolism. *Chem Biol Interact*. 1994;**92**(1–3):293–303.
  57. Trajkovic-Arsic M, Müller J, Darras VM, Groba C, Lee S, Weih D, Bauer K, Visser TJ, Heuer H. Impact of monocarboxylate transporter-8 deficiency on the hypothalamus-pituitary-thyroid axis in mice. *Endocrinology*. 2010;**151**(10):5053–5062.
  58. Citterio CE, Morishita Y, Dakka N, Veluswamy B, Arvan P. Relationship between the dimerization of thyroglobulin and its ability to form triiodothyronine. *J Biol Chem*. 2018;**293**(13):4860–4869.
  59. Citterio CE, Veluswamy B, Morgan SJ, Galton VA, Banga JP, Atkins S, Morishita Y, Neumann S, Latif R, Gershengorn MC, Smith TJ, Arvan P. *De novo* triiodothyronine formation from thyrocytes activated by thyroid-stimulating hormone. *J Biol Chem*. 2017;**292**(37):15434–15444.
  60. Di Jeso B, Arvan P. Thyroglobulin from molecular and cellular biology to clinical endocrinology. *Endocr Rev*. 2016;**37**(1):2–36.
  61. Nimalasuriya A, Spencer CA, Lin SC, Tse JK, Nicoloff JT. Studies on the diurnal pattern of serum 3,5,3'-triiodothyronine. *J Clin Endocrinol Metab*. 1986;**62**(1):153–158.
  62. Lartey LJ, Werneck-de-Castro JP, O-Sullivan I, Unterman TG, Bianco AC. Coupling between nutrient availability and thyroid hormone activation. *J Biol Chem*. 2015;**290**(51):30551–30561.
  63. de Vries EM, van Beeren HC, Ackermans MT, Kalsbeek A, Fliers E, Boelen A. Differential effects of

- fasting vs food restriction on liver thyroid hormone metabolism in male rats. *J Endocrinol*. 2015;**224**(1): 25–35.
64. Russell W, Harrison RF, Smith N, Darzy K, Shalet S, Weetman AP, Ross RJ. Free triiodothyronine has a distinct circadian rhythm that is delayed but parallels thyrotropin levels. *J Clin Endocrinol Metab*. 2008;**93**(6):2300–2306.
  65. Schneider MJ, Fiering SN, Pallud SE, Parlow AF, St Germain DL, Galton VA. Targeted disruption of the type 2 selenodeiodinase gene (*DIO2*) results in a phenotype of pituitary resistance to T4. *Mol Endocrinol*. 2001;**15**(12):2137–2148.
  66. Berry MJ, Grieco D, Taylor BA, Maia AL, Kieffer JD, Beamer W, Glover E, Poland A, Larsen PR. Physiological and genetic analyses of inbred mouse strains with a type I iodothyronine 5' deiodinase deficiency. *J Clin Invest*. 1993;**92**(3):1517–1528.
  67. Christoffolete MA, Arrojo e Drigo R, Gazoni F, Tente SM, Goncalves V, Amorim BS, Larsen PR, Bianco AC, Zavacki AM. Mice with impaired extrathyroidal thyroxine to 3,5,3'-triiodothyronine conversion maintain normal serum 3,5,3'-triiodothyronine concentrations. *Endocrinology*. 2007;**148**(3):954–960.
  68. Galton VA, Schneider M, Clark AS, Germain DL. Life without thyroxine to 3,5,3'-triiodothyronine conversion: studies in mice devoid of the 5'-deiodinases. *Endocrinology*. 2009;**150**(6):2957–2963.
  69. Fonseca TL, Correa-Medina M, Campos MP, Wittmann G, Werneck-de-Castro JP, Arrojo e Drigo R, Mora-Garzon M, Ueta CB, Caicedo A, Fekete C, Gereben B, Lechan RM, Bianco AC. Coordination of hypothalamic and pituitary T3 production regulates TSH expression. *J Clin Invest*. 2013;**123**(4):1492–1500.
  70. Bocco BM, Werneck-de-Castro JP, Oliveira KC, Fernandes GW, Fonseca TL, Nascimento BP, McAninch EA, Ricci E, Kvarita-Papp Z, Fekete C, Bernardi MM, Gereben B, Bianco AC, Ribeiro MO. Type 2 deiodinase disruption in astrocytes results in anxiety-depressive-like behavior in male mice. *Endocrinology*. 2016;**157**(9):3682–3695.
  71. Fonseca TL, Werneck-De-Castro JP, Castillo M, Bocco BM, Fernandes GW, McAninch EA, Ignacio DL, Moises CC, Ferreira AR, Gereben B, Bianco AC. Tissue-specific inactivation of type 2 deiodinase reveals multilevel control of fatty acid oxidation by thyroid hormone in the mouse (published correction appears in *Diabetes*. 2014;**63**(8):2895). *Diabetes*. 2014;**63**(5):1594–1604.
  72. Fonseca TL, Fernandes GW, McAninch EA, Bocco BM, Abdalla SM, Ribeiro MO, Mohácsik P, Fekete C, Li D, Xing X, Wang T, Gereben B, Bianco AC. Perinatal deiodinase 2 expression in hepatocytes defines epigenetic susceptibility to liver steatosis and obesity. *Proc Natl Acad Sci USA*. 2015;**112**(45): 14018–14023.
  73. Riesco G, Taurag A, Larsen R, Krülich L. Acute and chronic responses to iodine deficiency in rats. *Endocrinology*. 1977;**100**(2):303–313.
  74. Santisteban P, Obregon MJ, Rodriguez-Peña A, Lamas L, Del Rey FE, De Escobar GM. Are iodine-deficient rats euthyroid? *Endocrinology*. 1982;**110**(5): 1780–1789.
  75. Chopra IJ, Hershman JM, Hornabrook RW. Serum thyroid hormone and thyrotropin levels in subjects from endemic goiter regions of New Guinea. *J Clin Endocrinol Metab*. 1975;**40**(2):326–333.
  76. Gereben B, Salvatore D. Pretranslational regulation of type 2 deiodinase. *Thyroid*. 2005;**15**(8):855–864.
  77. Huang SA. Physiology and pathophysiology of type 3 deiodinase in humans. *Thyroid*. 2005;**15**(8):875–881.
  78. Inada M, Kasagi K, Kurata S, Kazama Y, Takayama H, Torizuka K, Fukase M, Soma T. Estimation of thyroxine and triiodothyronine distribution and of the conversion rate of thyroxine to triiodothyronine in man. *J Clin Invest*. 1975;**55**(6):1337–1348.
  79. Nicoloff JT, Lum SM, Spencer CA, Morris R. Peripheral autoregulation of thyroxine to triiodothyronine conversion in man. *Horm Metab Res Suppl*. 1984;**14**:74–79.
  80. Lum SM, Nicoloff JT, Spencer CA, Kaptein EM. Peripheral tissue mechanism for maintenance of serum triiodothyronine values in a thyroxine-deficient state in man. *J Clin Invest*. 1984;**73**(2):570–575.
  81. Kim SW, Harney JW, Larsen PR. Studies of the hormonal regulation of type 2 5'-iodothyronine deiodinase messenger ribonucleic acid in pituitary tumor cells using semiquantitative reverse transcription-polymerase chain reaction. *Endocrinology*. 1998;**139**(12):4895–4905.
  82. Steinsapir J, Bianco AC, Buettner C, Harney J, Larsen PR. Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme's active center. *Endocrinology*. 2000;**141**(3):1127–1135.
  83. Steinsapir J, Harney J, Larsen PR. Type 2 iodothyronine deiodinase in rat pituitary tumor cells is inactivated in proteasomes. *J Clin Invest*. 1998;**102**(11):1895–1899.
  84. Sagar GD, Gereben B, Callebaut I, Mornon JP, Zeöld A, da Silva WS, Luongo C, Dentice M, Tente SM, Freitas BC, Harney JW, Zavacki AM, Bianco AC. Ubiquitination-induced conformational change within the deiodinase dimer is a switch regulating enzyme activity. *Mol Cell Biol*. 2007;**27**(13): 4774–4783.
  85. Gereben B, Goncalves C, Harney JW, Larsen PR, Bianco AC. Selective proteolysis of human type 2 deiodinase: a novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. *Mol Endocrinol*. 2000;**14**(11):1697–1708.
  86. McAninch EA, Bianco AC. New insights into the variable effectiveness of levothyroxine monotherapy for hypothyroidism. *Lancet Diabetes Endocrinol*. 2015;**3**(10):756–758.
  87. Gereben B, McAninch EA, Ribeiro MO, Bianco AC. Scope and limitations of iodothyronine deiodinases in hypothyroidism. *Nat Rev Endocrinol*. 2015;**11**(11): 642–652.
  88. Zeöld A, Pormüller L, Dentice M, Harney JW, Curcio-Morelli C, Tente SM, Bianco AC, Gereben B. Metabolic instability of type 2 deiodinase is transferable to stable proteins independently of subcellular localization. *J Biol Chem*. 2006;**281**(42): 31538–31543.
  89. Dentice M, Bandyopadhyay A, Gereben B, Callebaut I, Christoffolete MA, Kim BW, Nissim S, Mornon JP, Zavacki AM, Zeöld A, Capelo LP, Curcio-Morelli C, Ribeiro R, Harney JW, Tabin CJ, Bianco AC. The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. *Nat Cell Biol*. 2005;**7**(7):698–705.
  90. Botero D, Gereben B, Goncalves C, De Jesus LA, Harney JW, Bianco AC. Ubc6p and Ubc7p are required for normal and substrate-induced endoplasmic reticulum-associated degradation of the human selenoprotein type 2 iodothyronine mono-deiodinase. *Mol Endocrinol*. 2002;**16**(9):1999–2007.
  91. Kim BW, Zavacki AM, Curcio-Morelli C, Dentice M, Harney JW, Larsen PR, Bianco AC. Endoplasmic reticulum-associated degradation of the human type 2 iodothyronine deiodinase (D2) is mediated via an association between mammalian UBC7 and the carboxyl region of D2. *Mol Endocrinol*. 2003;**17**(12):2603–2612.
  92. Zavacki AM, Arrojo E, Drigo R, Freitas BC, Chung M, Harney JW, Egri P, Wittmann G, Fekete C, Gereben B, Bianco AC. The E3 ubiquitin ligase TEB4 mediates degradation of type 2 iodothyronine deiodinase. *Mol Cell Biol*. 2009;**29**(19):5339–5347.
  93. Egri P, Gereben B. Minimal requirements for ubiquitination-mediated regulation of thyroid hormone activation. *J Mol Endocrinol*. 2014;**53**(2): 217–226.
  94. Curcio-Morelli C, Zavacki AM, Christoffolete M, Gereben B, de Freitas BC, Harney JW, Li Z, Wu G, Bianco AC. Deubiquitination of type 2 iodothyronine deiodinase by von Hippel-Lindau protein-interacting deubiquitinating enzymes regulates thyroid hormone activation. *J Clin Invest*. 2003;**112**(2):189–196.
  95. Arrojo E, Drigo R, Egri P, Jo S, Gereben B, Bianco AC. The type II deiodinase is retrotranslocated to the cytoplasm and proteasomes via p97/Atx3 complex. *Mol Endocrinol*. 2013;**27**(12):2105–2115.
  96. Spaulding SW, Chopra IJ, Sherwin RS, Lyall SS. Effect of caloric restriction and dietary composition of serum T3 and reverse T3 in man. *J Clin Endocrinol Metab*. 1976;**42**(1):197–200.
  97. Danforth E Jr, Horton ES, O'Connell M, Sims EA, Burger AG, Ingbar SH, Braverman L, Vagenakis AG. Dietary-induced alterations in thyroid hormone metabolism during overnutrition. *J Clin Invest*. 1979;**64**(5):1336–1347.
  98. Schebendach JE, Golden NH, Jacobson MS, Hertz S, Shenker IR. The metabolic responses to starvation and refeeding in adolescents with anorexia nervosa. *Ann N Y Acad Sci*. 1997;**817**:110–119.
  99. Park HK, Ahima RS. Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism. *Metabolism*. 2015;**64**(1):24–34.
  100. Boelen A, Wiersinga WM, Fliers E. Fasting-induced changes in the hypothalamus–pituitary–thyroid axis. *Thyroid*. 2008;**18**(2):123–129.
  101. Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. *J Clin Invest*. 2003;**111**(9):1409–1421.
  102. LoPresti JS, Gray D, Nicoloff JT. Influence of fasting and refeeding on 3,3',5'-triiodothyronine metabolism in man. *J Clin Endocrinol Metab*. 1991;**72**(1): 130–136.
  103. Spencer CA, Lum SM, Wilber JF, Kaptein EM, Nicoloff JT. Dynamics of serum thyrotropin and thyroid hormone changes in fasting. *J Clin Endocrinol Metab*. 1983;**56**(5):883–888.
  104. Diano S, Naftolin F, Goglia F, Horvath TL. Fasting-induced increase in type II iodothyronine deiodinase activity and messenger ribonucleic acid levels is not reversed by thyroxine in the rat hypothalamus. *Endocrinology*. 1998;**139**(6):2879–2884.
  105. Eisenstein Z, Hagg S, Vagenakis AG, Fang SL, Ransil B, Burger A, Balsam A, Braverman LE, Ingbar SH. Effect of starvation on the production and peripheral metabolism of 3,3',5'-triiodothyronine in euthyroid obese subjects. *J Clin Endocrinol Metab*. 1978;**47**(4): 889–893.
  106. LoPresti JS, Mizuno L, Nimalysuria A, Anderson KP, Spencer CA, Nicoloff JT. Characteristics of 3,5,3'-triiodothyronine sulfate metabolism in euthyroid man. *J Clin Endocrinol Metab*. 1991;**73**(4):703–709.
  107. Kinlaw WB, Schwartz HL, Oppenheimer JH. Decreased serum triiodothyronine in starving rats is due primarily to diminished thyroidal secretion of thyroxine. *J Clin Invest*. 1985;**75**(4):1238–1241.
  108. Balsam A, Ingbar SH. The influence of fasting, diabetes, and several pharmacological agents on the pathways of thyroxine metabolism in rat liver. *J Clin Invest*. 1978;**62**(2):415–424.

109. Zavacki AM, Ying H, Christoffolete MA, Aerts G, So E, Harney JW, Cheng SY, Larsen PR, Bianco AC. Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse. *Endocrinology*. 2005;**146**(3):1568–1575.
110. Galton VA, Hernandez A, St Germain DL. The 5'-deiodinases are not essential for the fasting-induced decrease in circulating thyroid hormone levels in male mice: possible roles for the type 3 deiodinase and tissue sequestration of hormone. *Endocrinology*. 2014;**155**(8):3172–3181.
111. Boelen A, van Beeren M, Vos X, Surovtseva O, Belegri E, Saaltink DJ, Vreugdenhil E, Kalsbeek A, Kwakkel J, Fliers E. Leptin administration restores the fasting-induced increase of hepatic type 3 deiodinase expression in mice. *Thyroid*. 2012;**22**(2):192–199.
112. Vella KR, Ramadoss P, Lam FS, Harris JC, Ye FD, Same PD, O'Neill NF, Maratos-Flier E, Hollenberg AN. NPY and MC4R signaling regulate thyroid hormone levels during fasting through both central and peripheral pathways. *Cell Metab*. 2011;**14**(6):780–790.
113. Kopp W. Nutrition, evolution and thyroid hormone levels—a link to iodine deficiency disorders? *Med Hypotheses*. 2004;**62**(6):871–875.
114. Mills I, Barge RM, Silva JE, Larsen PR. Insulin stimulation of iodothyronine 5'-deiodinase in rat brown adipocytes. *Biochem Biophys Res Commun*. 1987;**143**(1):81–86.
115. Grozovsky R, Ribich S, Rosene ML, Mulcahey MA, Huang SA, Patti ME, Bianco AC, Kim BW. Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor- $\gamma$  agonists in skeletal myocytes. *Endocrinology*. 2009;**150**(4):1976–1983.
116. Martinez-deMena R, Obregón MJ. Insulin increases the adrenergic stimulation of 5' deiodinase activity and mRNA expression in rat brown adipocytes; role of MAPK and PI3K. *J Mol Endocrinol*. 2005;**34**(1):139–151.
117. Laplante M, Sabatini DM. mTOR signaling at a glance. *J Cell Sci*. 2009;**122**(Pt 20):3589–3594.
118. Hoeffler CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. *Trends Neurosci*. 2010;**33**(2):67–75.
119. De Andrade PB, Neff LA, Strosova MK, Arsenijevic D, Patthey-Vuadens O, Scapozza L, Montani JP, Ruegg UT, Dulloo AG, Dachy C. Caloric restriction induces energy-sparing alterations in skeletal muscle contraction, fiber composition and local thyroid hormone metabolism that persist during catch-up fat upon refeeding. *Front Physiol*. 2015;**6**:254.
120. Heemstra KA, Soeters MR, Fliers E, Serlie MJ, Burggraaf J, van Doorn MB, van der Klaauw AA, Romijn JA, Smit JW, Corssmit EP, Visser TJ. Type 2 iodothyronine deiodinase in skeletal muscle: effects of hypothyroidism and fasting. *J Clin Endocrinol Metab*. 2009;**94**(6):2144–2150.
121. Laurberg P, Vestergaard H, Nielsen S, Christensen SE, Seefeldt T, Helleberg K, Pedersen KM. Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. *J Clin Endocrinol Metab*. 2007;**92**(6):2149–2156.
122. Ito M, Toyoda N, Nomura E, Takamura Y, Amino N, Wasaka T, Takamatsu J, Miyachi A, Nishikawa M. Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with 3,5,3'-triiodothyronine-predominant Graves' disease. *Eur J Endocrinol*. 2011;**164**(1):95–100.
123. Celi FS, Coppotelli G, Chidakel A, Kelly M, Brillante BA, Shawker T, Cherman N, Feuillan PP, Collins MT. The role of type 1 and type 2 5'-deiodinase in the pathophysiology of the 3,5,3'-triiodothyronine toxicosis of McCune-Albright syndrome. *J Clin Endocrinol Metab*. 2008;**93**(6):2383–2389.
124. Nishikawa M, Toyoda N, Yonemoto T, Ogawa Y, Tabata S, Sakaguchi N, Tokoro T, Gondou A, Yoshimura M, Yoshikawa N, Inada M. Quantitative measurements for type 1 deiodinase messenger ribonucleic acid in human peripheral blood mononuclear cells: mechanism of the preferential increase of T3 in hyperthyroid Graves' disease. *Biochem Biophys Res Commun*. 1998;**250**(3):642–646.
125. Abuid J, Larsen PR. Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents. *J Clin Invest*. 1974;**54**(1):201–208.
126. van Mullem AA, van Gucht AL, Visser WE, Meima ME, Peeters RP, Visser TJ. Effects of thyroid hormone transporters MCT8 and MCT10 on nuclear activity of T3. *Mol Cell Endocrinol*. 2016;**437**:252–260.
127. Oppenheimer JH, Schwartz HL. Stereospecific transport of triiodothyronine from plasma to cytosol and from cytosol to nucleus in rat liver, kidney, brain, and heart. *J Clin Invest*. 1985;**75**(1):147–154.
128. Bianco AC, Silva JE. Cold exposure rapidly induces virtual saturation of brown adipose tissue nuclear T3 receptors. *Am J Physiol*. 1988;**255**(4 Pt 1):E496–E503.
129. Campos-Barros A, Amma LL, Faris JS, Shailam R, Kelley MW, Forrest D. Type 2 iodothyronine deiodinase expression in the cochlea before the onset of hearing. *Proc Natl Acad Sci USA*. 2000;**97**(3):1287–1292.
130. Bocco BM, Louzada RA, Silvestre DH, Santos MC, Anne-Palmer E, Rangel IF, Abdalla S, Ferreira AC, Ribeiro MO, Gereben B, Carvalho DP, Bianco AC, Werneck-de-Castro JP. Thyroid hormone activation by type 2 deiodinase mediates exercise-induced peroxisome proliferator-activated receptor- $\gamma$  coactivator-1 $\alpha$  expression in skeletal muscle. *J Physiol*. 2016;**594**(18):5255–5269.
131. Bassett JH, Boyde A, Howell PG, Bassett RH, Galliford TM, Archanco M, Evans H, Lawson MA, Croucher P, St Germain DL, Galton VA, Williams GR. Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. *Proc Natl Acad Sci USA*. 2010;**107**(16):7604–7609.
132. Galton VA. The roles of the iodothyronine deiodinases in mammalian development. *Thyroid*. 2005;**15**(8):823–834.
133. Dentice M, Luongo C, Huang S, Ambrosio R, Elefante A, Mirebeau-Prunier D, Zavacki AM, Fenzi G, Grachtchouk M, Hutchin M, Dlugosz AA, Bianco AC, Missero C, Larsen PR, Salvatore D. Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes. *Proc Natl Acad Sci USA*. 2007;**104**(36):14466–14471.
134. Pachucki J, Hopkins J, Peeters R, Tu H, Carvalho SD, Kaulbach H, Abel ED, Wondisford FE, Ingwall JS, Larsen PR. Type 2 iodothyronine deiodinase transgene expression in the mouse heart causes cardiac-specific thyrotoxicosis. *Endocrinology*. 2001;**142**(1):13–20.
135. Trivieri MG, Oudit GY, Sah R, Kerfant BG, Sun H, Gramolini AO, Pan Y, Wickenden AD, Croteau W, Morreale de Escobar G, Pehlkeleski R, St Germain D, MacLennan DH, Backx PH. Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. *Proc Natl Acad Sci USA*. 2006;**103**(15):6043–6048.
136. Hernandez A, Quignodon L, Martinez ME, Flamant F, St Germain DL. Type 3 deiodinase deficiency causes spatial and temporal alterations in brain T3 signaling that are dissociated from serum thyroid hormone levels. *Endocrinology*. 2010;**151**(11):5550–5558.
137. Muzzio AM, Noyes PD, Stapleton HM, Lema SC. Tissue distribution and thyroid hormone effects on mRNA abundance for membrane transporters Mct8, Mct10, and organic anion-transporting polypeptides (Oatps) in a teleost fish. *Comp Biochem Physiol A Mol Integr Physiol*. 2014;**167**:77–89.
138. Mebis L, Paletta D, Debaveye Y, Ellger B, Langouche L, D'Hoore A, Darras VM, Visser TJ, Van den Berghe G. Expression of thyroid hormone transporters during critical illness. *Eur J Endocrinol*. 2009;**161**(2):243–250.
139. Badziung J, Ting S, Synoracki S, Tiedje V, Brix K, Brabant G, Moeller LC, Schmid KW, Fuhrer D, Zwanziger D. Differential regulation of monocarboxylate transporter 8 expression in thyroid cancer and hyperthyroidism. *Eur J Endocrinol*. 2017;**177**(3):243–250.
140. Wittmann G, Szabon J, Mohácsik P, Nouriel SS, Gereben B, Fekete C, Lechan RM. Parallel regulation of thyroid hormone transporters OATP1c1 and MCT8 during and after endotoxemia at the blood-brain barrier of male rodents. *Endocrinology*. 2015;**156**(4):1552–1564.
141. de Souza EC, Dias GR, Cardoso RC, Lima LP, Fortunato RS, Visser TJ, Vaisman M, Ferreira AC, Carvalho DP. MCT8 is downregulated by short time iodine overload in the thyroid gland of rats. *Horm Metab Res*. 2015;**47**(12):910–915.
142. Braun D, Schweizer U. Thyroid hormone transport and transporters. *Vitam Horm*. 2018;**106**:19–44.
143. Strømme P, Groeneweg S, Lima de Souza EC, Zevenbergen C, Torgersbraten A, Holmgren A, Gurcan E, Meima ME, Peeters RP, Visser WE, Honeren Johansson L, Babovic A, Zetterberg H, Heuer H, Frengen E, Misceo D, Visser TJ. Mutated thyroid hormone transporter OATP1C1 associates with severe brain hypometabolism and juvenile neurodegeneration. *Thyroid*. 2018;**28**(11):1406–1415.
144. Dumitrescu AM, Liao XH, Weiss RE, Millen K, Refetoff S. Tissue-specific thyroid hormone deprivation and excess in monocarboxylate transporter (Mct) 8-deficient mice. *Endocrinology*. 2006;**147**(9):4036–4043.
145. Trajkovic M, Visser TJ, Mittag J, Horn S, Lukas J, Darras VM, Raivich G, Bauer K, Heuer H. Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8. *J Clin Invest*. 2007;**117**(3):627–635.
146. Wirth EK, Roth S, Blechschmidt C, Hölter SM, Becker L, Racz I, Zimmer A, Klopstock T, Gailus-Dumer V, Fuchs H, Wurst W, Naumann T, Bräuer A, de Angelis MH, Köhrle J, Grüters A, Schweizer U. Neuronal 3',5'-triiodothyronine (T<sub>3</sub>) uptake and behavioral phenotype of mice deficient in Mct8, the neuronal T<sub>3</sub> transporter mutated in Allan-Herndon-Dudley syndrome. *J Neurosci*. 2009;**29**(30):9439–9449.
147. Mayerl S, Müller J, Bauer R, Richert S, Kassmann CM, Darras VM, Buder K, Boelen A, Visser TJ, Heuer H. Transporters MCT8 and OATP1C1 maintain murine brain thyroid hormone homeostasis. *J Clin Invest*. 2014;**124**(5):1987–1999.
148. Di Cosmo C, Liao XH, Dumitrescu AM, Weiss RE, Refetoff S. A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport. *Endocrinology*. 2009;**150**(9):4450–4458.
149. Kersseboom S, Horn S, Visser WE, Chen J, Friesema EC, Vours-Barrière C, Peeters RP, Heuer H, Visser TJ. In vitro and mouse studies supporting therapeutic utility of triiodothyroacetic acid in MCT8 deficiency. *Mol Endocrinol*. 2014;**28**(12):1961–1970.



150. Verge CF, Konrad D, Cohen M, Di Cosmo C, Dumitrescu AM, Marcinkowski T, Hameed S, Hamilton J, Weiss RE, Refetoff S. Diiodothyronine (DITPA) in the treatment of MCT8 deficiency. *J Clin Endocrinol Metab.* 2012;**97**(12):4515–4523.
151. Braverman LE, Ingbar SH, Sterling K. Conversion of thyroxine (T4) to triiodothyronine (T3) in athyrotic human subjects. *J Clin Invest.* 1970;**49**(5):855–864.
152. Larsen PR. Thyroid-pituitary interaction: feedback regulation of thyrotropin secretion by thyroid hormones. *N Engl J Med.* 1982;**306**(1):23–32.
153. Silva JE, Larsen PR. Pituitary nuclear 3,5,3'-triiodothyronine and thyrotropin secretion: an explanation for the effect of thyroxine. *Science.* 1977;**198**(4317):617–620.
154. Bianco AC, Silva JE. Intracellular conversion of thyroxine to triiodothyronine is required for the optimal thermogenic function of brown adipose tissue. *J Clin Invest.* 1987;**79**(1):295–300.
155. Carvalho SD, Kimura ET, Bianco AC, Silva JE. Central role of brown adipose tissue thyroxine 5'-deiodinase on thyroid hormone-dependent thermogenic response to cold. *Endocrinology.* 1991;**128**(4):2149–2159.
156. Bianco AC, Sheng XY, Silva JE. Triiodothyronine amplifies norepinephrine stimulation of uncoupling protein gene transcription by a mechanism not requiring protein synthesis. *J Biol Chem.* 1988;**263**(34):18168–18175.
157. Santini F, Pinchera A, Ceccarini G, Castagna M, Rosellini V, Mammoli C, Montanelli L, Zucchi V, Chopra IJ, Chiovato L. Evidence for a role of the type III-iodothyronine deiodinase in the regulation of 3,5,3'-triiodothyronine content in the human central nervous system. *Eur J Endocrinol.* 2001;**144**(6):577–583.
158. Li WW, Le Goascogne C, Ramaugé M, Schumacher M, Pierre M, Courtin F. Induction of type 3 iodothyronine deiodinase by nerve injury in the rat peripheral nervous system. *Endocrinology.* 2001;**142**(12):5190–5197.
159. Pallud S, Ramaugé M, Gavaret JM, Lennon AM, Munsch N, St Germain DL, Pierre M, Courtin F. Regulation of type 3 iodothyronine deiodinase expression in cultured rat astrocytes: role of the Erk cascade. *Endocrinology.* 1999;**140**(6):2917–2923.
160. Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP, Fishman SJ, Larsen PR. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. *N Engl J Med.* 2000;**343**(3):185–189.
161. Bates JM, St Germain DL, Galton VA. Expression profiles of the three iodothyronine deiodinases, D1, D2, and D3, in the developing rat. *Endocrinology.* 1999;**140**(2):844–851.
162. Van der Geyten S, Sanders JP, Kaptein E, Darras VM, Kühn ER, Leonard JL, Visser TJ. Expression of chicken hepatic type I and type III iodothyronine deiodinases during embryonic development. *Endocrinology.* 1997;**138**(12):5144–5152.
163. Baqui M, Botero D, Gereben B, Curcio C, Harney JW, Salvatore D, Sorimachi K, Larsen PR, Bianco AC. Human type 3 iodothyronine selenodeiodinase is located in the plasma membrane and undergoes rapid internalization to endosomes. *J Biol Chem.* 2003;**278**(2):1206–1211.
164. Jo S, Kalló I, Bardóczi Z, Arrojo e Drigo R, Zeöld A, Liposits Z, Oliva A, Lemmon VP, Bixby JL, Gereben B, Bianco AC. Neuronal hypoxia induces Hsp40-mediated nuclear import of type 3 deiodinase as an adaptive mechanism to reduce cellular metabolism. *J Neurosci.* 2012;**32**(25):8491–8500.
165. Silva JE, Larsen PR. Regulation of thyroid hormone expression at the prereceptor and receptor levels. In: Hennemann G, ed. *Thyroid Hormone Metabolism*. 1st ed. New York, NY: Marcel Dekker; 1986:441–500.
166. Peeters R, Fekete C, Goncalves C, Legradi G, Tu HM, Harney JW, Bianco AC, Lechan RM, Larsen PR. Regional physiological adaptation of the central nervous system deiodinases to iodine deficiency. *Am J Physiol Endocrinol Metab.* 2001;**281**(1):E54–E61.
167. Escobar del Rey F, Mallol J, Pastor R, Morreale de Escobar G. Effects of maternal iodine deficiency on thyroid hormone economy of lactating dams and pups: maintenance of normal cerebral 3,5,3'-triiodo-L-thyronine concentrations in pups during major phases of brain development. *Endocrinology.* 1987;**121**(2):803–811.
168. Abdalla SM, Bianco AC. Defending plasma T3 is a biological priority. *Clin Endocrinol (Oxf).* 2014;**81**(5):633–641.
169. Gereben B, Kollár A, Harney JW, Larsen PR. The mRNA structure has potent regulatory effects on type 2 iodothyronine deiodinase expression. *Mol Endocrinol.* 2002;**16**(7):1667–1679.
170. Ohba K, Yoshioka T, Muraki T. Identification of two novel splicing variants of human type II iodothyronine deiodinase mRNA. *Mol Cell Endocrinol.* 2001;**172**(1–2):169–175.
171. Bianco AC, Kim BS. Pathophysiological relevance of deiodinase polymorphism. *Curr Opin Endocrinol Diabetes Obes.* 2018;**25**(5):341–346.
172. Dora JM, Machado WE, Rheinheimer J, Crispim D, Maia AL. Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case-control study and meta-analysis. *Eur J Endocrinol.* 2010;**163**(3):427–434.
173. Mentuccia D, Proietti-Pannunzi L, Tanner K, Bacci V, Pollin TI, Poehlman ET, Shuldiner AR, Celi FS. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the  $\beta$ -3-adrenergic receptor. *Diabetes.* 2002;**51**(3):880–883.
174. Gumieniak O, Perlstein TS, Williams JS, Hopkins PN, Brown NJ, Raby BA, Williams GH. Ala92 type 2 deiodinase allele increases risk for the development of hypertension. *Hypertension.* 2007;**49**(3):461–466.
175. Estivalete AA, Leiria LB, Dora JM, Rheinheimer J, Bouças AP, Maia AL, Crispim D. D2 Thr92Ala and PPAR $\gamma$ 2 Pro12Ala polymorphisms interact in the modulation of insulin resistance in type 2 diabetic patients. *Obesity (Silver Spring).* 2011;**19**(4):825–832.
176. Nair S, Muller YL, Ortega E, Kobes S, Bogardus C, Baier LJ. Association analyses of variants in the DIO2 gene with early-onset type 2 diabetes mellitus in Pima Indians. *Thyroid.* 2012;**22**(1):80–87.
177. He B, Li J, Wang C, Ju W, Lu Y, Shi Y, He L, Zhong N. Association of genetic polymorphisms in the type II deiodinase gene with bipolar disorder in a subset of Chinese population. *Prog Neuropsychopharmacol Biol Psychiatry.* 2009;**33**(6):986–990.
178. Guo TW, Zhang FC, Yang MS, Gao XC, Bian L, Duan SW, Zheng ZJ, Gao JJ, Wang H, Li RL, Feng GY, St Clair D, He L. Positive association of the DIO2 (deiodinase type 2) gene with mental retardation in the iodine-deficient areas of China. *J Med Genet.* 2004;**41**(8):585–590.
179. Taylor PO, Sayers A, Pearce E, Gregory J, Lazarus J, Panicker V, Channon S, Timpson N, Dayan C. Effect of low thyroid hormone bioavailability on childhood cognitive development: data from the Avon Longitudinal Study of Parents and Children birth cohort. *Lancet.* 2014;**383**:S100.
180. Ma SF, Xie L, Pino-Yanes M, Sammani S, Wade MS, Letsiou E, Siegler J, Wang T, Infusino G, Kittles RA, Flores C, Zhou T, Prabhakar BS, Moreno-Vinasco L, Villar J, Jacobson JR, Dudek SM, Garcia JG. Type 2 deiodinase and host responses of sepsis and acute lung injury. *Am J Respir Cell Mol Biol.* 2011;**45**(6):1203–1211.
181. Meulenbelt I, Min JL, Bos S, Riyazi N, Houwing-Duistermaat JJ, van der Wijk HJ, Kroon HM, Nakajima M, Ikegawa S, Uitterlinden AG, van Meurs JB, van der Deure WM, Visser TJ, Seymour AB, Lakenberg N, van der Breggen R, Kremer D, van Duijn CM, Kloppenburg M, Loughlin J, Slagboom PE. Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. *Hum Mol Genet.* 2008;**17**(12):1867–1875.
182. Heemstra KA, Hoftijzer H, van der Deure WM, Peeters RP, Hamdy NA, Pereira A, Corssmit EP, Romijn JA, Visser TJ, Smit JW. The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. *J Bone Miner Res.* 2010;**25**(6):1385–1391.
183. Wouters HJ, van Loon HC, van der Klauw MM, Elderson MF, Slagter SN, Kobold AM, Kema IP, Links TP, van Vliet-Ostapchouk JV, Wolfenbuttel BH. No Effect of the Thr92Ala polymorphism of deiodinase-2 on thyroid hormone parameters, health-related quality of life, and cognitive functioning in a large population-based cohort study. *Thyroid.* 2017;**27**(2):147–155.
184. Canani LH, Capp C, Dora JM, Meyer EL, Wagner MS, Harney JW, Larsen PR, Gross JL, Bianco AC, Maia AL. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. *J Clin Endocrinol Metab.* 2005;**90**(6):3472–3478.
185. Peeters RP, van Toor H, Klootwijk W, de Rijke YB, Kuiper GG, Uitterlinden AG, Visser TJ. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. *J Clin Endocrinol Metab.* 2003;**88**(6):2880–2888.
186. Jo S, Fonseca TL, Da Costa Bocco BM, Fernandes GW, McAninch EA, Bolin AP, Da Conceicao RR, De Castro JPW, Ignacio DL, Egri P, Nemeth D, Fekete C, Bernardi MM, Leitch VD, Mannan NS, Curry KF, Butterfield NC, Bassett JHD, Williams GR, Gereben B, Ribeiro MO, Bianco AC. Type 2 deiodinase polymorphism causes ER stress and hypothyroidism in the brain. *J Clin Invest.* 2019;**129**(1):230–245.
187. Castagna MG, Dentice M, Cantara S, Ambrosio R, Maino F, Porcelli T, Marzocchi C, Garbi C, Pacini F, Salvatore D. DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients. *J Clin Endocrinol Metab.* 2017;**102**(5):1623–1630.
188. Torlontano M, Durante C, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R, Santini S, D'Arcangelo P, Dallapiccola B, Filetti S, Trischitta V. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. *J Clin Endocrinol Metab.* 2008;**93**(3):910–913.
189. Butler PW, Smith SM, Linderman JD, Brychta RJ, Alberobello AT, Dubaz OM, Luzon JA, Skarulis MC, Cochran CS, Wesley RA, Pucino F, Celi FS. The Thr92Ala 5' type 2 deiodinase gene polymorphism is associated with a delayed triiodothyronine secretion in response to the thyrotropin-releasing hormone-stimulation test: a pharmacogenomic study. *Thyroid.* 2010;**20**(12):1407–1412.



190. Cho YY, Kim HJ, Jang HW, Kim TH, Ki CS, Kim SW, Chung JH. The relationship of 19 functional polymorphisms in iodothyronine deiodinase and psychological well-being in hypothyroid patients. *Endocrine*. 2017;**57**(1):115–124.
191. de Jong FJ, Peeters RP, den Heijer T, van der Deure WM, Hofman A, Uitterlinden AG, Visser TJ, Breteler MM. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. *J Clin Endocrinol Metab*. 2007;**92**(2):636–640.
192. Panicker V, Cluett C, Shields B, Murray A, Parnell KS, Perry JR, Weedon MN, Singleton A, Hernandez D, Evans J, Durant C, Ferrucci L, Melzer D, Saravanan P, Visser TJ, Ceresini G, Hattersley AT, Vaidya B, Dayan CM, Frayling TM. A common variation in deiodinase 1 gene *DIO1* is associated with the relative levels of free thyroxine and triiodothyronine. *J Clin Endocrinol Metab*. 2008;**93**(8):3075–3081.
193. Verloop H, Dekkers OM, Peeters RP, Schoones JW, Smit JW. Genetics in endocrinology: genetic variation in deiodinases: a systematic review of potential clinical effects in humans. *Eur J Endocrinol*. 2014;**171**(3):R123–R135.
194. Maino F, Cantara S, Forleo R, Pilli T, Castagna MG. Clinical significance of type 2 iodothyronine deiodinase polymorphism. *Expert Rev Endocrinol Metab*. 2018;**13**(5):273–277.
195. Dumitrescu AM, Liao XH, Abdullah MS, Lado-Abeal J, Majed FA, Moeller LC, Boran G, Schomburg L, Weiss RE, Refetoff S. Mutations in *SECISBP2* result in abnormal thyroid hormone metabolism. *Nat Genet*. 2005;**37**(11):1247–1252.
196. Schoenmakers E, Carlson B, Agostini M, Moran C, Rajanayagam O, Bochukova E, Tobe R, Peat R, Gevers E, Munttoni F, Guicheney P, Schoenmakers N, Farooqi S, Lyons G, Hatfield D, Chatterjee K. Mutation in human selenocysteine transfer RNA selectively disrupts selenoprotein synthesis. *J Clin Invest*. 2016;**126**(3):992–996.
197. Papp LV, Wang J, Kennedy D, Boucher D, Zhang Y, Gladyshev VN, Singh RN, Khanna KK. Functional characterization of alternatively spliced human *SECISBP2* transcript variants. *Nucleic Acids Res*. 2008;**36**(22):7192–7206.
198. Çatlı G, Fujisawa H, Kirbiyik Ö, Mimoto MS, Gençpinar P, Özdemir TR, Dündar BN, Dumitrescu AM. A novel homozygous selenocysteine insertion sequence binding protein 2 (*SECISBP2*, *SBP2*) gene mutation in a Turkish boy. *Thyroid*. 2018;**28**(9):1221–1223.
199. Fu J, Dumitrescu AM. Inherited defects in thyroid hormone cell-membrane transport and metabolism. *Best Pract Res Clin Endocrinol Metab*. 2014;**28**(2):189–201.
200. Schoenmakers E, Agostini M, Mitchell C, Schoenmakers N, Papp L, Rajanayagam O, Padidela R, Ceron-Gutierrez L, Doffinger R, Prevosto C, Luan J, Montano S, Lu J, Castanet M, Clemons N, Groeneveld M, Castets P, Karbaschi M, Aitken S, Dixon A, Williams J, Campi I, Blount M, Burton H, Munttoni F, O'Donovan D, Dean A, Warren A, Brierley C, Baguley D, Guicheney P, Fitzgerald R, Coles A, Gaston H, Todd P, Holmgren A, Khanna KK, Cooke M, Semple R, Halsall D, Wareham N, Schwabe J, Grasso L, Beck-Peccoz P, Ogunko A, Dattani M, Gurnell M, Chatterjee K. Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. *J Clin Invest*. 2010;**120**(12):4220–4235.
201. Seehr S, Atassi T, Mahdi Y, Carlson BA, Braun D, Wirth EK, Klein MO, Reix N, Miniard AC, Schomburg L, Hatfield DL, Driscoll DM, Schweizer U. *Secisbp2* is essential for embryonic development and enhances selenoprotein expression. *Antioxid Redox Signal*. 2014;**21**(6):835–849.
202. Fu J, Fujisawa H, Follman B, Liao XH, Dumitrescu AM. Thyroid hormone metabolism defects in a mouse model of *SBP2* deficiency. *Endocrinology*. 2017;**158**(12):4317–4330.
203. Seehr S, Schweizer U. Targeted deletion of *Secisbp2* reduces, but does not abrogate, selenoprotein expression and leads to striatal interneuron loss. *Free Radic Biol Med*. 2014;**75**(Suppl 1):S9.
204. Galton VA, de Waard E, Parlow AF, St Germain DL, Hernandez A. Life without the iodothyronine deiodinases. *Endocrinology*. 2014;**155**(10):4081–4087.
205. Carlson BA, Yoo MH, Tsuji PA, Gladyshev VN, Hatfield DL. Mouse models targeting selenocysteine tRNA expression for elucidating the role of selenoproteins in health and development. *Molecules*. 2009;**14**(9):3509–3527.
206. Dumitrescu AM, Refetoff S. The syndromes of reduced sensitivity to thyroid hormone. *Biochim Biophys Acta*. 2013;**1830**(7):3987–4003.
207. van Mullem A, van Heerebeek R, Chrysis D, Visser E, Medici M, Andrikoula M, Tsatsoulis A, Peeters R, Visser TJ. Clinical phenotype and mutant  $TR\alpha 1$ . *N Engl J Med*. 2012;**366**(15):1451–1453.
208. Bochukova E, Schoenmakers N, Agostini M, Schoenmakers E, Rajanayagam O, Keogh JM, Henning E, Reinemund J, Gevers E, Sarri M, Downes K, Offiah A, Albanese A, Halsall D, Schwabe JW, Bain M, Lindley K, Munttoni F, Vargha-Khadem F, Dattani M, Farooqi IS, Gurnell M, Chatterjee K. A mutation in the thyroid hormone receptor alpha gene (published correction appears in *N Engl J Med*. 2012;**367**(15):1474). *N Engl J Med*. 2012;**366**(3):243–249.
209. van Gucht ALM, Moran C, Meima ME, Visser WE, Chatterjee K, Visser TJ, Peeters RP. Resistance to thyroid hormone due to heterozygous mutations in thyroid hormone receptor alpha. *Curr Top Dev Biol*. 2017;**125**:337–355.
210. Franklyn JA, Ramsden DB, Sheppard MC. Down-regulation of nuclear T3 receptors by thyroid hormones in the rat anterior pituitary. *Mol Cell Endocrinol*. 1985;**40**(2–3):145–148.
211. Knopp J, Brtko J. Effect of different thyroid state on ornithine decarboxylase activity and receptors of T3 in rat liver. *Exp Clin Endocrinol*. 1989;**94**(3):319–323.
212. Hodin RA, Lazar MA, Chin WW. Differential and tissue-specific regulation of the multiple rat *c-erbA* messenger RNA species by thyroid hormone. *J Clin Invest*. 1990;**85**(1):101–105.
213. Williams GR, Franklyn JA, Neuberger JM, Sheppard MC. Thyroid hormone receptor expression in the "sick euthyroid" syndrome. *Lancet*. 1989;**2**(8678–8679):1477–1481.
214. Lado-Abeal J, Romero A, Castro-Piedras I, Rodriguez-Perez A, Alvarez-Escudero J. Thyroid hormone receptors are down-regulated in skeletal muscle of patients with non-thyroidal illness syndrome secondary to non-septic shock. *Eur J Endocrinol*. 2010;**163**(5):765–773.
215. Liu YY, Brent GA. Posttranslational modification of thyroid hormone nuclear receptor by sumoylation. *Methods Mol Biol*. 2018;**1801**:47–59.
216. Liu YY, Brent GA. Posttranslational modification of thyroid hormone nuclear receptor by phosphorylation. *Methods Mol Biol*. 2018;**1801**:39–46.
217. Martin NP, Marron Fernandez de Velasco E, Mizuno F, Scappini EL, Gloss B, Erxleben C, Williams JG, Stapleton HM, Gentile S, Armstrong DL. A rapid cytoplasmic mechanism for PI3 kinase regulation by the nuclear thyroid hormone receptor,  $TR\beta$ , and genetic evidence for its role in the maturation of mouse hippocampal synapses in vivo. *Endocrinology*. 2014;**155**(9):3713–3724.
218. Aoki T, Tsunekawa K, Araki O, Ogiwara T, Nara M, Sumino H, Kimura T, Murakami M. Type 2 iodothyronine deiodinase activity is required for rapid stimulation of PI3K by thyroxine in human umbilical vein endothelial cells. *Endocrinology*. 2015;**156**(11):4312–4324.
219. You SH, Lim HW, Sun Z, Broache M, Won KJ, Lazar MA. Nuclear receptor co-repressors are required for the histone-deacetylase activity of HDAC3 in vivo. *Nat Struct Mol Biol*. 2013;**20**(2):182–187.
220. Sun Z, Feng D, Fang B, Mullican SE, You SH, Lim HW, Everett LJ, Nabel CS, Li Y, Selvakumar V, Won KJ, Lazar MA. Deacetylase-independent function of HDAC3 in transcription and metabolism requires nuclear receptor corepressor. *Mol Cell*. 2013;**52**(6):769–782.
221. Astapova I. Role of co-regulators in metabolic and transcriptional actions of thyroid hormone. *J Mol Endocrinol*. 2016;**56**(3):73–97.
222. Vella KR, Ramadoss P, Costa-E-Sousa RH, Astapova I, Ye FD, Holtz KA, Harris JC, Hollenberg AN. Thyroid hormone signaling in vivo requires a balance between coactivators and corepressors. *Mol Cell Biol*. 2014;**34**(9):1564–1575.
223. Shimizu H, Astapova I, Ye F, Bilban M, Cohen RN, Hollenberg AN. NCoR1 and SMRT play unique roles in thyroid hormone action in vivo. *Mol Cell Biol*. 2015;**35**(3):555–565.
224. Suh JH, Sieglaff DH, Zhang A, Xia X, Cvoro A, Winnier GE, Webb P. SIRT1 is a direct coactivator of thyroid hormone receptor  $\beta 1$  with gene-specific actions. *PLoS One*. 2013;**8**(7):e70097.
225. Fondell JD. The Mediator complex in thyroid hormone receptor action. *Biochim Biophys Acta*. 2013;**1830**(7):3867–3875.
226. Yamamoto H, Williams EG, Mouchiroud L, Cantó C, Fan W, Downes M, Héligon C, Barish GD, Desvergne B, Evans RM, Schoonjans K, Auwerx J. NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. *Cell*. 2011;**147**(4):827–839.
227. Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. *Nature*. 2010;**468**(7327):1100–1104.
228. Pihlajamäki J, Boes T, Kim EY, Dearie F, Kim BW, Schroeder J, Mun E, Nasser I, Park PJ, Bianco AC, Goldfine AB, Patti ME. Thyroid hormone-related regulation of gene expression in human fatty liver. *J Clin Endocrinol Metab*. 2009;**94**(9):3521–3529.
229. Crunkhorn S, Patti ME. Links between thyroid hormone action, oxidative metabolism, and diabetes risk? *Thyroid*. 2008;**18**(2):227–237.
230. Crunkhorn S, Dearie F, Mantzoros C, Gami H, da Silva WS, Espinoza D, Faucette R, Barry K, Bianco AC, Patti ME. Peroxisome proliferator activator receptor gamma coactivator-1 expression is reduced in obesity: potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation. *J Biol Chem*. 2007;**282**(21):15439–15450.
231. Krause C, Grohs M, El Gammal A, Wolter S, Lehnert H, Mann O, Mittag J, Kirchner H. Reduced expression of thyroid hormone receptor  $\beta$  in human nonalcoholic steatohepatitis. *Endocr Connect*. 2018;**7**(12):1448–1456.
232. Castillo M, Freitas BC, Rosene ML, Drigo RA, Grozovsky R, Maciel RM, Patti ME, Ribeiro MO, Bianco AC. Impaired metabolic effects of a thyroid hormone receptor beta-selective agonist in a mouse model of diet-induced obesity. *Thyroid*. 2010;**20**(5):545–553.
233. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. *Lancet Diabetes Endocrinol*. 2015;**3**(10):816–825.

234. Fekete C, Gereben B, Doleschall M, Harney JW, Dora JM, Bianco AC, Sarkar S, Liposits Z, Rand W, Emerson C, Kacsokovics I, Larsen PR, Lechan RM. Lipopolysaccharide induces type 2 iodothyronine deiodinase in the mediobasal hypothalamus: implications for the nonthyroidal illness syndrome. *Endocrinology*. 2004;**145**(4):1649–1655.
235. Zeöld A, Doleschall M, Haffner MC, Capelo LP, Menyért J, Liposits Z, da Silva WS, Bianco AC, Kacsokovics I, Fekete C, Gereben B. Characterization of the nuclear factor- $\kappa$ B responsiveness of the human *dio2* gene. *Endocrinology*. 2006;**147**(9):4419–4429.
236. Boelen A, Kwakkel J, Alkemade A, Renckens R, Kaptein E, Kuiper G, Wiersinga WM, Visser TJ. Induction of type 3 deiodinase activity in inflammatory cells of mice with chronic local inflammation. *Endocrinology*. 2005;**146**(12):5128–5134.
237. Fekete C, Sarkar S, Christoffolete MA, Emerson CH, Bianco AC, Lechan RM. Bacterial lipopolysaccharide (LPS)-induced type 2 iodothyronine deiodinase (D2) activation in the mediobasal hypothalamus (MBH) is independent of the LPS-induced fall in serum thyroid hormone levels. *Brain Res*. 2005;**1056**(1):97–99.
238. Fekete C, Lechan RM. Central regulation of hypothalamic-pituitary-thyroid axis under physiological and pathophysiological conditions. *Endocr Rev*. 2014;**35**(2):159–194.
239. Freitas BC, Gereben B, Castillo M, Kálló I, Zeöld A, Egri P, Liposits Z, Zavacki AM, Maciel RM, Jo S, Singru P, Sanchez E, Lechan RM, Bianco AC. Paracrine signaling by glial cell-derived triiodothyronine activates neuronal gene expression in the rodent brain and human cells. *J Clin Invest*. 2010;**120**(6):2206–2217.
240. Boelen A, van der Spek AH, Bloise F, de Vries EM, Surovtseva OV, van Beeren M, Ackermans MT, Kwakkel J, Fliers E. Tissue thyroid hormone metabolism is differentially regulated during illness in mice. *J Endocrinol*. 2017;**233**(1):25–36.
241. Bloise FF, van der Spek AH, Surovtseva OV, Ortiga-Carvalho TM, Fliers E, Boelen A. Differential effects of sepsis and chronic inflammation on diaphragm muscle fiber type, thyroid hormone metabolism, and mitochondrial function. *Thyroid*. 2016;**26**(4):600–609.
242. van der Spek AH, Fliers E, Boelen A. Thyroid hormone metabolism in innate immune cells. *J Endocrinol*. 2017;**232**(2):R67–R81.
243. De Vito P, Incerpi S, Pedersen JZ, Luly P, Davis FB, Davis PJ. Thyroid hormones as modulators of immune activities at the cellular level. *Thyroid*. 2011;**21**(8):879–890.
244. Perrotta C, Buldorini M, Assi E, Cazzato D, De Palma C, Clementi E, Cervia D. The thyroid hormone triiodothyronine controls macrophage maturation and functions: protective role during inflammation. *Am J Pathol*. 2014;**184**(1):230–247.
245. Kwakkel J, Surovtseva OV, de Vries EM, Stap J, Fliers E, Boelen A. A novel role for the thyroid hormone-activating enzyme type 2 deiodinase in the inflammatory response of macrophages. *Endocrinology*. 2014;**155**(7):2725–2734.
246. Kwakkel J, van Beeren HC, Ackermans MT, Platvoet-T Schiphorst MC, Fliers E, Wiersinga WM, Boelen A. Skeletal muscle deiodinase type 2 regulation during illness in mice. *J Endocrinol*. 2009;**203**(2):263–270.
247. Billon C, Canaple L, Fleury S, Deloivre A, Beylot M, Dombrowicz D, Del Carmine P, Samarut J, Gauthier K. TR $\alpha$  protects against atherosclerosis in male mice: identification of a novel anti-inflammatory property for TR $\alpha$  in mice. *Endocrinology*. 2014;**155**(7):2735–2745.
248. Forner MA, Barriga C, Ortega E. Exercise-induced stimulation of murine macrophage phagocytosis may be mediated by thyroxine. *J Appl Physiol* (1985). 1996;**80**(3):899–903.
249. Ortega E, Rodriguez MJ, Barriga C, Forner MA. Corticosterone, prolactin and thyroid hormones as hormonal mediators of the stimulated phagocytic capacity of peritoneal macrophages after high-intensity exercise. *Int J Sports Med*. 1996;**17**(2):149–155.
250. Chen Y, Sjölander M, Wang X, Altenbacher G, Hagner M, Berglund P, Gao Y, Lu T, Jonsson AB, Sjölander H. Thyroid hormone enhances nitric oxide-mediated bacterial clearance and promotes survival after meningococcal infection. *PLoS One*. 2012;**7**(7):e41445.
251. van der Spek AH, Bloise FF, Tigchelaar W, Dentice M, Salvatore D, van der Wel NN, Fliers E, Boelen A. The thyroid hormone inactivating enzyme type 3 deiodinase is present in bactericidal granules and the cytoplasm of human neutrophils. *Endocrinology*. 2016;**157**(8):3293–3305.
252. Boelen A, Kwakkel J, Wieland CW, St Germain DL, Fliers E, Hernandez A. Impaired bacterial clearance in type 3 deiodinase-deficient mice infected with *Streptococcus pneumoniae*. *Endocrinology*. 2009;**150**(4):1984–1990.
253. Klebanoff SJ. Iodination of bacteria: a bactericidal mechanism. *J Exp Med*. 1967;**126**(6):1063–1078.
254. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. *Endocr Rev*. 2011;**32**(5):670–693.
255. van der Spek AH, Jim KK, Karaczyn A, van Beeren HC, Ackermans MT, Darras VM, Vandenbroucke-Grauls CM, Hernandez A, Brouwer MC, Fliers E, van de Beek D, Boelen A. The thyroid hormone inactivating type 3 deiodinase is essential for optimal neutrophil function: observations from three species. *Endocrinology*. 2018;**159**(2):826–835.
256. Gefner DL, Azukizawa M, Hershman JM. Propylthiouracil blocks extrathyroidal conversion of thyroxine to triiodothyronine and augments thyrotropin secretion in man. *J Clin Invest*. 1975;**55**(2):224–229.
257. Kálló I, Mohácsik P, Vida B, Zeöld A, Bardóczi Z, Zavacki AM, Farkas E, Kádár A, Hrabovszky E, Arroyo E, Drigo R, Dong L, Barna L, Palkovits M, Borsay BA, Herczeg L, Lechan RM, Bianco AC, Liposits Z, Fekete C, Gereben B. A novel pathway regulates thyroid hormone availability in rat and human hypothalamic neurosecretory neurons. *PLoS One*. 2012;**7**(6):e37860.
258. Alvarez-Salas E, Mengod G, García-Luna C, Soberanes-Chávez P, Matamoros-Trejo G, de Gortari P. Mct8 and trh co-expression throughout the hypothalamic paraventricular nucleus is modified by dehydration-induced anorexia in rats. *Neuropeptides*. 2016;**56**:33–40.
259. Mayerl S, Visser TJ, Darras VM, Horn S, Heuer H. Impact of Oatp1c1 deficiency on thyroid hormone metabolism and action in the mouse brain. *Endocrinology*. 2012;**153**(3):1528–1537.
260. Roberts LM, Woodford K, Zhou M, Black DS, Haggerty JE, Tate EH, Grindstaff KK, Mengesha W, Raman C, Zerangue N. Expression of the thyroid hormone transporters monocarboxylate transporter-8 (SLC16A2) and organic ion transporter-14 (SLC01C1) at the blood-brain barrier. *Endocrinology*. 2008;**149**(12):6251–6261.
261. Réthelyi M, Fockter V. The fiber architecture of the rat median eminence with some accidental observations on the significance of tanycyte processes. *Acta Biol Acad Sci Hung*. 1982;**33**(2–3):289–300.
262. Alkemade A, Friesema EC, Unmehopa UA, Fabriek BO, Kuiper GG, Leonard JL, Wiersinga WM, Swaab DF, Visser TJ, Fliers E. Neuroanatomical pathways for thyroid hormone feedback in the human hypothalamus. *J Clin Endocrinol Metab*. 2005;**90**(7):4322–4334.
263. Fliers E, Alkemade A, Wiersinga WM, Swaab DF. Hypothalamic thyroid hormone feedback in health and disease. *Prog Brain Res*. 2006;**153**:189–207.
264. Christoffolete MA, Ribeiro R, Singru P, Fekete C, da Silva WS, Gordon DF, Huang SA, Crescenzi A, Harney JW, Ridgway EC, Larsen PR, Lechan RM, Bianco AC. Atypical expression of type 2 iodothyronine deiodinase in thyrotrophs explains the thyroxine-mediated pituitary thyrotropin feedback mechanism. *Endocrinology*. 2006;**147**(4):1735–1743.
265. Spencer CA, Schwarzbein D, Guttler RB, LoPresti JS, Nicoloff JT. Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and fourth generation TSH assays. *J Clin Endocrinol Metab*. 1993;**76**(2):494–498.
266. Hernandez A, Martinez ME, Fiering S, Galton VA, St Germain D. Type 3 deiodinase is critical for the maturation and function of the thyroid axis. *J Clin Invest*. 2006;**116**(2):476–484.
267. Srichomkwan P, Anselmo J, Liao XH, Hönes GS, Moeller LC, Alonso-Sampedro M, Weiss RE, Dumitrescu AM, Refetoff S. Fetal exposure to high maternal thyroid hormone levels causes central resistance to thyroid hormone in adult humans and mice. *J Clin Endocrinol Metab*. 2017;**102**(9):3234–3240.
268. Werneck de Castro JP, Fonseca TL, Ueta CB, McAninch EA, Abdalla S, Wittmann G, Lechan RM, Gereben B, Bianco AC. Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine. *J Clin Invest*. 2015;**125**(2):769–781.
269. Trohman RG, Sharma PS, McAninch EA, Bianco AC. Amiodarone and the thyroid physiology, pathophysiology, diagnosis and management [published online ahead of print 20 September 2018]. *Trends Cardiovasc Med*. 2018;**S1050-1738**(18):30195–30196. doi: 10.1016/j.tcm.2018.09.005.
270. Rosene ML, Wittmann G, Arroyo E, Drigo R, Singru PS, Lechan RM, Bianco AC. Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment. *Endocrinology*. 2010;**151**(12):5961–5970.
271. Brown WH, Gillum MP, Lee HY, Camporez JP, Zhang XM, Jeong JK, Alves TC, Erion DM, Guigni BA, Kahn M, Samuel VT, Cravatt BF, Diano S, Shulman GI. Fatty acid amide hydrolase ablation promotes ectopic lipid storage and insulin resistance due to centrally mediated hypothyroidism. *Proc Natl Acad Sci USA*. 2012;**109**(37):14966–14971.
272. McAninch EA, Bianco AC. The history and future of treatment of hypothyroidism. *Ann Intern Med*. 2016;**164**(1):50–56.
273. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JL, Pessah-Pollack R, Singer PA, Woeber KA. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Endocr Pract*. 2012;**18**(6):988–1028.
274. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, Segal RL. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of

- hyperthyroidism and hypothyroidism. *Endocr Pract.* 2002;**8**(6):457–469.
275. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, Greenspan FS, McDougall IR, Nikolai TF. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. *JAMA.* 1995;**273**(10):808–812.
276. Gullo D, Latina A, Frasca F, Le Moli R, Pellegriti G, Vigneri R. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. *PLoS One.* 2011;**6**(8):e22552.
277. Stock JM, Surks MI, Oppenheimer JH. Replacement dosage of L-thyroxine in hypothyroidism. A re-evaluation. *N Engl J Med.* 1974;**290**(10):529–533.
278. Jonklaas J, Davidson B, Bhagat S, Soldin SJ. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. *JAMA.* 2008;**299**(7):769–777.
279. Pearce CJ, Himsworth RL. Total and free thyroid hormone concentrations in patients receiving maintenance replacement treatment with thyroxine. *Br Med J (Clin Res Ed).* 1984;**288**(6418):693–695.
280. Ito M, Miyauchi A, Morita S, Kudo T, Nishihara E, Kihara M, Takamura Y, Ito Y, Kobayashi K, Miya A, Kubota S, Amino N. TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. *Eur J Endocrinol.* 2012;**167**(3):373–378.
281. Escobar-Morreale HF, del Rey FE, Obregón MJ, de Escobar GM. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. *Endocrinology.* 1996;**137**(6):2490–2502.
282. Peterson SJ, McAninch EA, Bianco AC. Is a normal TSH synonymous with “euthyroidism” in levothyroxine monotherapy? *J Clin Endocrinol Metab.* 2016;**101**(12):4964–4973.
283. Gorman CA, Jiang NS, Ellefson RD, Elveback LR. Comparative effectiveness of dextrothyroxine and levothyroxine in correcting hypothyroidism and lowering blood lipid levels in hypothyroid patients. *J Clin Endocrinol Metab.* 1979;**49**(1):1–7.
284. Samuels MH, Kolobova I, Smeraglio A, Peters D, Purnell JQ, Schuff KG. Effects of levothyroxine replacement or suppressive therapy on energy expenditure and body composition. *Thyroid.* 2016;**26**(3):347–355.
285. McAninch EA, Rajan KB, Miller CH, Bianco AC. Systemic thyroid hormone status during levothyroxine therapy in hypothyroidism: a systematic review and meta-analysis. *J Clin Endocrinol Metab.* 2018;**108**(12):4533–4542.
286. Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM, Dayan CM. Common variation in the *DIO2* gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. *J Clin Endocrinol Metab.* 2009;**94**(5):1623–1629.
287. Kim BW, Bianco AC. For some, L-thyroxine replacement might not be enough: a genetic rationale. *J Clin Endocrinol Metab.* 2009;**94**(5):1521–1523.
288. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on “adequate” doses of L-thyroxine: results of a large, controlled community-based questionnaire study. *Clin Endocrinol (Oxf).* 2002;**57**(5):577–585.
289. Carlé A, Faber J, Steffensen R, Laurberg P, Nygaard B. Hypothyroid patients encoding combined MCT10 and *DIO2* gene polymorphisms may prefer L-T3 + L-T4 combination treatment—data using a blind, randomized, clinical study. *Eur Thyroid J.* 2017;**6**(3):143–151.
290. Bernal J. Thyroid hormone receptors in brain development and function. *Nat Clin Pract Endocrinol Metab.* 2007;**3**(3):249–259.
291. Gogakos AI, Duncan Bassett JH, Williams GR. Thyroid and bone. *Arch Biochem Biophys.* 2010;**503**(1):129–136.
292. Remaud S, Gothié JD, Morvan-Dubois G, Demeneix BA. Thyroid hormone signaling and adult neurogenesis in mammals. *Front Endocrinol (Lausanne).* 2014;**5**:62.
293. Flamant F, Gauthier K, Richard S. Genetic investigation of thyroid hormone receptor function in the developing and adult brain. *Curr Top Dev Biol.* 2017;**125**:303–335.
294. Mohácsik P, Zeöld A, Bianco AC, Gereben B. Thyroid hormone and the neuroglia: both source and target. *J Thyroid Res.* 2011;**2011**:215718.
295. Crantz FR, Silva JE, Larsen PR. An analysis of the sources and quantity of 3,5,3'-triiodothyronine specifically bound to nuclear receptors in rat cerebral cortex and cerebellum. *Endocrinology.* 1982;**110**(2):367–375.
296. Galton VA, Wood ET, St Germain EA, Withrow CA, Aldrich G, St Germain GM, Clark AS, St Germain DL. Thyroid hormone homeostasis and action in the type 2 deiodinase-deficient rodent brain during development. *Endocrinology.* 2007;**148**(7):3080–3088.
297. Báñez-López S, Guadaño-Ferraz A. Thyroid hormone availability and action during brain development in rodents. *Front Cell Neurosci.* 2017;**11**:240.
298. Richard S, Flamant F. Regulation of T3 availability in the developing brain: the mouse genetics contribution. *Front Endocrinol (Lausanne).* 2018;**9**:265.
299. Morte B, Bernal J. Thyroid hormone action: astrocyte-neuron communication. *Front Endocrinol (Lausanne).* 2014;**5**:82.
300. Bernal J. The significance of thyroid hormone transporters in the brain. *Endocrinology.* 2005;**146**(4):1698–1700.
301. Grijiota-Martínez C, Samarut E, Scanlan TS, Morte B, Bernal J. In vivo activity of the thyroid hormone receptor  $\beta$ - and  $\alpha$ -selective agonists GC-24 and CO23 on rat liver, heart, and brain. *Endocrinology.* 2011;**152**(3):1136–1142.
302. Tu HM, Legradi G, Bartha T, Salvatore D, Lechan RM, Larsen PR. Regional expression of the type 3 iodothyronine deiodinase messenger ribonucleic acid in the rat central nervous system and its regulation by thyroid hormone. *Endocrinology.* 1999;**140**(2):784–790.
303. Tu HM, Kim SW, Salvatore D, Bartha T, Legradi G, Larsen PR, Lechan RM. Regional distribution of type 2 thyroxine deiodinase messenger ribonucleic acid in rat hypothalamus and pituitary and its regulation by thyroid hormone. *Endocrinology.* 1997;**138**(8):3359–3368.
304. Hernandez A, Morte B, Belinchón MM, Ceballos A, Bernal J. Critical role of types 2 and 3 deiodinases in the negative regulation of gene expression by T<sub>3</sub> in the mouse cerebral cortex. *Endocrinology.* 2012;**153**(6):2919–2928.
305. Guadaño-Ferraz A, Obregón MJ, St Germain DL, Bernal J. The type 2 iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat brain. *Proc Natl Acad Sci USA.* 1997;**94**(19):10391–10396.
306. Rovet J, Daneman D. Congenital hypothyroidism: a review of current diagnostic and treatment practices in relation to neuropsychologic outcome. *Paediatr Drugs.* 2003;**5**(3):141–149.
307. Forrest D, Swaroop A. Minireview: the role of nuclear receptors in photoreceptor differentiation and disease. *Mol Endocrinol.* 2012;**26**(6):905–915.
308. Sharlin DS, Visser TJ, Forrest D. Developmental and cell-specific expression of thyroid hormone transporters in the mouse cochlea. *Endocrinology.* 2011;**152**(12):5053–5064.
309. Forrest D, Erway LC, Ng L, Altschuler R, Curran T. Thyroid hormone receptor  $\beta$  is essential for development of auditory function. *Nat Genet.* 1996;**13**(3):354–357.
310. Rüschi A, Erway LC, Oliver D, Vennström B, Forrest D. Thyroid hormone receptor  $\beta$ -dependent expression of a potassium conductance in inner hair cells at the onset of hearing. *Proc Natl Acad Sci USA.* 1998;**95**(26):15758–15762.
311. Ng L, Hernandez A, He W, Ren T, Srinivas M, Ma M, Galton VA, St Germain DL, Forrest D. A protective role for type 3 deiodinase, a thyroid hormone-inactivating enzyme, in cochlear development and auditory function. *Endocrinology.* 2009;**150**(4):1952–1960.
312. Ng L, Goodyear RJ, Woods CA, Schneider MJ, Diamond E, Richardson GP, Kelley MW, Germain DL, Galton VA, Forrest D. Hearing loss and retarded cochlear development in mice lacking type 2 iodothyronine deiodinase. *Proc Natl Acad Sci USA.* 2004;**101**(10):3474–3479.
313. Sharlin DS, Ng L, Verrey F, Visser TJ, Liu Y, Olszewski RT, Hoa M, Heuer H, Forrest D. Deafness and loss of cochlear hair cells in the absence of thyroid hormone transporters *Slc16a2* (*Mct8*) and *Slc16a10* (*Mct10*). *Sci Rep.* 2018;**8**(1):4403.
314. Ng L, Hurler JB, Dierks B, Srinivas M, Saltó C, Vennström B, Reh TA, Forrest D. A thyroid hormone receptor that is required for the development of green cone photoreceptors. *Nat Genet.* 2001;**27**(1):94–98.
315. Roberts MR, Srinivas M, Forrest D, Morreale de Escobar G, Reh TA. Making the gradient: thyroid hormone regulates cone opsin expression in the developing mouse retina. *Proc Natl Acad Sci USA.* 2006;**103**(16):6218–6223.
316. Ng L, Lyubarsky A, Nikonov SS, Ma M, Srinivas M, Kefas B, St Germain DL, Hernandez A, Pugh EN Jr, Forrest D. Type 3 deiodinase, a thyroid-hormone-inactivating enzyme, controls survival and maturation of cone photoreceptors. *J Neurosci.* 2010;**30**(9):3347–3357.
317. Eldred KC, Hadyniak SE, Hussey KA, Brennerman B, Zhang PW, Chamling X, Sluch VM, Welsbie DS, Hattar S, Taylor J, Wahlin K, Zack DJ, Johnston RJ Jr. Thyroid hormone signaling specifies cone subtypes in human retinal organoids. *Science.* 2018;**362**(6411):eaau6348.
318. Yang F, Ma H, Butler MR, Ding XQ. Deficiency of type 2 iodothyronine deiodinase reduces necroptosis activity and oxidative stress responses in retinas of Leber congenital amaurosis model mice. *FASEB J.* 2018;fj201800484RR.
319. Yang F, Ma H, Boye SL, Hauswirth WW, Ding XQ. Overexpression of type 3 iodothyronine deiodinase reduces cone death in the leber congenital amaurosis model mice. *Adv Exp Med Biol.* 2018;**1074**:125–131.
320. Peeters RP, Hernandez A, Ng L, Ma M, Sharlin DS, Pandey M, Simonds WF, St Germain DL, Forrest D. Cerebellar abnormalities in mice lacking type 3 deiodinase and partial reversal of phenotype by deletion of thyroid hormone receptor  $\alpha 1$ . *Endocrinology.* 2013;**154**(1):550–561.
321. Báñez-López S, Bosch-García D, Gómez-Andrés D, Pulido-Valdeolivas J, Montero-Pedrazuela A, Obregon MJ, Guadaño-Ferraz A. Abnormal motor phenotype at adult stages in mice lacking type 2 deiodinase. *PLoS One.* 2014;**9**(8):e103857.
322. Báñez-López S, Montero-Pedrazuela A, Bosch-García D, Venero C, Guadaño-Ferraz A. Increased anxiety



- and fear memory in adult mice lacking type 2 deiodinase. *Psychoneuroendocrinology*. 2017;**84**:51–60.
323. Stohn JP, Martinez ME, Hernandez A. Decreased anxiety- and depression-like behaviors and hyperactivity in a type 3 deiodinase-deficient mouse showing brain thyrotoxicosis and peripheral hypothyroidism. *Psychoneuroendocrinology*. 2016;**74**:46–56.
324. Stohn JP, Martinez ME, Zafer M, López-Espíndola D, Keyes LM, Hernandez A. Increased aggression and lack of maternal behavior in Dio3-deficient mice are associated with abnormalities in oxytocin and vasopressin systems. *Genes Brain Behav*. 2018;**17**(1): 23–35.
325. Martinez ME, Duarte CW, Stohn JP, Karaczyn A, Wu Z, DeMambro VE, Hernandez A. Thyroid hormone influences brain gene expression programs and behaviors in later generations by altering germ line epigenetic information [published online ahead of print 24 October 2018]. *Mol Psychiatry*. doi: 10.1038/s41380-018-0281-4.
326. Li J, Donangelo I, Abe K, Scremin O, Ke S, Li F, Milanese A, Liu YY, Brent GA. Thyroid hormone treatment activates protective pathways in both in vivo and in vitro models of neuronal injury. *Mol Cell Endocrinol*. 2017;**452**:120–130.
327. Pol CJ, Muller A, Zuidwijk MJ, van Deel ED, Kaptein E, Saba A, Marchini M, Zucchi R, Visser TJ, Paulus WJ, Duncker DJ, Simonides WS. Left-ventricular remodeling after myocardial infarction is associated with a cardiomyocyte-specific hypothyroid condition. *Endocrinology*. 2011;**152**(2):669–679.
328. Olivares EL, Marassi MP, Fortunato RS, da Silva AC, Costa-e-Sousa RH, Araújo IG, Mattos EC, Masuda MO, Mulcahey MA, Huang SA, Bianco AC, Carvalho DP. Thyroid function disturbance and type 3 iodothyronine deiodinase induction after myocardial infarction in rats a time course study. *Endocrinology*. 2007;**148**(10):4786–4792.
329. Nascimento BPP, Bocco BM, Fernandes GW, Fonseca TL, McAninch EA, Cardoso CV, Bondan EF, Nassif RJ, Cysneiros RM, Bianco AC, Ribeiro MO. Induction of type 2 iodothyronine deiodinase after status epilepticus modifies hippocampal gene expression in male mice. *Endocrinology*. 2018;**159**(8): 3090–3104.
330. Margail I, Royer J, Lerouet D, Ramaugé M, Le Goascogne C, Li WW, Plotkine M, Pierre M, Courtin F. Induction of type 2 iodothyronine deiodinase in astrocytes after transient focal cerebral ischemia in the rat. *J Cereb Blood Flow Metab*. 2005;**25**(4):468–476.
331. Lamirand A, Mercier G, Ramaugé M, Pierre M, Courtin F. Hypoxia stabilizes type 2 deiodinase activity in rat astrocytes. *Endocrinology*. 2007;**148**(10):4745–4753.
332. Burmeister LA, Pachucki J, St Germain DL. Thyroid hormones inhibit type 2 iodothyronine deiodinase in the rat cerebral cortex by both pre- and post-translational mechanisms. *Endocrinology*. 1997;**138**(12):5231–5237.
333. Zou L, Burmeister LA, Styren SD, Kochanek PM, DeKosky ST. Up-regulation of type 2 iodothyronine deiodinase mRNA in reactive astrocytes following traumatic brain injury in the rat. *J Neurochem*. 1998;**71**(2):887–890.
334. Rastogi L, Godbole MM, Ray M, Rathore P, Rathore P, Pradhan S, Gupta SK, Pandey CM. Reduction in oxidative stress and cell death explains hypothyroidism induced neuroprotection subsequent to ischemia/reperfusion insult. *Exp Neurol*. 2006;**200**(2):290–300.
335. Rastogi L, Godbole MM, Sinha RA, Pradhan S. Reverse triiodothyronine (rT3) attenuates ischemia-reperfusion injury. *Biochem Biophys Res Commun*. 2018;**506**(3):597–603.
336. Liu YY, Brent GA. Thyroid hormone and the brain: mechanisms of action in development and role in protection and promotion of recovery after brain injury. *Pharmacol Ther*. 2018;**186**:176–185.
337. Barres BA, Lazar MA, Raff MC. A novel role for thyroid hormone, glucocorticoids and retinoic acid in timing oligodendrocyte development. *Development*. 1994;**120**(5):1097–1108.
338. Billon N, Jolicoeur C, Ying QL, Smith A, Raff M. Normal timing of oligodendrocyte development from genetically engineered, lineage-selectable mouse ES cells. *J Cell Sci*. 2002;**115**(Pt 18):3657–3665.
339. Dugas JC, Ibrahim A, Barres BA. The T3-induced gene KLF9 regulates oligodendrocyte differentiation and myelin regeneration. *Mol Cell Neurosci*. 2012;**50**(1):45–57.
340. Rемаud S, Ortiz FC, Perret-Jeanerret M, Aigrot MS, Gonthié JD, Fekete C, Kvářta-Papp Z, Gereben B, Langui D, Lubetzki C, Angulo MC, Zalc B, Demeneix B. Transient hypothyroidism favors oligodendrocyte generation providing functional remyelination in the adult mouse brain. *eLife*. 2017;**6**e29996.
341. Vose LR, Vinukonda G, Jo S, Miry O, Diamond D, Korumilli R, Arshad A, Zia MT, Hu F, Kayton RJ, La Gamma EF, Bansal R, Bianco AC, Ballabh P. Treatment with thyroxine restores myelination and clinical recovery after intraventricular hemorrhage. *J Neurosci*. 2013;**33**(44):17232–17246.
342. McAninch EA, Jo S, Preite NZ, Farkas E, Mohácsik P, Fekete C, Egri P, Gereben B, Li Y, Deng Y, Patti ME, Zevenbergen C, Peeters RP, Mash DC, Bianco AC. Prevalent polymorphism in thyroid hormone-activating enzyme leaves a genetic fingerprint that underlies associated clinical syndromes. *J Clin Endocrinol Metab*. 2015;**100**(3):920–933.
343. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Morón FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Flévet N, Huentelman MW, Gill M, Brown K, Kambh M, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogava E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossù P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, Meebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Mead S, Mosley TH Jr, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JJ, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltunen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nöthen MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van
- Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P; European Alzheimer's Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer's Disease; Alzheimer's Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet*. 2013;**45**(12):1452–1458.
344. Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BN, Wang LS, Valladares O, Lin CF, Larson EB, Graff-Radford NR, Evans D, De Jager PL, Crane PK, Buxbaum JD, Murrell JR, Raj T, Ertekin-Taner N, Logue M, Baldwin CT, Green RC, Barnes LL, Cantwell LB, Fallin MD, Go RC, Griffith P, Obisesan TO, Manly JJ, Lunetta KL, Kambh M, Lopez OL, Bennett DA, Hendrie H, Hall KS, Goate AM, Byrd GS, Kukull WA, Foroud TM, Haines JL, Farrer LA, Pericak-Vance MA, Schellenberg GD, Mayeux R; Alzheimer Disease Genetics Consortium. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E  $\epsilon$ 4, and the risk of late-onset Alzheimer disease in African Americans. *JAMA*. 2013;**309**:1483–1492.
345. Jun GR, Chung J, Mez J, Barber R, Beecham GW, Bennett DA, Buxbaum JD, Byrd GS, Carrasquillo MM, Crane PK, Cruchaga C, De Jager P, Ertekin-Taner N, Evans D, Fallin MD, Foroud TM, Friedland RP, Goate AM, Graff-Radford NR, Hendrie H, Hall KS, Hamilton-Nelson KL, Inzelberg R, Kambh M, Kauwe JS, Kukull WA, Kunkle BW, Kuwano R, Larson EB, Logue MW, Manly JJ, Martin ER, Montine TJ, Mukherjee S, Naj A, Reiman EM, Reitz C, Sherva R, St George-Hyslop PH, Thornton T, Younkin SG, Vardarajan BN, Wang LS, Wendlund JR, Winslow AR, Haines J, Mayeux R, Pericak-Vance MA, Schellenberg G, Lunetta KL, Farrer LA; Alzheimer's Disease Genetics Consortium. Transethnic genome-wide scan identifies novel Alzheimer's disease loci. *Alzheimers Dement*. 2017;**13**(7):727–738.
346. Hong EP, Park JW. Sample size and statistical power calculation in genetic association studies. *Genomics Inform*. 2012;**10**(2):117–122.
347. Wilkening S, Chen B, Bermejo JL, Canzian F. Is there still a need for candidate gene approaches in the era of genome-wide association studies? *Genomics*. 2009;**93**(5):415–419.
348. Steenland K, Goldstein FC, Levey A, Wharton W. A meta-analysis of Alzheimer's disease incidence and prevalence comparing African-Americans and Caucasians. *J Alzheimers Dis*. 2016;**50**(1):71–76.
349. McAninch EA, Rajan KB, Evans DA, Jo S, Chaker L, Peeters RP, Bennett DA, Mash DC, Bianco AC. A common DIO2 polymorphism and Alzheimer disease dementia in African and European Americans. *J Clin Endocrinol Metab*. 2018;**103**(5):1818–1826.
350. Bianco AC, Maia AL, da Silva WS, Christoffolete MA. Adaptive activation of thyroid hormone and energy expenditure. *Biosci Rep*. 2005;**25**(3–4):191–208.
351. Bianco AC, McAninch EA. The role of thyroid hormone and brown adipose tissue in energy homeostasis. *Lancet Diabetes Endocrinol*. 2013;**1**(3): 250–258.
352. Martínez-Sánchez N, Seoane-Collazo P, Contreras C, Varela L, Villarroya J, Rial-Pensado E, Buque X, Aurrekoetxea I, Delgado TC, Vazquez-Martinez R, Gonzalez-Garcia I, Roa J, Whittle AJ, Gomez-Santos B, Velagapudi V, Tung YC, Morgan DA, Voshol PJ, Martinez de Morentin PB, Lopez-Gonzalez T, Linares-Pose L, Gonzalez F, Chatterjee K, Sobrino T, Medina-Gomez G, Davis RJ, Casals N, Oresic M, Coll AP, Vidal-Puig A, Mittag J, Tena-Sempere M, Malagon MM, Dieguez C, Martinez-Chantar ML, Aspichueta P, Rahmouni K, Nogueiras R, Sabio G,



- Villarroya F, Lopez M. Hypothalamic AMPK-ER stress-JNK1 axis mediates the central actions of thyroid hormones on energy balance. *Cell Metab*. 2017;**26**(1):212–229.e12.
353. Zhang Z, Boelen A, Bisschop PH, Kalsbeek A, Fliers E. Hypothalamic effects of thyroid hormone. *Mol Cell Endocrinol*. 2017;**458**:143–148.
354. Cioffi F, Gentile A, Silvestri E, Goglia F, Lombardi A. Effect of iodothyronines on thermogenesis: focus on brown adipose tissue. *Front Endocrinol (Lausanne)*. 2018;**9**:254.
355. Senese R, de Lange P, Petito G, Moreno M, Goglia F, Lanni A. 3,5-Diiodothyronine: a novel thyroid hormone metabolite and potent modulator of energy metabolism. *Front Endocrinol (Lausanne)*. 2018;**9**:427.
356. Fontes KN, Cabanelas A, Bloise FF, de Andrade CBV, Souza LL, Willeman M, Trevenzoli IH, Agra LC, Silva JD, Bandeira-Melo C, Silva PL, Rocco PRM, Ortiga-Carvalho TM. Differential regulation of thyroid hormone metabolism target genes during non-thyroidal illness syndrome triggered by fasting or sepsis in adult mice (published correction appears in *Front Physiol*. 2017;**8**:995). *Front Physiol*. 2017;**8**:828.
357. Kong WM, Martin NM, Smith KL, Gardiner JV, Connolly IP, Stephens DA, Dhillo WS, Ghatei MA, Small CJ, Bloom SR. Triiodothyronine stimulates food intake via the hypothalamic ventromedial nucleus independent of changes in energy expenditure. *Endocrinology*. 2004;**145**(11):5252–5258.
358. Cubuk C, Markowsky H, Herwig A. Hypothalamic control systems show differential gene expression during spontaneous daily torpor and fasting-induced torpor in the Djungarian hamster (*Phodopus sungorus*). *PLoS One*. 2017;**12**(10):e0186299.
359. Yasuo S, Watanabe M, Nakao N, Takagi T, Follett BK, Ebihara S, Yoshimura T. The reciprocal switching of two thyroid hormone-activating and -inactivating enzyme genes is involved in the photoperiodic gonadal response of Japanese quail. *Endocrinology*. 2005;**146**(6):2551–2554.
360. Watanabe T, Yamamura T, Watanabe M, Yasuo S, Nakao N, Dawson A, Ebihara S, Yoshimura T. Hypothalamic expression of thyroid hormone-activating and -inactivating enzyme genes in relation to photorefractoriness in birds and mammals. *Am J Physiol Regul Integr Comp Physiol*. 2007;**292**(1):R568–R572.
361. Wu Z, Martinez ME, St Germain DL, Hernandez A. Type 3 deiodinase role on central thyroid hormone action affects the leptin–melanocortin system and circadian activity. *Endocrinology*. 2017;**158**(2):419–430.
362. McAninch EA, Bianco AC. Thyroid hormone signaling in energy homeostasis and energy metabolism. *Ann N Y Acad Sci*. 2014;**1311**(1):77–87.
363. Bianco AC. Minireview: cracking the metabolic code for thyroid hormone signaling. *Endocrinology*. 2011;**152**(9):3306–3311.
364. Silva JE. Thyroid hormone and the energetic cost of keeping body temperature. *Biosci Rep*. 2005;**25**(3–4):129–148.
365. Hernández A, Obregón MJ. Presence and mRNA expression of T3 receptors in differentiating rat brown adipocytes. *Mol Cell Endocrinol*. 1996;**121**(1):37–46.
366. Preite NZ, Nascimento BP, Muller CR, Américo AL, Higa TS, Evangelista FS, Lancellotti CL, Henriques FS, Batista ML Jr, Bianco AC, Ribeiro MO. Disruption of beta3 adrenergic receptor increases susceptibility to DIO in mouse. *J Endocrinol*. 2016;**231**(3):259–269.
367. Fernandes GW, Ueta CB, Fonseca TL, Gouveia CH, Lancellotti CL, Brum PC, Christoffolete MA, Bianco AC, Ribeiro MO. Inactivation of the adrenergic receptor  $\beta_2$  disrupts glucose homeostasis in mice. *J Endocrinol*. 2014;**221**(3):381–390.
368. Ueta CB, Fernandes GW, Capelo LP, Fonseca TL, Maculan FD, Gouveia CH, Brum PC, Christoffolete MA, Aoki MS, Lancellotti CL, Kim B, Bianco AC, Ribeiro MO.  $\beta_1$  Adrenergic receptor is key to cold- and diet-induced thermogenesis in mice. *J Endocrinol*. 2012;**214**(3):359–365.
369. Branco M, Ribeiro M, Negrão N, Bianco AC. 3,5,3'-Triiodothyronine actively stimulates UCP in brown fat under minimal sympathetic activity. *Am J Physiol*. 1999;**276**(1):E179–E187.
370. Bianco AC, Kieffer JD, Silva JE. Adenosine 3',5'-monophosphate and thyroid hormone control of uncoupling protein messenger ribonucleic acid in freshly dispersed brown adipocytes. *Endocrinology*. 1992;**130**(5):2625–2633.
371. Bianco AC, Carvalho SD, Carvalho CR, Rabelo R, Moriscot AS. Thyroxine 5'-deiodination mediates norepinephrine-induced lipogenesis in dispersed brown adipocytes. *Endocrinology*. 1998;**139**(2):571–578.
372. Carvalho SD, Negrão N, Bianco AC. Hormonal regulation of malic enzyme and glucose-6-phosphate dehydrogenase in brown adipose tissue. *Am J Physiol*. 1993;**264**(6 Pt 1):E874–E881.
373. Bianco AC, Silva JE. Optimal response of key enzymes and uncoupling protein to cold in BAT depends on local T3 generation. *Am J Physiol*. 1987;**253**(3 Pt 1):E255–E263.
374. Katz LS, Xu S, Ge K, Scott DK, Gershengorn MC. T3 and glucose coordinately stimulate ChREBP-mediated Ucp1 expression in brown adipocytes from male mice. *Endocrinology*. 2018;**159**(1):557–569.
375. Keipert S, Kutschke M, Ost M, Schwarzmayr T, van Schothorst EM, Lamp D, Brachthäuser L, Hamp I, Mazibuko SE, Hartwig S, Lehr S, Graf E, Plettenburg O, Neff F, Tschop MH, Jastroch M. Long-term cold adaptation does not require FGF21 or UCP1. *Cell Metab*. 2017 Aug 1;**26**(2):437–446.e5.
376. Ribeiro MO, Carvalho SD, Schultz JJ, Chiellini G, Scanlan TS, Bianco AC, Brent GA. Thyroid hormone–sympathetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform–specific. *J Clin Invest*. 2001;**108**(1):97–105.
377. Lin JZ, Martagón AJ, Cimini SL, Gonzalez DD, Tinkey DW, Biter A, Baxter JD, Webb P, Gustafsson JA, Hartig SM, Phillips KJ. Pharmacological activation of thyroid hormone receptors elicits a functional conversion of white to brown fat. *Cell Reports*. 2015;**13**(8):1528–1537.
378. Reiter RJ, Klaus S, Ebbinghaus C, Heldmaier G, Redlin U, Ricquier D, Vaughan MK, Steinlechner S. Inhibition of 5'-deiodination of thyroxine suppresses the cold-induced increase in brown adipose tissue messenger ribonucleic acid for mitochondrial uncoupling protein without influencing lipoprotein lipase activity. *Endocrinology*. 1990;**126**(5):2550–2554.
379. de Jesus LA, Carvalho SD, Ribeiro MO, Schneider M, Kim SW, Harney JW, Larsen PR, Bianco AC. The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. *J Clin Invest*. 2001;**108**(9):1379–1385.
380. Christoffolete MA, Linardi CC, de Jesus L, Ebina KN, Carvalho SD, Ribeiro MO, Rabelo R, Curcio C, Martins L, Kimura ET, Bianco AC. Mice with targeted disruption of the Dio2 gene have cold-induced overexpression of the uncoupling protein 1 gene but fail to increase brown adipose tissue lipogenesis and adaptive thermogenesis. *Diabetes*. 2004;**53**(3):577–584.
381. Castillo M, Hall JA, Correa-Medina M, Ueta C, Kang HW, Cohen DE, Bianco AC. Disruption of thyroid hormone activation in type 2 deiodinase knockout mice causes obesity with glucose intolerance and liver steatosis only at thermoneutrality. *Diabetes*. 2011;**60**(4):1082–1089.
382. Hall JA, Ribich S, Christoffolete MA, Simovic G, Correa-Medina M, Patti ME, Bianco AC. Absence of thyroid hormone activation during development underlies a permanent defect in adaptive thermogenesis. *Endocrinology*. 2010;**151**(9):4573–4582.
383. Watanabe M, Houten SM, Matakai C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature*. 2006;**439**(7075):484–489.
384. da-Silva WS, Harney JW, Kim BW, Li J, Bianco SD, Crescenzi A, Christoffolete MA, Huang SA, Bianco AC. The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation. *Diabetes*. 2007;**56**(3):767–776.
385. da-Silva WS, Ribich S, Arrojo E, Drigo R, Castillo M, Patti ME, Bianco AC. The chemical chaperones tauroursodeoxycholic and 4-phenylbutyric acid accelerate thyroid hormone activation and energy expenditure. *FEBS Lett*. 2011;**585**(3):539–544.
386. Shu L, Hoo RL, Wu X, Pan Y, Lee IP, Cheong LY, Bornstein SR, Rong X, Guo J, Xu A. A-FABP mediates adaptive thermogenesis by promoting intracellular activation of thyroid hormones in brown adipocytes. *Nat Commun*. 2017;**8**:14147.
387. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Matakai C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. *Cell Metab*. 2009;**10**(3):167–177.
388. Broeders EP, Nascimento EB, Havekes B, Brans B, Roumans KH, Tailleux A, Schaart G, Kouach M, Charton J, Deprez B, Bouvy ND, Mottaghy F, Staels B, van Marken Lichtenbelt WD, Schrauwen P. The bile acid chenodeoxycholic acid increases human brown adipose tissue activity. *Cell Metab*. 2015;**22**(3):418–426.
389. Ockenga J, Valentini L, Schuetz T, Wohlgemuth F, Glaeser S, Omar A, Kasim E, duPlessis D, Featherstone K, Davis JR, Tietge UJ, Kroencke T, Biebermann H, Köhrle J, Brabant G. Plasma bile acids are associated with energy expenditure and thyroid function in humans. *J Clin Endocrinol Metab*. 2012;**97**(2):535–542.
390. Arrojo E, Drigo R, Fonseca TL, Castillo M, Salathe M, Simovic G, Mohácsik P, Gereben B, Bianco AC. Endoplasmic reticulum stress decreases intracellular thyroid hormone activation via an eIF2 $\alpha$ -mediated decrease in type 2 deiodinase synthesis. *Mol Endocrinol*. 2011;**25**(12):2065–2075.
391. Hetz C, Saxena S. ER stress and the unfolded protein response in neurodegeneration. *Nat Rev Neurol*. 2017;**13**(8):477–491.
392. Qi L, Tsai B, Arvan P. New insights into the physiological role of endoplasmic reticulum-associated degradation. *Trends Cell Biol*. 2017;**27**(6):430–440.
393. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Görgün C, Glimcher LK, Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science*. 2004;**306**(5695):457–461.
394. Houstěk J, Vízek K, Pavelka S, Kopecký J, Krejčová E, Hermánská J, Cermáková M. Type II iodothyronine 5'-deiodinase and uncoupling protein in brown adipose tissue of human newborns. *J Clin Endocrinol Metab*. 1993;**77**(2):382–387.

395. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen M, Laine J, Savisto NJ, Enerbäck S, Nuutila P. Functional brown adipose tissue in healthy adults. *N Engl J Med*. 2009;**360**(15):1518–1525.
396. Almind K, Manier M, Sivitz WI, Cinti S, Kahn CR. Ectopic brown adipose tissue in muscle provides a mechanism for differences in risk of metabolic syndrome in mice. *Proc Natl Acad Sci USA*. 2007;**104**(7):2366–2371.
397. Peeters RP, van der Deure WM, Visser TJ. Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. *Eur J Endocrinol*. 2006;**155**(5):655–662.
398. Kimura K, Sasaki N, Asano A, Mizukami J, Kayahashi S, Kawada T, Fushiki T, Morimatsu M, Yoshida T, Saito M. Mutated human  $\beta$ 3-adrenergic receptor (Trp64Arg) lowers the response to  $\beta$ 3-adrenergic agonists in transfected 3T3-L1 preadipocytes. *Horm Metab Res*. 2000;**32**(3):91–96.
399. Canani LH, Leie MA, Machado WE, Capp C, Maia AL. Type 2 deiodinase Thr92Ala polymorphism is not associated with arterial hypertension in type 2 diabetes mellitus patients. *Hypertension*. 2007;**49**(6):e47.
400. Girarup N, Andersen MK, Andreassen CH, Albrechtsen A, Borch-Johnsen K, Jørgensen T, Auwerx J, Schmitz O, Hansen T, Pedersen O. Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects. *J Clin Endocrinol Metab*. 2007;**92**(1):363–366.
401. Gumieniak O, Williams GH. Response to type 2 deiodinase Thr92Ala polymorphism is not associated with arterial hypertension in type 2 diabetes mellitus patients. *Hypertension*. 2007;**49**(6):e48.
402. Heemstra KA, Hofstijzer HC, van der Deure WM, Peeters RP, Fliers E, Appelhof BC, Wiersinga WM, Corssmit EP, Visser TJ, Smit JW. Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis. *Clin Endocrinol (Oxf)*. 2009;**71**(2):279–283.
403. van der Deure WM, Peeters RP, Uitterlinden AC, Hofman A, Breteler MM, Witteman J, Visser TJ. Impact of thyroid function and polymorphisms in the type 2 deiodinase on blood pressure: the Rotterdam Study and the Rotterdam Scan Study. *Clin Endocrinol (Oxf)*. 2009;**71**(1):137–144.
404. Mentuccia D, Thomas MJ, Coppotelli G, Reinhart LJ, Mitchell BD, Shuldiner AR, Celi FS. The Thr92Ala deiodinase type 2 (DIO2) variant is not associated with type 2 diabetes or indices of insulin resistance in the old order of Amish. *Thyroid*. 2005;**15**(11):1223–1227.
405. Croteau W, Davey JC, Galton VA, St Germain DL. Cloning of the mammalian type II iodothyronine deiodinase. A selenoprotein differentially expressed and regulated in human and rat brain and other tissues. *J Clin Invest*. 1996;**98**(2):405–417.
406. Christoffolete MA, Doleschall M, Egri P, Liposits Z, Zavacki AM, Bianco AC, Gereben B. Regulation of thyroid hormone activation via the liver X-receptor/retinoid X-receptor pathway. *J Endocrinol*. 2010;**205**(2):179–186.
407. Kalaany NY, Gauthier KC, Zavacki AM, Mammen PP, Kitazume T, Peterson JA, Horton JD, Garry DJ, Bianco AC, Mangelsdorf DJ. LXRs regulate the balance between fat storage and oxidation. *Cell Metab*. 2005;**1**(4):231–244.
408. Fernandes GW, Bocco BM, Fonseca TL, McAninch EA, Jo S, Lartey LJ, O'Sullivan I, Unterman TG, Preite NZ, Voigt RM, Forsyth CB, Keshavarzian A, Sinkó R, Goldfine AB, Patti ME, Ribeiro MO, Gereben B, Bianco AC. The FoxO1-inducible transcriptional repressor Zfp125 causes hepatic steatosis and hypercholesterolemia. *Cell Rep*. 2018;**22**(2):523–534.
409. Arjona FJ, de Vrieze E, Visser TJ, Flik G, Klaren PH. Identification and functional characterization of zebrafish solute carrier Slc16a2 (Mct8) as a thyroid hormone membrane transporter. *Endocrinology*. 2011;**152**(12):5065–5073.
410. Kim M, Deacon P, Tirona RG, Kim RB, Pin CL, Meyer Zu Schwabedissen HE, Wang R, Schwarz UL. Characterization of OATP1B3 and OATP2B1 transporter expression in the islet of the adult human pancreas. *Histochem Cell Biol*. 2017;**148**(4):345–357.
411. Zinke A, Schmoll D, Zachmann M, Schmoll J, Junker H, Grempler R, Kirsch G, Walther R. Expression of thyroid hormone receptor isoform  $\alpha$ 1 in pancreatic islets. *Exp Clin Endocrinol Diabetes*. 2003;**111**(4):198–202.
412. Matsuda H, Mullapudi ST, Zhang Y, Hesselson D, Stainer DYR. Thyroid hormone coordinates pancreatic islet maturation during the zebrafish larval-to-juvenile transition to maintain glucose homeostasis. *Diabetes*. 2017;**66**(10):2623–2635.
413. Aguayo-Mazzucato C, Lee TB Jr, Matzko M, Dilenno A, Rezanejad H, Ramadoss P, Scanlan T, Zavacki AM, Larsen PR, Hollenberg A, Colton C, Sharma A, Bonner-Weir S. T<sub>3</sub> induces both markers of maturation and aging in pancreatic  $\beta$ -cells. *Diabetes*. 2018;**67**(7):1322–1331.
414. Harris SE, De Blasio MJ, Davis MA, Kelly AC, Davenport HM, Wooding FBP, Blache D, Meredith D, Anderson M, Fowden AL, Limesand SW, Forhead AJ. Hypothyroidism in utero stimulates pancreatic beta cell proliferation and hyperinsulinaemia in the ovine fetus during late gestation. *J Physiol*. 2017;**595**(11):3331–3343.
415. Akiyama S, Ogiwara T, Aoki T, Tsunekawa K, Araki O, Murakami M. Glucagon-like peptide-1 stimulates type 3 iodothyronine deiodinase expression in a mouse insulinoma cell line. *Life Sci*. 2014;**115**(1–2):22–28.
416. Stoykov I, Zandieh-Doulabi B, Moorman AF, Christoffels V, Wiersinga WM, Bakker O. Expression pattern and ontogenesis of thyroid hormone receptor isoforms in the mouse heart. *J Endocrinol*. 2006;**189**(2):231–245.
417. Nishimura K, Takeda M, Yamashita JK, Shiojima I, Toyoda N. Type 3 iodothyronine deiodinase is expressed in human induced pluripotent stem cell derived cardiomyocytes. *Life Sci*. 2018;**203**:276–281.
418. Salvatore D, Bartha T, Harney JW, Larsen PR. Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. *Endocrinology*. 1996;**137**(8):3308–3315.
419. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. *JAMA*. 2007;**298**(11):1312–1322.
420. Krenning EP, Docter R, Bernard B, Visser T, Hennemann G. Decreased transport of thyroxine (T<sub>4</sub>), 3,3',5'-triiodothyronine (T<sub>3</sub>) and 3,3',5'-triiodothyronine (rT<sub>3</sub>) into rat hepatocytes in primary culture due to a decrease of cellular ATP content and various drugs. *FEBS Lett*. 1982;**140**(2):229–233.
421. Bakker O, van Beeren HC, Wiersinga WM. Desethylamiodarone is a noncompetitive inhibitor of the binding of thyroid hormone to the thyroid hormone beta 1-receptor protein. *Endocrinology*. 1994;**134**(4):1665–1670.
422. van Beeren HC, Bakker O, Wiersinga WM. Desethylamiodarone is a competitive inhibitor of the binding of thyroid hormone to the thyroid hormone  $\alpha$ -receptor protein. *Mol Cell Endocrinol*. 1995;**112**(1):15–19.
423. Bogazzi F, Bartalena L, Brogioni S, Burelli A, Raggi F, Ultimieri F, Cosci C, Vitale M, Fenzi G, Martino E. Desethylamiodarone antagonizes the effect of thyroid hormone at the molecular level. *Eur J Endocrinol*. 2001;**145**(1):59–64.
424. Hong EG, Kim BV, Jung DY, Kim JH, Yu T, Seixas Da Silva W, Friedline RH, Bianco SD, Seslar SP, Wakimoto H, Berul CI, Russell KS, Lee KW, Larsen PR, Bianco AC, Kim JK. Cardiac expression of human type 2 iodothyronine deiodinase increases glucose metabolism and protects against doxorubicin-induced cardiac dysfunction in male mice. *Endocrinology*. 2013;**154**(10):3937–3946.
425. Carvalho-Bianco SD, Kim BW, Zhang JX, Harney JW, Ribeiro RS, Gereben B, Bianco AC, Mende U, Larsen PR. Chronic cardiac-specific thyrotoxicosis increases myocardial  $\beta$ -adrenergic responsiveness. *Mol Endocrinol*. 2004;**18**(7):1840–1849.
426. Wang YY, Morimoto S, Du CK, Lu QW, Zhan DY, Tsutsumi T, Ide T, Miwa Y, Takahashi-Yanaga F, Sasaguri T. Up-regulation of type 2 iodothyronine deiodinase in dilated cardiomyopathy. *Cardiovasc Res*. 2010;**87**(4):636–646.
427. Chowdhury D, Parnell VA, Ojamaa K, Boxer R, Cooper R, Klein I. Usefulness of triiodothyronine (T<sub>3</sub>) treatment after surgery for complex congenital heart disease in infants and children. *Am J Cardiol*. 1999;**84**(9):1107–1109.
428. Klemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ, Isom OW, Krieger K. Thyroid hormone treatment after coronary-artery bypass surgery. *N Engl J Med*. 1995;**333**(23):1522–1527.
429. Klemperer JD, Klein IL, Ojamaa K, Helm RE, Gomez M, Isom OW, Krieger KH. Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations. *Ann Thorac Surg*. 1996;**61**(5):1323–1327.
430. Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, L'abbate A, Mariotti R, Iervasi G. Acute effects of triiodothyronine (T<sub>3</sub>) replacement therapy in patients with chronic heart failure and low-T<sub>3</sub> syndrome: a randomized, placebo-controlled study. *J Clin Endocrinol Metab*. 2008;**93**(4):1351–1358.
431. Ueta CB, Oskoueji BN, Olivares EL, Pinto JR, Correa MM, Simovic G, Simonides WS, Hare JM, Bianco AC. Absence of myocardial thyroid hormone inactivating deiodinase results in restrictive cardiomyopathy in mice. *Mol Endocrinol*. 2012;**26**(5):809–818.
432. Janssen R, Muller A, Simonides WS. Cardiac thyroid hormone metabolism and heart failure. *Eur Thyroid J*. 2017;**6**(3):130–137.
433. Pantos C, Mourouzis I. Thyroid hormone receptor  $\alpha$ 1 as a novel therapeutic target for tissue repair. *Ann Transl Med*. 2018;**6**(12):254.
434. Pantos C, Mourouzis I, Xinaris C, Kokkinos AD, Markakis K, Dimopoulos A, Panagiotou M, Saranteas T, Kostopanagiotou G, Cokkinos DV. Time-dependent changes in the expression of thyroid hormone receptor  $\alpha$ 1 in the myocardium after acute myocardial infarction: possible implications in cardiac remodelling. *Eur J Endocrinol*. 2007;**156**(4):415–424.
435. Wassner AJ, Jung RH, Dorfman DM, Padera RF, Maynard MA, Zavacki AM, Jay PY, Huang SA. Myocardial induction of type 3 deiodinase in dilated cardiomyopathy. *Thyroid*. 2017;**27**(5):732–737.
436. Janssen R, Zuidwijk MJ, Muller A, van Mil A, Dirx E, Oudejans CB, Paulus WJ, Simonides WS. MicroRNA 214 is a potential regulator of thyroid hormone levels in the mouse heart following myocardial infarction, by targeting the thyroid-hormone-inactivating enzyme deiodinase type III. *Front Endocrinol (Lausanne)*. 2016;**7**:22.
437. Paolino BS, Pomerantz PM, Dallan LAO, Gaiotto FA, Preite NZ, Latronico AC, Nicolau JC, Bianco AC,

- Giraldez R. Myocardial inactivation of thyroid hormones in patients with aortic stenosis. *Thyroid*. 2017;**27**(5):738–745.
438. Suarez J, Wang H, Scott BT, Ling H, Makino A, Swanson E, Brown JH, Suarez JA, Feinstein S, Diaz-Juarez J, Dillmann WH. In vivo selective expression of thyroid hormone receptor  $\alpha_1$  in endothelial cells attenuates myocardial injury in experimental myocardial infarction in mice. *Am J Physiol Regul Integr Comp Physiol*. 2014;**307**(3):R340–R346.
439. Wawrzynska L, Sakowicz A, Rudzinski P, Langfort R, Kurzyna M. The conversion of thyroxine to triiodothyronine in the lung: comparison of activity of type I iodothyronine 5' deiodinase in lung cancer with peripheral lung tissues. *Monaldi Arch Chest Dis*. 2003;**59**(2):140–145.
440. Pei L, Leblanc M, Barish G, Atkins A, Nofsinger R, Whyte J, Gold D, He M, Kawamura K, Li HR, Downes M, Yu RT, Powell HC, Lingrel JB, Evans RM. Thyroid hormone receptor repression is linked to type I pneumocyte-associated respiratory distress syndrome. *Nat Med*. 2011;**17**(11):1466–1472.
441. Barca-Mayo O, Liao XH, DiCosmo C, Dumitrescu A, Moreno-Vinasco L, Wade MS, Sammani S, Mirzapozazova T, Garcia JG, Refetoff S, Weiss RE. Role of type 2 deiodinase in response to acute lung injury (ALI) in mice. *Proc Natl Acad Sci USA*. 2011;**108**(49):E1321–E1329.
442. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. *Lancet*. 2012;**380**(9842):680–688.
443. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, Brown KK, Chapman HA, Collard HR, Cosgrove GP, Deterding R, Doyle R, Flaherty KR, Garcia CK, Hagood JC, Henke CA, Herzog E, Hogaboam CM, Horowitz JC, King TE Jr, Loyd JE, Lawson WE, Marsh CB, Noble PW, Noth I, Sheppard D, Olsson J, Ortiz LA, O'Riordan TG, Oury TD, Raghu G, Roman J, Sime PJ, Sisson TH, Tschumperlin D, Violette SM, Weaver TE, Wells RC, White ES, Kaminski N, Martinez FJ, Wynn TA, Thannickal VJ, Eu JP. Future directions in idiopathic pulmonary fibrosis research: an NHLBI workshop report. *Am J Respir Crit Care Med*. 2014;**189**(2):214–222.
444. Raghu G, Rochwerf B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schönemann HJ; American Thoracic Society; European Respiratory Society; Japanese Respiratory Society; Latin American Thoracic Association. An Official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline (published correction appears in *Am J Respir Crit Care Med*. 2015;**192**(5):644). *Am J Respir Crit Care Med*. 2015;**192**(2):e3–e19.
445. Myllärniemi M. Idiopathic pulmonary fibrosis in the USA. *Lancet Respir Med*. 2014;**2**(7):515–516.
446. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? *PLoS Med*. 2008;**5**(3):e62.
447. Yu C, Tzouveleki A, Wang R, Herazo-Maya JD, Ibarra GH, Srivastava A, de Castro JP, Deluili G, Ahangari F, Woolard T, Aurelien N, Arrojo E, Drigo R, Gan Y, Graham M, Liu X, Homer RJ, Scanlan TS, Mannam P, Lee PJ, Herzog EL, Bianco AC, Kaminski N. Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. *Nat Med*. 2018;**24**(1):39–49.
448. Yu F, Göthe S, Wikström L, Forrest D, Vennström B, Larsson L. Effects of thyroid hormone receptor gene disruption on myosin isoform expression in mouse skeletal muscles. *Am J Physiol Regul Integr Comp Physiol*. 2000;**278**(6):R1545–R1554.
449. Arrojo E, Drigo R, Fonseca TL, Werneck-de-Castro JP, Bianco AC. Role of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone signaling. *Biochim Biophys Acta*. 2013;**1830**(7):3956–3964.
450. Ambrosio R, Damiano V, Sibilio A, De Stefano MA, Avvedimento VE, Salvatore D, Dentice M. Epigenetic control of type 2 and 3 deiodinases in myogenesis: role of lysine-specific demethylase enzyme and FoxO3. *Nucleic Acids Res*. 2013;**41**(6):3551–3562.
451. Salvatore D, Simonides WS, Dentice M, Zavacki AM, Larsen PR. Thyroid hormones and skeletal muscle—new insights and potential implications. *Nat Rev Endocrinol*. 2014;**10**(4):206–214.
452. Werneck-de-Castro JP, Fonseca TL, Ignacio DL, Fernandes GW, Andrade-Feraud CM, Lartey LJ, Ribeiro MB, Ribeiro MO, Gereben B, Bianco AC. Thyroid hormone signaling in male mouse skeletal muscle is largely independent of D2 in myocytes. *Endocrinology*. 2015;**156**(10):3842–3852.
453. Ramadan W, Marsili A, Huang S, Larsen PR, Silva JE. Type-2 iodothyronine 5' deiodinase in skeletal muscle of C57BL/6 mice. I. Identity, subcellular localization, and characterization. *Endocrinology*. 2011;**152**(8):3082–3092.
454. Marsili A, Ramadan W, Harney JW, Mulcahey M, Castroneves LA, Goemann IM, Wajner SM, Huang SA, Zavacki AM, Maia AL, Dentice M, Salvatore D, Silva JE, Larsen PR. Type 2 iodothyronine deiodinase levels are higher in slow-twitch than fast-twitch mouse skeletal muscle and are increased in hypothyroidism. *Endocrinology*. 2010;**151**(12):5952–5960.
455. Ramadan W, Marsili A, Larsen PR, Zavacki AM, Silva JE. Type-2 iodothyronine 5' deiodinase (D2) in skeletal muscle of C57BL/6 mice. II. Evidence for a role of D2 in the hypermetabolism of thyroid hormone receptor  $\alpha$ -deficient mice. *Endocrinology*. 2011;**152**(8):3093–3102.
456. Dentice M, Marsili A, Ambrosio R, Guardiola O, Sibilio A, Paik JH, Minchiotti G, DePinho RA, Fenzi G, Larsen PR, Salvatore D. The FoxO3/type 2 deiodinase pathway is required for normal mouse myogenesis and muscle regeneration. *J Clin Invest*. 2010;**120**(11):4021–4030.
457. Otto A, Collins-Hooper H, Patel K. The origin, molecular regulation and therapeutic potential of myogenic stem cell populations. *J Anat*. 2009;**215**(5):477–497.
458. Mauro A. Satellite cell of skeletal muscle fibers. *J Biophys Biochem Cytol*. 1961;**9**(2):493–495.
459. Ignacio DL, Silvestre DH, Anne-Palmer E, Bocco BM, Fonseca TL, Ribeiro MO, Gereben B, Bianco AC, Werneck-de-Castro JP. Early developmental disruption of type 2 deiodinase pathway in mouse skeletal muscle does not impair muscle function. *Thyroid*. 2017;**27**(4):577–586.
460. Bassett JH, Williams GR. Role of thyroid hormones in skeletal development and bone maintenance. *Endocr Rev*. 2016;**37**(2):135–187.
461. Gouveia CH, Miranda-Rodrigues M, Martins GM, Neofiti-Papi B. Thyroid hormone and skeletal development. *Vitam Horm*. 2018;**106**:383–472.
462. Leitch VD, Di Cosmo C, Liao XH, O'Boy S, Galliford TM, Evans H, Croucher PJ, Boyde A, Dumitrescu A, Weiss RE, Refetoff S, Williams GR, Bassett JH. An essential physiological role for MCT8 in bone in male mice. *Endocrinology*. 2017;**158**(9):3055–3066.
463. Capelo LP, Beber EH, Huang SA, Zorn TM, Bianco AC, Gouveia CH. Deiodinase-mediated thyroid hormone inactivation minimizes thyroid hormone signaling in the early development of fetal skeleton. *Bone*. 2008;**43**(5):921–930.
464. Miura M, Tanaka K, Komatsu Y, Suda M, Yasoda A, Sakuma Y, Ozasa A, Nakao K. Thyroid hormones promote chondrocyte differentiation in mouse ATDC5 cells and stimulate endochondral ossification in fetal mouse tibias through iodothyronine deiodinases in the growth plate. *J Bone Miner Res*. 2002;**17**(3):443–454.
465. Waung JA, Bassett JH, Williams GR. Adult mice lacking the type 2 iodothyronine deiodinase have increased subchondral bone but normal articular cartilage. *Thyroid*. 2015;**25**(3):269–277.
466. Hernandez A. Thyroid hormone deiodination and action in the gonads. *Curr Opin Endocr Metab Res*. 2018;**2**:18–23.
467. Shen Y, Yue F, McCleary DF, Ye Z, Edsall L, Kuan S, Wagner U, Dixon J, Lee L, Lobanenko VV, Ren B. A map of the cis-regulatory sequences in the mouse genome. *Nature*. 2012;**488**(7409):116–120.
468. Yue F, Cheng Y, Breschi A, Vierstra J, Wu Y, Ryba T, Sandstrom R, Ma Z, Davis C, Pope BD, Shen Y, Pervouchine DD, Djebali S, Thurman RE, Kaul R, Rynes E, Kirilusha A, Marinov GK, Williams BA, Trout D, Amrhein H, Fisher-Aylor K, Antoshechkin I, DeSalvo G, See LH, Fastuca M, Drenkow J, Zaleski C, Dobin A, Prieto P, Lagarde J, Bussotti G, Tanzer A, Denas O, Li K, Bender MA, Zhang M, Byron R, Groudine MT, McCleary D, Pham L, Ye Z, Kuan S, Edsall L, Wu YC, Rasmussen MD, Bansal MS, Kellis M, Keller CA, Morrissey CS, Mishra T, Jain D, Dogan N, Harris RS, Cayting P, Kawli T, Boyle AP, Euskirchen G, Kundaje A, Lin S, Lin Y, Jansen C, Malladi VS, Cline MS, Erickson DT, Kirkup VM, Learned K, Sloan CA, Rosenbloom KR, Lacerda de Sousa B, Beal K, Pignatelli M, Flicek P, Lian J, Kahveci T, Lee D, Kent WJ, Ramalho Santos M, Herrero J, Notredame C, Johnson A, Vong S, Lee K, Bates D, Neri F, Diegel M, Canfield T, Sabo PJ, Wilken MS, Reh TA, Giste E, Shafer A, Kutayvin T, Haugen E, Dunn D, Reynolds AP, Neph S, Humbert R, Hansen RS, De Bruijn M, Selleri L, Rudensky A, Josefowicz S, Samstein R, Eichler EE, Orkin SH, Levasseur D, Papayannopoulou T, Chang KH, Skoutelchi A, Gosh S, Disteche C, Treuting P, Wang Y, Weiss MJ, Blobel GA, Cao X, Zhong S, Wang T, Good PJ, Lowdown RF, Adams LB, Zhou XQ, Pazin MJ, Feingold EA, Wold B, Taylor J, Mortazavi A, Weissman SM, Stamatoyannopoulos JA, Snyder MP, Guigo R, Gingeras TR, Gilbert DM, Hardison RC, Beer MA, Ren B; Mouse ENCODE Consortium. A comparative encyclopedia of DNA elements in the mouse genome. *Nature*. 2014;**515**(7527):355–364.
469. López Navarro E, Ortega FJ, Francisco-Busquets E, Sabater-Masdeu M, Alvarez-Castano E, Ricart W, Fernandez-Real JM. Thyroid hormone receptors are differentially expressed in granulosa and cervical cells of infertile women. *Thyroid*. 2016;**26**(3):466–473.
470. Hernandez A. Thyroid hormone role and economy in the developing testis. *Vitam Horm*. 2018;**106**:473–500.
471. Martinez ME, Karaczyn A, Stohn JP, Donnelly WT, Croteau W, Peeters RP, Galton VA, Forrest D, St Germain D, Hernandez A. The Type 3 deiodinase is a critical determinant of appropriate thyroid hormone action in the developing testis. *Endocrinology*. 2016;**157**(3):1276–1288.
472. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. *Pflugers Arch*. 2004;**447**(5):653–665.



473. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. *Mol Endocrinol*. 2002;**16**(10):2283–2296.
474. Picut CA, Remick AK, de Rijk EP, Simons ML, Stump DG, Parker GA. Postnatal development of the testis in the rat: morphologic study and correlation of morphology to neuroendocrine parameters. *Toxicol Pathol*. 2015;**43**(3):326–342.
475. Oner J, Oner H. Immunodetection of thyroid hormone receptor (alpha1/alpha2) in the rat uterus and oviduct. *Acta Histochem Cytochem*. 2007;**40**(3):77–81.
476. Galton VA, Martinez E, Hernandez A, St Germain EA, Bates JM, St Germain DL. Pregnant rat uterus expresses high levels of the type 3 iodothyronine deiodinase. *J Clin Invest*. 1999;**103**(7):979–987.
477. Huang SA, Dorfman DM, Genest DR, Salvatore D, Larsen PR. Type 3 iodothyronine deiodinase is highly expressed in the human uteroplacental unit and in fetal epithelium. *J Clin Endocrinol Metab*. 2003;**88**(3):1384–1388.
478. Galton VA, Martinez E, Hernandez A, St Germain EA, Bates JM, St Germain DL. The type 2 iodothyronine deiodinase is expressed in the rat uterus and induced during pregnancy. *Endocrinology*. 2001;**142**(5):2123–2128.
479. Deng WB, Liang XH, Liu JL, Yang ZM. Regulation and function of deiodinases during decidualization in female mice. *Endocrinology*. 2014;**155**(7):2704–2717.
480. Leonard AJ, Evans IM, Pickard MR, Bandoopathy R, Sinha AK, Ekins RP. Thyroid hormone receptor expression in rat placenta. *Placenta*. 2001;**22**(4):353–359.
481. Chan S, Murray PG, Franklyn JA, McCabe CJ, Kilby MD. The use of laser capture microdissection (LCM) and quantitative polymerase chain reaction to define thyroid hormone receptor expression in human “term” placenta. *Placenta*. 2004;**25**(8–9):758–762.
482. Visser TJ. Thyroid hormone transport across the placenta. *Ann Endocrinol (Paris)*. 2016;**77**(6):680–683.
483. Koopdonk-Kool JM, de Vijlder JJ, Veenboer GJ, Ristalpers C, Kok JH, Vulsma T, Boer K, Visser TJ. Type II and type III deiodinase activity in human placenta as a function of gestational age. *J Clin Endocrinol Metab*. 1996;**81**(6):2154–2158.
484. Hidal JT, Kaplan MM. Characteristics of thyroxine 5'-deiodination in cultured human placental cells. Regulation by iodothyronines. *J Clin Invest*. 1985;**76**(3):947–955.
485. Maruo T, Matsuo H, Mochizuki M. Thyroid hormone as a biological amplifier of differentiated trophoblast function in early pregnancy. *Acta Endocrinol (Copenh)*. 1991;**125**(1):58–66.
486. Asahara S, Sato A, Aljona AA, Maruo T. Thyroid hormone synergizes with follicle stimulating hormone to inhibit apoptosis in porcine granulosa cells selectively from small follicles. *Kobe J Med Sci*. 2003;**49**(5–6):107–116.
487. Maruo T, Hiramatsu S, Otani T, Hayashi M, Mochizuki M. Increase in the expression of thyroid hormone receptors in porcine granulosa cells early in follicular maturation. *Acta Endocrinol (Copenh)*. 1992;**127**(2):152–160.
488. Maruo T, Katayama K, Barnea ER, Mochizuki M. A role for thyroid hormone in the induction of ovulation and corpus luteum function. *Horm Res*. 1992;**37**(Suppl 1):12–18.
489. Matsuo H, Maruo T, Hayashi M, Mochizuki M. Modification of endocrine function of trophoblasts by thyroid hormone [in Japanese]. *Nippon Sanka Fujinka Gakkai Zasshi*. 1991;**43**(11):1533–1538.
490. Matsuo H, Maruo T, Murata K, Mochizuki M. Human early placental trophoblasts produce an epidermal growth factor-like substance in synergy with thyroid hormone. *Acta Endocrinol (Copenh)*. 1993;**128**(3):225–229.
491. Mortimer RH, Galligan JP, Cannell GR, Addison RS, Roberts MS. Maternal to fetal thyroxine transmission in the human term placenta is limited by inner ring deiodination. *J Clin Endocrinol Metab*. 1996;**81**(6):2247–2249.
492. Santini F, Chiovato L, Ghirri P, Lapi P, Mammoli C, Montanelli L, Scartabelli G, Ceccarini G, Coccoli L, Chopra IJ, Boldrini A, Pinchera A. Serum iodothyronines in the human fetus and the newborn: evidence for an important role of placenta in fetal thyroid hormone homeostasis. *J Clin Endocrinol Metab*. 1999;**84**(2):493–498.
493. Dentice M, Luongo C, Ambrosio R, Sibilio A, Casillo A, Iaccarino A, Troncone G, Fenzi G, Larsen PR, Salvatore D.  $\beta$ -Catenin regulates deiodinase levels and thyroid hormone signaling in colon cancer cells. *Gastroenterology*. 2012;**143**(4):1037–1047.
494. Catalano V, Dentice M, Ambrosio R, Luongo C, Carollo R, Benfante A, Todaro M, Stassi G, Salvatore D. Activated thyroid hormone promotes differentiation and chemotherapeutic sensitization of colorectal cancer stem cells by regulating Wnt and BMP4 signaling. *Cancer Res*. 2016;**76**(5):1237–1244.
495. Huang SA, Mulcahey MA, Crescenzi A, Chung M, Kim B, Barnes CA, Kuijt W, Tu HM, Harney JW, Larsen PR. Transforming growth factor- $\beta$  promotes inactivation of extracellular thyroid hormones via transcriptional stimulation of type 3 iodothyronine deiodinase. *Mol Endocrinol*. 2005;**19**:3126–3136.
496. Dentice M. Hedgehog-mediated regulation of thyroid hormone action through iodothyronine deiodinases. *Expert Opin Ther Targets*. 2011;**15**(4):493–504.
497. Pospisilik JA, Schramek D, Schnidar H, Cronin SJ, Nehme NT, Zhang X, Knauf C, Cani PD, Aumayr K, Todoric J, Bayer M, Haschemi A, Puvindran V, Tar K, Orthofer M, Neely GG, Dietzl G, Manoukian A, Funtovics M, Prager G, Wagner O, Ferrandon D, Aberger F, Hui CC, Esterbauer H, Penninger JM. *Drosophila* genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate. *Cell*. 2010;**140**(1):148–160.
498. Casula S, Bianco AC. Thyroid hormone deiodinases and cancer. *Front Endocrinol (Lausanne)*. 2012;**3**:74.
499. Popławski P, Wiśniewski JR, Rijntjes E, Richards K, Rybicka B, Köhrle J, Piekliko-Witkowska A. Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system. *PLoS One*. 2017;**12**(12):e0190179.
500. Balazs AE, Athanassaki I, Gunn SK, Tatevian N, Huang SA, Haymond MW, Karaviti LP. Rapid resolution of consumptive hypothyroidism in a child with hepatic hemangioendothelioma following liver transplantation. *Ann Clin Lab Sci*. 2007;**37**(3):280–284.
501. Peters C, Langham S, Mullis PE, Dattani MT. Use of combined liothyronine and thyroxine therapy for consumptive hypothyroidism associated with hepatic haemangiomas in infancy. *Horm Res Paediatr*. 2010;**74**(2):149–152.
502. Mori K, Yoshida K, Kayama T, Kaise N, Fukazawa H, Kiso Y, Kikuchi K, Aizawa Y, Abe K. Thyroxine 5-deiodinase in human brain tumors. *J Clin Endocrinol Metab*. 1993;**77**(5):1198–1202.
503. Nauman P, Bonicki W, Michalik R, Warzecha A, Czernicki Z. The concentration of thyroid hormones and activities of iodothyronine deiodinases are altered in human brain gliomas. *Folia Neuro-pathol*. 2004;**42**(2):67–73.
504. Tannahill LA, Visser TJ, McCabe CJ, Kachilele S, Boelaert K, Sheppard MC, Franklyn JA, Gittoes NJ. Dysregulation of iodothyronine deiodinase enzyme expression and function in human pituitary tumours. *Clin Endocrinol (Oxf)*. 2002;**56**(6):735–743.
505. Howard D, La Rosa FG, Huang S, Salvatore D, Mulcahey M, Sang-Lee J, Wachs M, Kloppner JP. Consumptive hypothyroidism resulting from hepatic vascular tumors in an athyreotic adult. *J Clin Endocrinol Metab*. 2011;**96**(7):1966–1970.
506. Kester MH, Kuiper GG, Versteeg R, Visser TJ. Regulation of type III iodothyronine deiodinase expression in human cell lines. *Endocrinology*. 2006;**147**(12):5845–5854.
507. Dentice M, Ambrosio R, Salvatore D. Role of type 3 deiodinase in cancer. *Expert Opin Ther Targets*. 2009;**13**(11):1363–1373.
508. Romitti M, Wajner SM, Ceolin L, Ferreira CV, Ribeiro RV, Rohenkohl H, Weber SS, Lopez PL, Fuziwara CS, Kimura ET, Maia AL. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma. *Endocr Relat Cancer*. 2016;**23**(3):135–146.
509. Romitti M, Wajner SM, Zennig N, Goemann IM, Bueno AL, Meyer EL, Maia AL. Increased type 3 deiodinase expression in papillary thyroid carcinoma. *Thyroid*. 2012;**22**(9):897–904.
510. Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, Gulotta G, Dieli F, de Maria R, Stassi G. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. *Gastroenterology*. 2011;**140**(1):297–309.
511. Kappers MH, van Esch JH, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, Sleijfer S, Leijten F, Danser AH, van den Meiracker AH, Visser TJ. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. *J Clin Endocrinol Metab*. 2011;**96**(10):3087–3094.
512. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. *Ann Intern Med*. 2006;**145**(9):660–664.
513. Maynard MA, Huang SA. Thyroid hormone inactivation in gastrointestinal stromal tumors. *N Engl J Med*. 2014;**371**(1):86–87.
514. Ruppe MD, Huang SA, Jan de Beur SM. Consumptive hypothyroidism caused by paraneoplastic production of type 3 iodothyronine deiodinase. *Thyroid*. 2005;**15**(12):1369–1372.
515. Beukhof CM, van Doorn L, Visser TJ, Bins S, Visser WE, van Heerebeek R, van Kemenade FJ, de Rijke YB, de Herder WW, Chaker L, Mathijssen RH, Peeters RP. Sorafenib-induced changes in thyroid hormone levels in patients treated for hepatocellular carcinoma. *J Clin Endocrinol Metab*. 2017;**102**(8):2922–2929.
516. Kim BW, Daniels GH, Harrison BJ, Price A, Harney JW, Larsen PR, Weetman AP. Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. *J Clin Endocrinol Metab*. 2003;**88**(2):594–598.
517. Miyauchi A, Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, Amino N, Toyoda N, Nomura E, Nishikawa M. 3,5,3'-Triiodothyronine thyrotoxicosis due to increased conversion of administered liothyronine in patients with massive metastatic follicular thyroid carcinoma. *J Clin Endocrinol Metab*. 2008;**93**(6):2239–2242.



518. Arnaldi LA, Borra RC, Maciel RM, Cerutti JM. Gene expression profiles reveal that *DCN*, *DIO1*, and *DIO2* are underexpressed in benign and malignant thyroid tumors. *Thyroid*. 2005;**15**(3):210–221.
519. de Souza Meyer EL, Dora JM, Wagner MS, Maia AL. Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentiation towards papillary carcinoma. *Clin Endocrinol (Oxf)*. 2005;**62**(6):672–678.
520. Piekliko-Witkowska A, Master A, Wojcicka A, Boguslawska J, Brozda I, Tanski Z, Nauman A. Disturbed expression of type 1 iodothyronine deiodinase splice variants in human renal cancer. *Thyroid*. 2009;**19**(10):1105–1113.
521. Boguslawska J, Wojcicka A, Piekliko-Witkowska A, Master A, Nauman A. MiR-224 targets the 3' UTR of type 1 5'-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer. *PLoS One*. 2011;**6**(9):e24541.
522. Debski MG, Pachucki J, Ambroziak M, Olszewski W, Bar-Andziak E. Human breast cancer tissue expresses high level of type 1 5'-deiodinase. *Thyroid*. 2007 Jan;**17**(1):3–10.
523. Sabatino L, Iervasi G, Ferrazzi P, Francesconi D, Chopra IJ. A study of iodothyronine 5'-mono-deiodinase activities in normal and pathological tissues in man and their comparison with activities in rat tissues. *Life Sci*. 2000;**68**(2):191–202.
524. Lan X, Xing J, Gao H, Li S, Quan L, Jiang Y, Ding S, Xue Y. Decreased expression of selenoproteins as a poor prognosticator of gastric cancer in humans. *Biol Trace Elem Res*. 2017;**178**(1):22–28.
525. Poplawski P, Rybicka B, Boguslawska J, Rodzik K, Visser TJ, Nauman A, Piekliko-Witkowska A. Induction of type 1 iodothyronine deiodinase expression inhibits proliferation and migration of renal cancer cells. *Mol Cell Endocrinol*. 2017;**442**:58–67.
526. Poplawski P, Piekliko-Witkowska A, Nauman A. The significance of TRIP11 and T3 signalling pathway in renal cancer progression and survival of patients. *Endokrynol Pol*. 2017;**68**(6):631–641.
527. Kim WG, Cheng SY. Thyroid hormone receptors and cancer. *Biochim Biophys Acta*. 2013;**1830**(7):3928–3936.
528. Martínez-Iglesias O, García-Silva S, Tenbaum SP, Regadera J, Larcher F, Paramio JM, Vennström B, Aranda A. Thyroid hormone receptor  $\beta$ 1 acts as a potent suppressor of tumor invasiveness and metastasis. *Cancer Res*. 2009;**69**(2):501–509.
529. Martínez-Iglesias OA, Alonso-Merino E, Gómez-Rey S, Velasco-Martín JP, Martín Orozco R, Luengo E, García Martín R, Ibáñez de Cáceres I, Fernández AF, Fraga MF, González-Peramato P, Varona C, Palacios J, Regadera J, Aranda A. Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis. *Proc Natl Acad Sci USA*. 2016;**113**(3):E328–E337.
530. Uchuya-Castillo J, Aznar N, Frau C, Martínez P, Le Nevé C, Marisa L, Penalva LOF, Laurent-Puig P, Puisieux A, Scoazec JY, Samarut J, Ansieau S, Plateroti M. Increased expression of the thyroid hormone nuclear receptor TR $\alpha$ 1 characterizes intestinal tumors with high Wnt activity. *Oncotarget*. 2018;**9**(57):30979–30996.
531. Kress E, Skah S, Sirakov M, Nadjar J, Gadot N, Scoazec JY, Samarut J, Plateroti M. Cooperation between the thyroid hormone receptor TR $\alpha$ 1 and the WNT pathway in the induction of intestinal tumorigenesis. *Gastroenterology*. 2010;**138**(5):1863–1874.e1.
532. Cheng SY. Interplay between TR $\alpha$ 1 and Wnt signaling: a dangerous liaison. *Oncotarget*. 2018;**9**(62):31939–31940.
533. Dentice M, Ambrosio R, Damiano V, Sibilio A, Luongo C, Guardiola O, Yennek S, Zordan P, Minchiotti G, Colao A, Marsili A, Brunelli S, Del Vecchio L, Larsen PR, Tajbakhsh S, Salvatore D. Intracellular inactivation of thyroid hormone is a survival mechanism for muscle stem cell proliferation and lineage progression. *Cell Metab*. 2014;**20**(6):1038–1048.
534. Kester MH, Toussaint MJ, Punt CA, Matondo R, Aarnio AM, Darras VM, Everts ME, de Bruin A, Visser TJ. Large induction of type III deiodinase expression after partial hepatectomy in the regenerating mouse and rat liver. *Endocrinology*. 2009;**150**(1):540–545.
535. Bohinc BN, Michelotti G, Xie G, Pang H, Suzuki A, Guy CD, Piercy D, Kruger L, Swiderska-Syn M, Machado M, Pereira T, Zavacki AM, Abdelmalek M, Diehl AM. Repair-related activation of Hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism. *Endocrinology*. 2014;**155**(11):4591–4601.
536. Castroneves LA, Jugo RH, Maynard MA, Lee JS, Wassner AJ, Dorfman D, Bronson RT, Ukomadu C, Agoston AT, Ding L, Luongo C, Guo C, Song H, Demchev V, Lee NY, Feldman HA, Vella KR, Peake RW, Hartigan C, Kellogg MD, Desai A, Salvatore D, Dentice M, Huang SA. Mice with hepatocyte-specific deficiency of type 3 deiodinase have intact liver regeneration and accelerated recovery from non-thyroidal illness after toxin-induced hepatonecrosis. *Endocrinology*. 2014;**155**(10):4061–4068.

#### Acknowledgments

The authors thank Cezar Bianchi for the artwork with the figures and illustrations.

**Financial Support:** This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants DK58538 and DK65055, the American Thyroid Association, Hungarian Brain Research Program 2.0, European Union Horizon 2020 “Thyrage” Grant 666869, National Research, Development and Innovation Office (NKFIH) of Hungary Grants 109415 and 125247, FAPESP 2017/18277-0, and by CAPES PROEX (grant 0653/2018).

**Correspondence and Reprint Requests:** Antonio C. Bianco, MD, PhD, 5841 South Maryland Avenue, MC1027,

Room M267, Chicago, Illinois 60637. E-mail: [abianco@deiodinase.org](mailto:abianco@deiodinase.org).

**Disclosure Summary:** A.C.B. is a consultant for Synthetics, Inc and BLA Technology LLC; he also served as a consultant for Sentier LLC during 2018. The remaining authors have nothing to disclose.

#### Abbreviations

4PBA, 4-phenyl butyric acid; AD, Alzheimer's disease; AFABP, adipocyte-specific fatty acid-binding protein; AKT, serine/threonine kinase 1; Alb-D2KO, (mouse with) liver-specific *Dio2* inactivation; AMIO, amiodarone; Astro-D2KO, (mouse with) astrocyte-specific *Dio2* inactivation; ATP2a, ATPase sarcoplasmic/ER  $\text{Ca}^{2+}$  transporting; BAT, brown adipose tissue; BBB, blood–brain barrier; BCC, basal cell carcinoma; CNS, central nervous system; D1, type I iodothyronine deiodinase; D2, type II iodothyronine deiodinase; D3, type III iodothyronine deiodinase; DEA, desethylamiodarone; *Dio1*, gene encoding D1; *Dio2*, gene encoding D2; *Dio3*, gene encoding D3; E, embryonic day; ER, endoplasmic reticulum; FAAH, fatty acid amide hydrolase; Fat-D2KO, (mouse with) fat-specific *Dio2* inactivation; FT3, free T3; FT4, free T4; Foxo, forkhead box, subgroup O; global-D2KO, (mouse with) global *Dio2* inactivation; global-D3KO, (mouse with) global *Dio3* inactivation; GLP1, glucagon-like peptide 1; HFD, high-fat diet; HIF, hypoxia-inducible factor; HPT, hypothalamic–pituitary–thyroid; HSP40, heat shock protein 40; iCKO, inducible conditional KO; IVH, intraventricular hemorrhage; IPF, idiopathic pulmonary fibrosis; KO, knockout; LAT, L-type amino acid transporter; LDL, low-density lipoprotein; L-T3, liothyronine; L-T4, levothyroxine; LXR, liver X receptor; MBH, medial basal hypothalamus; MCT, monocarboxylate transporter; *Mct8*-KO, (mouse with) global *Mct8* inactivation; MHC, myosin heavy chain; miR, miRNA; mTOR, mammalian target of rapamycin; mTORC, mammalian target of rapamycin complex; MYF5, myogenic regulator factor-5; MYH, myosin, heavy polypeptide; MYOD, muscle determination gene; NCOR, nuclear receptor corepressor; NE, norepinephrine; NTIS, non-thyroidal illness syndrome; OATP, organic anion-transporting polypeptide; OPC, oligodendrocyte precursor cell; PGC1 $\alpha$ , PPAR $\gamma$  coactivator 1 $\alpha$ ; PI3K, phosphatidylinositol 3-kinase; PPAR $\gamma$ , peroxisome proliferator-activated receptor- $\gamma$ ; PTU, propylthiouracil; PVN, paraventricular nucleus; RCC, renal cell cancer; RDS, respiratory distress syndrome; rT3, reverse T3; RXR, retinoid X receptor; SBP2, selenocysteine insertion sequence binding protein 2; SECIS, selenocysteine insertion sequence; SKM, skeletal muscle; *Skm*-D2KO, (mouse with) skeletal muscle-specific *Dio2* inactivation; SMRT, NcoR2; SNP, single-nucleotide polymorphism; SOL, soleus; STB, syncytiotrophoblast; T2, 3,3'-diiodo-L-thyronine; T3S, sulfated T3; TBI, traumatic brain injury; TGR5, G-protein-coupled bile acid receptor 1 (GPBAR1); TH, thyroid hormone; TR, thyroid hormone receptor; TRE, thyroid responsive element; TRH, TSH-releasing hormone; TRIAD, transmembrane transport, intracellular deiodination, and TR-mediated gene transcription; TUDCA, tauroursodeoxycholic acid; UBC, ubiquitin-activating enzyme; UbD2, ubiquitinated D2; UCP1, uncoupling protein 1; USP, ubiquitin-specific peptidase; VILI, ventilator-induced lung injury; VLDL, very LDL; WSB1, WD repeat and SOCS box-containing 1; Zfp125, zinc finger protein-125.